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ABSTRACT
Efficacy studies are often done on diseased animals while pharmacokinetic
studies are done on healthy animals. Disease models are inherently difficult to
standardize because o f the many variables associated with measuring pharmacokinetic
parameters in abnormal animals. Information derived from pharmacokinitic studies
with diseased animals could be useful to determine if therapeutic doses of a drug or
antimicrobial becomes less effective or toxic due to changes in distribution and
clearance.
The objectives o f this study were to: characterize a pulmonary infection model
in swine using Actinobacillus pleuropneumoniae; evaluate the pharmacokinetic changes
associated with the pulmonary infection model and dexamethasone after the infusion of
enrofloxacin and urine enrofloxacin and ciprofloxacin concentrations: and the
comparison endotoxin administration and dexamethasone to the pharmacokinetic
changes o f the infection model.
In the infection study, infected pigs became ill within two hours of inoculation
and had microscopic lesions of necrotizing, fibrinopurulent pneumonia consistent with
Actinobacillus pleuropneumoniae infection; plasma interleukin-6 was slightly elevated
in the infected pigs and not the dexamethasone pigs: clearance of enrofloxacin was
increased in the dexamethasone treated pigs: volume o f distribution of the elimination
phase and at steady state were decreased in the infection: and the urine
enrofloxacin/creatinine ratios were decreased in the dexamethasone treated pigs.
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In the endotoxin study, the endotoxin treated pigs exhibited toxic signs within
30 minutes; the plasma interleukin-6 concentrations were markedly elevated in the
endotoxin treated pigs; the dexamethasone treated pigs showed an increased clearance
o f enrofloxacin; volumes of distribution was increased in the dexamethasone treated
pigs; the urine enrofloxacin/creatinine ratios were elevated in the endotoxin group
compared to control, dexamethasone and endotoxin-dexamethasone groups while the
ciprofloxacin/creatinine ratios in the endotoxin group was elevated and the
dexamethasone treated pigs had elevated urine ciprofloxacin/creatinine ratio at 24 h but
decreased at 48 and 72 h. These results show that the infection model was reliable,
infection had no effect on enrofloxacin distribution and clearance, dexamethasone
concurrent administration with enrofloxacin may reduce efficacy because o f increased
clearance and the comparison of the endotoxin model compared to the infection model
gave incongruous results.

xii
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INTRODUCTION
Factors Affecting Xenobiotic Disposition
It has been shown that the disposition o f xenobiotic substances may be affected
by the disease process (Gibson & Skett. 1986; Monshouwer et al.. 1995b). Alterations
in absorption, distribution, metabolism and excretion depend on the microorganism,
compound and route o f exposure of a drug or antimicrobial (Monshouwer et al., 1995a).
An alteration o f one o f these variables may have a profound impact on pharmacokinetic
parameters exhibited by a particular drug. All four processes can be affected during an
infection-induced acute-phase response. The acute-phase response occurs when
physiological homeostasis is upset by infection, inflammation, tissue injury, neoplastic
growth, or immunological disorders. The physiological response starts with a local
reaction at the site o f injury and progress to a systemic reaction. The local reaction is
characterized by platelet aggregation, increase vascular permeability and activation and
accumulation o f granulocytes and mononuclear cells. The systemic reaction is
characterized by fever, anorexia, increased white blood cell-counts. inhibition of gastric
function, increased release of endocrine hormones and alterations in plasma cation
concentrations. The term, acute-phase. refers to changes in several plasma proteins.
Delayed gastric emptying can reduce drug absorption from the duodenum and
jejunum. The rate o f gastric emptying can be affected by anxiety, stress, food and
infections. In pigs, an experimentally induced acute-phase response decreased the
absorption rate o f orally administered trimethoprim or oxytetracycline (Ladefoged.
1979; Pijpers et al.. 1991). Gastric secretion and gastrointestinal motility can be

1
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affected during infection, which results in altered absorption rate (Groothius et al..
1978; Leenen & van Miert, 1969). The binding of drugs to plasma proteins can
influence drug disposition. Albumin and a l-acid glycoprotein (AGP) are the main drug
binding proteins. Inflammation and infection induce an acute-phase response which
decreases albumin and increases a r acid glycoprotein production (Eckersall et al.. 1996;
Heinrich et al., 1990; Kushner & Mackiewicz. 1993). Alpha,-acid glycoprotein is an
important binder o f basic drugs such as propanolol. while albumin binds acidic drugs
like penicillin. Increased concentrations of a r acid glycoprotein and albumin can alter
the volume o f distribution and drug half-life. The kidney is the most important organ
for the excretion o f most drugs below 400 Daltons (Da) molecular weight and drugs
greater than 400 Da are excreted by the liver. Therefore, renal or hepatic dysfunction or
diminished renal or hepatic blood flow may affect the excretion rate of drugs
(Monshouwer et al.. 1995a). Metabolism can also be affected by either infection or
inflammation.
Domestic animals are especially at risk to infections, because of crowding and
poor housing conditions where outbreaks of disease are common (Fedorka-Cray et al..
1993a). The swine industry is an example o f high density production. Diseases in
countries raising pigs were high and economic losses were large. Observations from
laboratory animals and humans provide supporting evidence that infection impairs drug
disposition, but information is lacking in domestic animals. Infection may induce
pharmacokinetic changes in domestic animals to the same extent as laboratory species
and humans. These alterations may have clinical consequences such as increased drug

i
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toxicity or diminished drug efficacy: or decreased toxicity and increased efficacy.
Decreased half-life, decreased volume of distribution and increased clearance may be
manifested by decreased efficacy. On the other hand, increased half-life, increased
volume o f distribution and decreased clearance may lead to drug toxicity. Alternatively,
increased half-life, increased volume o f distribution and decreased clearance may signal
pharmacokinetic changes leading to excessive residue concentrations o f veterinary
drugs and metabolites in food. The potential for a human food safety problem is likely
because levels o f drugs residues may be increased in animal tissues due to decreased
metabolism o f the parent compound.
Infections and Drug iMetabolism
The main site o f drug metabolism is the liver, but lung. skin, kidney and small
intestine may also metabolize xenobiotic substances. Drug metabolism reactions are
classified into Phase I and Phase II reactions. Phase I reactions consist o f oxidative and
reductive reactions that create or alter functional groups and Phase II reactions are
conjugations. Phase II reactions may depend upon the activities of Phase I enzymes.
Phase II reactions couple a drug or metabolite to an endogenous substrate such as
glucuronic acid, glutathione, sulphate, aceytl or glycine. Metabolism of most drugs is
accomplished by families I to IV of the microsomal cytochrome P450's (Nebert &
Gonzalez, 1987; Paine. 1991). Hydroxylation. dealkylation. dehalogenation.
epoxidation and deamination are typical oxidation reactions. In humans studies,
bacterial, viral and parasitic infections have been shown to impede drug metabolism by
suppressing cytochrome P450's (Armstrong & Renton. 1993a.b: Azri & Renton. 1987;
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Chang et al.. 1978: Descotes et al., 1985; Farquar et al.. 1983; Galtier et al.. 1986:
Glazier et al.. 1994: Kokwaro et al.. 1993; Kramer & McClain. 1981; Maffei et al..
1981: Renton. 1981.1986; Selgrade et al., 1984; Soykaef al.. 1976). A variety o f
infections all showed an impairment o f drug metabolizing activities, which
demonstrates that the source o f infection does not necessarily dictate the expected
effect. Experimental animals exposed to either microbial infection or inflammatory
stimuli, endotoxin or turpentine, respond by manifesting physiological, hematological
and metabolic changes that characterize the acute-phase response (Ballmer et al., 1991;
van Miert. 1990).
Previous work has focused on Phase I metabolism, but only limited information
is available on the effects o f infection on Phase II metabolism. Malarial infection
decreased the glucuronidation o f 3'-azido-3' deoxythymidine and paracetamol in rat
liver microsomes (Ismail et al.. 1992). Ehrlichiaphagocytophilia or Trypanosoma
infection in goats depressed the glucuronidation of chloramphenicol and sulfadimidine
metabolites (Anika et al., 1986; van Gogh et al.. 1989). In Salmonella dublin infected
calves, it was observed that the elimination half-life of chloramphenicol was increased
(Groothuis & van Miert, 1987). Prolongation of the elimination half-life of paracetamol
in malaria-infected rats was also shown (Mansor et al.. 1991). Immunosupressed mice,
infected with Schistosoma mansoni, had prolonged pentobarbital induced sleep-times
(Tonelli et al.. 1995).

4
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Cytokines and Metabolism
The acute-phase response may be triggered by cytokines released from
macrophages-monocytes. Interleukins l a and 1(5 (IL-1 a /p ). tumor necrosis factors a
and P (TNF-a/p) and interferons a and P (INF-a/p) are cytokines that inhibit oxidative
and conjugative drug metabolism in laboratory animals (Craig et al., 1989b; Ghezzi et
al., 1986a.b; Morgan & Norman. 1990; Renton & Knickle. 1990). The interferoninducer (INF-a), tilorone. was shown to decrease the activity o f several drug
metabolizing enzymes in the rat (Renton & Mannering. 1976b) such as Bordetella
pertusis. E. coli. lipopolysaccharide (LPS) and polyinosinic acid-polycytidylic acid
(poly IC). that induced INF decreased total cytochrome P450 (P450) and related enzyme
activities (Renton & Mannering. 1976a). Bordatellapertusis and LPS also induced
tumor necrosis factor-a (TNF-a). interleukin-l (IL-1) and interleukin-6 (IL-6). In
following years, many reports described the effects of cytokine inducers. polylC and
LPS effects on cytochrome P450 mediated drug metabolism (Cribb et al.. 1994;
Delaporte et al., 1993; Ghezzi et al., 1986b; Morgan. 1989; Morgan & Norman. 1990;
Sakai et al.. 1992; Shedlofsky et al.. 1994; Stanley et al., 1988).
When it was proven that cytokines were involved in infections, cytochrome
P450 activity was decreased by lowering concentrations o f mRNA and apoprotein to
suppress drug metabolism. Other studies were performed to directly expose laboratory
animals to cytokines. Tumor necrosis factor-a, IL-1. IL-6 or interferons depressed
cytochrome P450 dependent enzyme activities of P450IIC11 and P450I1C12 genes in
male and female rat livers, respectively (Ghezzi et al., 1986a.b.c; Shedlofsky et al.,

5
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1987: Stanley et al.. 1991; Wright & Morgan. 1991). When administered in
combination to female rats. IL-1 and dexamethasone significantly depressed total P450
and P450IIC12 apoenzyme and mRNA (Wright & Morgan. 1991. Interleukin-la alone
significantly suppressed total P450 content. P450IIC11 apoenzyme and P450IIC12
mRNA. Interleukin-6 was not as potent, but it did potentiate the effects of
dexamethasone. In another investigation, the effects o f IL-1 and IL-6 on P450IIC12
expression in rat hepatocyte cultures were examined (Morgan et al.. 1994). The effects
on expression o f multiple cytochrome P450 gene products in male rat livers was also
examined in vitro. Interleukin-1 suppressed the expression of P450IIC12 mRNA and
protein in cultured hepatocytes. No consistent effect o f IL-6 was observed. Maximal
suppression o f P45II2C12 mRNA after 24 h of IL-1 treatment reached 12 and 32% of
control concentrations in two separate experiments. Cytochrome P450IIC12 protein
was suppressed to 28% o f control concentrations as early as 12 h after IL-1 treatment.
Injection o f IL-1. low doses o f dexamethasone. or both, in male rats produced decreases
in total P450 and in P450IIIA2 and P450IIC11 mRNA and protein expression similar to
effects previously seen for P450IIC12 expression in females. Cytochrome P450IIEI
mRNA and protein was significantly suppressed only by the combination of IL-1 and
dexamethasone. Interleukin-6 treatment of male rats down-regulated the P450IIC11 and
P450IIE1 mRNAs at a dose o f 4.5 pg/kg, which was lower than that required to induce
haptoglobin mRNA. a prototype acute phase gene product. Cytochrome P450IIC11
protein content o f the microsomes was also decreased by IL-6 treatment, with a slower
time-course than for suppression o f its mRNA. No significant effects of IL-6 treatment
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were seen on P450IIIA2 mRNA or P450IIIA2/1. Therefore. IL-1 and IL-6 treatments.
in vivo. differentially affect subsets of P450 gene products in rat liver. The effects o f
LPS. TNF-a and IL-1 on the mixed-fimction oxidase system, in vivo, may be due partly
to an induction o f IL-6 in vivo (Chen et al.. 1992). The different sensitivities of the
enzymes to IL-6. but not to IL-1 or TNF-a may be due to the involvement o f two
distinct mechanisms where ethylmorphine-N-demethylase and ethoxycoumarin-Odeethylase were affected; ethoxyresorufin-O-deethylase was minimally affected and
pentoxyresorufm-O-deethylase was not affected.
The differential effects o f IL-1 a and IL-P may be difficult to explain because
they both bind to the same biological receptor (Type I) and elicit the same biological
responses (Kalian et al.. 1986. 1990). For example, IL -la /p may coordinate the brainendocrine-immune responses to physiological and pharmacological stimuli by binding
to the same receptor (Takao et al.. 1992). The binding o f radiolabeled IL-1R antagonist
(IL-ra) in homogenates of mouse hippocampus, spleen and testis was linear over a broad
range o f membrane protein concentrations, saturable, reversible and of high affinity. In
competition studies. IL-lra. recombinant human IL-1 a . IL -ip and a weak IL-ip analog
inhibited radiolabeled IL-lra binding to mouse tissues in parallel with their biological
activities. The binding characteristics and distribution o f IL-lra were comparable to
those of previously characterized Type I IL-1 receptors. The biological effects of IL-1 P
have been more extensively studied, because I L - la is not released into the systemic
circulation. Nonetheless, differential effects o f IL-1 P on cytochrome P450 were
observed in arthritic rats (Ferrari et al.. 1993b). Interleukin-la may have similar
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effects, but this has not been studied. Experimental arthritis and inflammation reduced
liver cytochrome P450-dependent monooxygenase activities with subsequent
impairment o f drug metabolism. Arthritis was induced on day 0 by type II collagen and
a low dose (0.2 mg) o f N-acetylmuramyl-L-alanyl-D-isoglutamine and human
recombinant IL-1 was administered subcutaneously at the daily dose o f 0.02. 0.2 or 2.0
micrograms to each arthritic rat. from day 21 to 25 and on day 28. Ethoxyresorufin-Odeethylation was depressed 6-fold in arthritic rat liver microsomes and the 2.0 pg
dosage o f IL-1 potentiated this depression. Pentoxyresorufm-O-deethylation activity
was decreased by 50% in arthritic rats, following IL-1 treatment. Progesterone 60hydroxvlation and P450IIIA protein increased by 2-fold in both untreated arthritic rat
liver microsomes and after the low dose o f IL-1. The two higher doses o f IL-1
decreased this activity to baseline concentrations in the arthritic rats. Laurie acid
hydroxylation increased 2-fold in arthritic rats and was further potentiated by IL-1. This
study demonstrated that main liver drug-metabolizing isoenzymes during established
collagen-induced arthritis in rats were affected by systemic IL-1. Treatment with IL-1
mimicked or reversed the influence of the inflammatory process on these enzymes.
Actinobacillus Pleuropneumoniae Infection in Swine
This study tested a specific drug, enrofloxacin. in the presence o f a pulmonary
infection with Actinobacillus pleuropneumoniae (APP). whereas previous studies have
employed non-therapeutic or classical substrates . such as antipyrine. instead of
pharmaceuticals to measure pharmacokinetic parameters in diseased animals
(Monshouwer et al.. 1995a). It is the intent o f this study to characterize the disposition
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and clearance o f enrofloxacin in the infected animal with Actinobacillus
pleuropneumoniae using a field strain o f serotype 1 that has a low virulence (Baarsch et.
al.. 1995: van Leengoed et. al.. 1987, 1989. 1990; H enselefn/.. 1996). Subsequently,
the morbidity rate was high, but the mortality rate was low.
Actinobacillus pleuropneumoniae can cause peracute. acute or chronic
respiratory disease in swine. The host's response to an acute infection includes a
moderate hyperthermia, lethargy and reduced feed and water consumption. The
infection occurs in many swine producing countries and causes great economic loss due
to high morbidity and mortality (Monshouwer. 1996). This study has employed a
domestic APP field strain. L91-2. belonging to serotype 1 which is common in the
United States (Baarsch et al.. 1995). The low virulence of the culture was produced by
serial in vitro passage on solid growth media. In the Netherlands serotype 9. strain
13261. was employed to perform pharmacokinetic studies. This strain was only passed
once in mouse lungs to decrease virulence (Monshouwer et al.. 1995a). In the present
study, only the attenuated field strain. L91-2, was inoculated into swine. High
morbidity, but low mortality occurred because of the reduced virulence o f the field
strain, L91-2.
The acute and peracute forms of porcine Actinobacillus pleuropneumoniae
resemble septic shock in humans. Therefore, an Actinobacillus pleuropneumoniae
infection model may prove to be useful as a model for septic shock. Bacterial sepsis
produced by Actinobacillus pleuropneumoniae depends on a variety o f virulence
factors: capsule, endotoxin, hemolysin and cytotoxins which play important roles in the
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pathogenesis (Fedorka-Cray et al.. 1994). Other Gram-negative bacteria, such as
Escherichia coli. also produce endotoxin. Lipopolysaccharides have been shown to
induce TN F-a and other inflammatory cytokines which altered pharmacokinetic
parameters. Endotoxin down-regulated cytochrome P450 and decreased hepatic
microsomal enzyme activities. Furthermore, endotoxin stimulated transmembrane Larginine transport in pulmonary endothelial cells (Cendan et al.. 1995).
Lipopolysaccharide stimulation of plasmal membrane L-arginine transport was
mediated via an autocrine loop involving TNF-a and IL-1. The marked increase in
carrier mediated L-arginine transport activity produced by LPS. IL-1 and TN F-a may
represent an adaptive response by pulmonary endothelium to support argininedependent biosynthetic pathways during sepsis. Lipopolysaccharide stimulation of
arginine transport was partially mediated through an autocrine mechanism that involves
IL-1 and TNF.
Definitive studies showing that cytokines affect P450 mediated reaction in food
and companion animals are lacking. Past research concentrated on viral or bacterial
infection and vaccinations to achieve changes in drug metabolism in domestic animals
(Beadle et al.. 1989; Short. 1986). For example, a soft tissue infection model was
created in horses by infecting subcutaneous tissue chambers with Streptococcus
zooepidemicus organisms (Beadle et al.. 1989). The horses were treated with cephapirin
which decreased systemic neutrophilia, pyrexia, anemia and chamber bacterial counts.
Cephapirin failed to eliminate the infection in the tissue chambers. Another
subcutaneous tissue chamber model was designed to study the interaction o f Pasteurella
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hemolytica. sulfadiazine/trimethoprim and bovine viral diarrhea virus in calves (Clarke
et al.. 1989b). Bacteria were not cleared from the tissue chambers, despite exceeding
the in vitro minimum bactericidal antimicrobial concentration in the chamber. The lack
o f antimicrobial effectiveness was related to decreased pH and increased protein
concentrations in chamber fluids after inoculation. Infection with bovine viral diarrhea
virus had no effect on the Pasteurella hemolytica response to sulfadiazine/trimethoprim
antimicrobial therapy. Bovine viral diarrhea virus was thought to suppress host
responses to inflammation (Clarke et al.. 1989b).
Another tissue cham ber study explored the effect o f infection on the distribution
o f sulfadiazine and trimethoprim in cattle (Clarke et al.. 1989a). Increased total serum
protein and albumin concentrations, decreased pH. distention o f blood vessels and
erosion o f surface capillaries were associated with marked increase in the penetration o f
sulfadiazine and trimethoprim into infected tissue chambers compared to non-infected
chambers. A concurrent increase in the apparent volume o f distribution for sulfadiazine
and trimethoprim was associated with increased tissue penetration (Clarke et al..
1989a).
Naturally occurring diseases have provided much insight into the effects of
infection on pharmacokinetic parameters, but were difficult to control to insure
reproducibility between groups. Theophylline pharmacokinetic parameters were
unaltered in horses vaccinated with killed equine influenza vaccine (Short et al.. 1979).
This apparent contradiction to the previously mentioned studies may be explained by
vaccination failure with no measurable antibody titer or the failure to induce appropriate
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cytokines that would cause pharmacokinetic changes to include down-regulation of
cytochrome P450. The APP infection model was developed as an experimental
respiratory disease model (Baarsch et al.. 1995: et al.. I995a.b). The Baarsch model
was standardized by optical density readings, while the Netherlands model was
standardized by plating serial dilutions in order to obtain the correct bacterial
concentration.
An in vitro study was conducted to determine the effect of APP infection on
Phase I and Phase II hepatic microsomal enzymes in castrated pigs (barrows)
(Monshouwer et al.. 1995b). Actinobacilluspleuropneumonicie infection produced
significant suppression o f 33% or more of all oxidative activities after 24 h post
infection. All glucuonyltransferase activities were unaffected by APP infection after 24
and 40 hours. To further clarify the mechanism o f oxidative suppression of enzyme
activities. mRNA analysis were performed by dot blot using a human cytochrome
P450IIIA4 cDNA probe (Monshouwer et al.. 1995b). Infection with APP seemed to
reduce P450iIIA activity associated with in vitro reduction of 6P-hydroxyIation of
testosterone, aniline hydroxylation. ethoxyresorufin O-deethylation and
pentoxyresorufin O-depentylation enzyme activities. While these results were
interesting, the suppression o f model oxidative reactions may not be indicative of
effects with a therapeutic drug. Furthermore, the use of dot blots to measure total RNA
may not be as accurate as Northern blots. In another study, the effect o f bacterial acutephase response model was investigated in vivo. Plasma clearances o f antipvrine.
caffeine, paracetamol and indocyanine green were measured in healthy and APP
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infected pigs (Monshouwer et al., 1995a). The most meaningful change was
suppression o f oxidative hepatic biotransformation during the acute-phase response
elicited by APP. Again, the study predicted the fate o f a model drug rather than verify
the fate o f a pharmaceutical.
In one study, endotoxin was non-selective in down-regulating cytochrome P450
metabolism and depressed different forms o f several P450's (Monshouwer et al..
1996a), while a separate study indicated that endotoxin was isoform specific (Dr.
Michael Myers, unpublished). Another report compared the endotoxin model to an APP
infection model in swine (Monshouwer et al.. I995a.b. 1996a). The lipopolvsaccharide
model showed a close similarity to the APP infection model based on the large decrease
o f antipyrine plasma clearance. Total cytochrome P450 content and microsomal P450
enzyme activities were also decreased 24 h after LPS administration. In swine,
endotoxin decreased the activities o f ethoxyresorufin O-deethyiase. caffeine 3demethylase and testosterone 6p-hydroxyIase which corresponded to rat P4501A1,
P450IA2 and P450IIIA. respectively. The decreased enzyme activities were
accompanied by a corresponding decrease in P450IA and P450IIIA apoprotein
concentrations. In rats and mice, all constitutive P450 isoforms were down-regulated by
LPS (Chen et al.. 1992: Ferrari et al., 1993a; Morgan. 1993). Western blots were
performed on P450IA and IIIA. The representative control and treated animals had
nearly equal band widths in the representative Western blots, which may be interpreted
that their was no difference between controls and treated pigs.
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Growing swine (35 kg) and finishing swine (85 kg) received intravenous
endotoxin (2 or 20 (ig/kg) 24 h prior to harvesting the livers. Western blots o f
constitutive P450 showed that endotoxin had no effect on the concentrations o f P450IIE
or IIIA (Dr. Michael Myers, unpublished). The relative concentrations o f P450IA2 and
IID6 were unaffected in finishing swine, but were reduced or absent in growing animals.
Endotoxin challenge completely eliminated detectable cytochrome P450IIA6 and IIB2
in growing and finishing swine. Endotoxin also eliminated cytochrome P450IA2 and
reduced the level o f IID6 in growing swine. Growing swine had less ethoxyresorufinO-deethylase and coumarin-O-dealkylase than finishing swine and these changes were
independent of endotoxin dose. Therefore, it was concluded that: cytochrome P450
expression in swine was dependent upon the age o f the animal: cytochrome P450's was
not universally down-regulated by endotoxin administration in swine; and. results from
growing animais may not adequately explain the metabolic fate of drugs in finishing
swine.
Enrofloxacin
Enrofloxacin. a fluoroquinolone antibiotic, was chosen to assess the influence of
infection on metabolism, for these primary reasons: First, it was very effective in
treating porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae
(Gutierrez et al.. 1993). Forty-two antimicrobial agents were tested in 57 field strains of
Actinobacillus pleuropneumoniae. The in vitro susceptibility of 839 isolates o f
Actinobacillus pleuropneumoniae showed that danofloxacin had high potency over
other less effective antimicrobials (Raemdonck et al.. 1994). Cephalosporins and
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quinolones (ciprofloxacin, enrofloxacin and sparfloxacin) were the most active
antibiotics for treating porcine pleuropneumonia. Enrofloxacin fed in the diet (150
mg/kg) produced a marked control of Actinobacillus pleuropneumoniae infection with
reduction o f the severity o f thoracic lesions and a reduced prevalence o f the organism in
the lung at necropsy (Smith et al.. 1991). In a Japanese study, enrofloxacin and
orbifloxacin were effective when administered subcutaneously. intramuscularly or
orally administered to swine for pneumonia due to Actinobacillus pleuropneumoniae
(Nakamura. 1995). In other countries, comparison o f minimum inhibitory
concentrations tested the effectiveness of 12 antimicrobial agents on swine pathogens,
including Actinobacillus pleuropneumoniae. in the United States. Canada and Denmark
(Salmon et al.. 1995). Enrofloxacin had similar minimum inhibitory concentrations
from one country to another, but variations in the M IC 's of the remaining antimicrobial
agents were observed. Secondly, approval is being sought for the use o f
fluoroquinolones in food animals (Hannan et al.. 1989: fCung et al.. I993a.b). Thirdly,
enrofloxacin undergoes N-dealkylation of the ethyl group on the piperazinvl ring, which
serves as useful marker to determine the effect o f porcine Actinobacillus
pleuropneumoniae infection on metabolism. Presently, the most likely porcine
dealkylating P450 subfamily might be IIIA. Inhibitors o f IIIA included tiamulin,
SKF525A, cimetidine and ketoconazole in pig livers (Witkamp et al.. 1994). When
tiamulin was added to the incubation medium, the N-demethylation rate of
ethylmorphine and the hydroxylation of testosterone at the 6p- and 1la-positions were
strongly inhibited. The microsomal N-demethylation rate of erythromycin and the
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hydroxvlation o f testosterone at the 2P-position were inhibited to a lesser degree,
whereas the ethoxyresorufin-O-deethylation. aniline hydroxylation and testosterone
hydroxylations at the 15a- and 15p-positions were not affected by tiamulin. In the rat.
the IIIA subfamily was inducible by steroids (dexamethasone). macrolide antibiotics,
imidazole antifungals. clotrimazole and phenobarbital (Bachmann et al. 1992: Gonzalez.
1988; Watkins, 1990). Further support o f oxidative metabolism by P450IIIA was
presented in a study using APP (Monshouwer et al.. 1995b) where the effect o f APP
infection on both oxidative and conjugative microsomal enzyme activities was
investigated in castrated male commercial pigs. All oxidative enzyme activities were
suppressed by 33%. To further clarify the mechanism o f the suppression of oxidative
enzyme activities, analysis o f mRNA were conducted by dot blot analysis using a
human cytochrome P450IIIA4 cDNA probe. The reduction in cytochrome P450IIIA
activity, specific for 6a-hydroxyIation of testosterone, was postulated to be at a pretranslational level, as measured by a decrease in the amount o f mRNA. Flavincontaining monooxygenases (FMO) are more likely than heme-protein P450s to be
involved in N-oxidation and N-dealkvlation o f enrofloxacin. but absolute proof is
lacking in swine (Sorgel, 1989). Although, the specific isozyme for the dealkylation is
unknown, the biotransformation of enrofloxacin to ciprofloxacin may be decreased by
down-regulation of P450 due to APP infection or endotoxin in this study.
In the past, there has been widespread extra-label use of fluoroquinolones in
food animals and enrofloxacin, norfloxacin and ciprofloxacin were the ones most
frequently used in veterinary medicine. Fluoroquinolones have been used, in an extra-
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label manner, by veterinarians to treat swine enteric infection, enzoonotic pneumonia,
septicemia, mastitis-metritis-agalactia and pleuropneumonia (Guitterrez et al.. 1993:
Kung et al.. 1993a.b). However, the extra-label use o f fluoroquinolones in food animals
was banned in 1997 by the United States Food and Drug Administration. Therapeutic
use o f approved fluoroquinolones in non-food animals was not affected by the ban.
Rationale
The hypothesis o f this investigation is: infection with APP or endotoxin
administration may alter enrofloxacin pharmacokinetic parameters. Therefore, a
combination of one or more o f the following five conclusions are possible: 1) In
domestic animals, pharmacokinetic studies have historically been conducted in healthy
animals, while efficacy studies are conducted in diseased animals. However, infected
animals may have altered pharmacokinetic parameters when compared to normal
animals. 2) Target animal safety problems could arise in drug development and
approval whereby therapeutic doses are actually toxic. 3) Conversely, increased rate of
clearance could indicate a need for more frequent dosing. Previously effective doses
may not be adequate to treat an infected animal. 4) Human food safety is an important
concern. Potential reductions in therapeutic drug clearance in food animals would result
in elevated residues concentrations even after a proper withdrawal period. Withdrawal
times are derived from non-infected animals. The purpose o f the present study was to
determine if the pharmacokinetic parameters of a therapeutic drug (enrofloxacin) are
altered by APP infection and pleuropneumonia in swine. 5) Infection with APP does
not alter pharmacokinetic parameters.
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This study was designed to demonstrate that pharmacokinetic alterations can be
induced by a specific disease, porcine pleuropneumonia, coupled with a specific
antibiotic, enrofloxacin. in swine. Other investigators have approached this question,
but have not strongly connected a natural disease with a therapeutic drug to demonstrate
altered pharmacokinetic parameters.
Few studies have explored the possibility o f altered pharmacokinetic parameters
in infected domestic animals. An Actinobacillus pleuropneumoniae infection model has
been used, but it is a different serotype (9) than the United States field serotype (1) used
in this study (Monshouwer et al., 1995a;b). The virulence may vary between the strains
and influence the experimental results. Variation in virulence may mean a variation in
bacterial toxins which may directly relate to the amount of P450 down-regulation and
the suppression o f metabolism. The use o f in vitro methods or classic substrates to
explore pharmacokinetic changes can not accurately predict real world pharmacokinetic
parameters without using a specific pharmaceutical, test species and microbial disease.
Dot blot analysis is a good screening tool, but can not compare to the specific molecular
weight controls o f the protein and mRNA bands found in Western and Northern blots.
Large doses o f endotoxin were administered in the endotoxin study (Monshouwer et al.,
1996a). However, a single dose of 20 pg/kg o f endotoxin was nearly lethal to swine
while five doses o f 17 pg/kg at 1 hour (hr) intervals was not lethal in separate study
(Monshouw'er et al.. 1995a; Myers et al., 1997). A single dose of 17 ug/kg LPS should
desensitize hepatic microsomal enzymes and create a maximum reduction o f
metabolism (Dr. Michael Myers, unpublished). Furthermore, the results were related to
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the weight o f the pig; growing pigs respond differently to LPS than finishing pigs (Dr.
Michael Myers, unpublished). High doses o f LPS should reduce some cytochrome
P450 activity to undetectable levels.
On one hand, cytochrome P450IIIA is an important constitutive enzyme in the
pig and total cytochrome P450 content was decreased in infected pigs (Monshouwer et
al.. 1995b). On the other hand. LPS down-regulation is selective for IIA6 and IIB2. but
there is no effect on IIE and IIIA (Dr. Michael Myers, unpublished). In the dot-blot.
two control and two infected animals were used to show that mRNA was reduced in the
treated pigs (Monshouwer et al.. 1995b). Measurement o f protein by Western and
Northern blots would be more direct and reflect a more accurate picture of P450 status.
Unfortunately, there is no statistical analysis o f variability between the control and
treated animals. The dot blot of total mRNA revealed visual differences in the size and
intensity o f the blot between control and treated pigs. In a group o f 23 normal pigs, the
amount of several cytochrome P450's varied by as much as 6 fold for IIIA (Dr. Michael
Myers, unpublished). The mean differences in enzyme activities were real, but within
normal variability with no statistical differences among the 23 control pigs (Dr. Michael
Myers, unpublished). The Western blot in the endotoxin study requires careful
interpretation, when the two control pigs were compared to the two LPS treated pigs
(Monshouwer et al., 1995b). Cytochrome P450IA and IIIA were decreased, but the
width of the protein bands in the photograph were almost identical. These studies with
dot blots fall short without specific P450 probes that target purified proteins (controls)
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and use too few animals to allow for adequate quantitative and statistical analysis
pertaining to dot and Western blots.
Therefore, this study has four objectives to: I) to determine whether endotoxin
administration will serve as an acceptable model for Actionobacillus pleuropneumoniae
and other Gram-negative pathogens: 2) determine whether infection with APP alters the
disposition kinetics and urinary- metabolite profile of enrofloxacin: 3) determine whether
the potential inhibition o f enrofloxacin metabolism is associated with specific
cytochrome P450 isozymes; and 4) compare the endotoxin exposure with the porcine
Actinobacillus pleuropneumoniae infection model.
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CHAPTER I
LITERATURE REVIEW
Cytochrome P450 Inhibition
History
Agents that inhibited reticuloendothelial system (RES) phagocytosis also
prolonged the sleep-times of sodium pentobarbital anesthesia (Samaras & Dietz. 1953).
Additional research by other investigators showed that increased RES phagocytosis
increased the barbiturate sleep-times during anesthesia (Di Carlo et al.. 1965; Wooles &
Borzelleca. 1966; Wooles & Munson. 1971). Sleep-times were used as an indirect
measure of hepatic microsomal activity and drug metabolism in vivo. This dilemma
was solved by demonstrating that prolonged barbiturate sleep-time was directly related
to the depression of the microsomes and was independent o f activation o f RESmediated phagocytosis (Wooles & Munson. 1971). Treated animals had abnormal
sleep-times lasting 10 days after administration of an RES inhibitor which meant that
the effect of the activating agents was long-lasting (Wooles & Munson. 1971).
Zymosan was one of the agents that enhanced phagocytic activity and depressed several
drug metabolizing enzymes; aminopyrine-N-demethvlase. /?-nitroanisole Odemethylase and aniline hydroxylase in both male and female mice (Hojo et al.. 1976).
The effect on enzyme activities was also long-lasting (7 days) after exposure to
zymosan.
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Cytokines as effectors in the acute-phase response
Infections are clinically manifested by stimulation of RES activity and other
components o f the immune system such as pro-inflammatory cytokines (Myers and
Kavvalek. 1995: Whicher & Evans, 1990). The source of infection should be irrelevant
and infection should depress levels and activities o f drug-metabolizing enzymes after
the release o f cytokines in the acute-phase response (Myers and Kavvalek. 1995).
Therefore, infections are well-known inducers o f the acute-phase response
(Monshouwer. 1996). The acute-phase response is characterized by an initial local
reaction at the site o f injury and a subsequent systemic reaction (Kushner. 1982: van
Miert. 1995: Monshouwer et al., 1995a.b. 1996a). After tissue injury, infection,
inflammation, neoplastic proliferation, or immunological disorders, the local reaction
consists o f processes such as platelet aggregation, increased vascular permeability and
activation and accumulation o f granulocytes and mononuclear cells. The systemic
reaction consists o f fever, anorexia, leukocytosis, inhibition of gastric emptying,
increased endocrine hormone release and alterations in plasma cation concentration. In
a classical sense, the acute-phase response infers fluctuations of plasma protein
concentrations at different rates and to different degrees (Gitlin & Colten. 1987).
Elevated acute-phase proteins include: serum amyloid A. fibrinogen, haptoglobin. Creactive protein and a,-acid glycoprotein (Heinrich et al., 1990; Kushner &
Mackiewicz. 1993). Albumin and transferrin plasma concentrations diminish during the
acute-phase response and are "negative" acute-phase proteins. Acute-phase proteins are
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mostly synthesized in the liver and aid in the defense against the causes o f tissue
damage and infection (Volanakis. 1993).
Activated immune cells secrete cytokines that have a complex role in the acutephase response (Monshouwer 1996). Cytokines are peptides or glycoproteins weighing
from 6 to 60 kiloDaltons (kDa) that act in a non-enzymatic. hormone-like fashion as
intercellular messengers (Richards et al.. 1995). Cytokines act on a variety o f tissues
and a single cytokine can be released by multiple cell types (Richards et al.. 1995).
These proteins act in an autocrine or paracrine manner, but they may act systemically in
an endocrine manner. High affinity for receptors accounts for their potency
(Monshouwer et al.. 1996b). Over 80 cytokines are known to have a wide variety o f
functions, but mainly stimulate growth and differentiation. Every cell type expresses
multiple receptors and responds to many cytokines, which makes it impossible to assign
unique biological activities. Furthermore, a particular cytokine may have multiple
biological effects with other cytokines so that there is substantial redundancy in their
mode o f actions (Paul. 1989).
Pro-inflammatory cytokines and infection
Acute-phase responses are readily induced by infection. Pro-inflammatory
cytokines, such as T N F -a. IL-1. IL-6 and the interferons have important roles in
response to infections by the host (Whicher & Evans. 1990a). In animals and humans.
TNF-a is one o f the first cytokines to appear after release as an initial burst (Beutler et
al.. 1985). Generally, peak systemic concentrations were reached one to two hours after
induction. Interleukin-1 is released after TN F-a and before IL-6 (Fong et al.. 1989).
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Interleukin-6 is released as a secondary burst about one hour after TN F-a and it
gradually rises for several hours (Fong et al.. 1989; Schalaby et al.. 1989; Van Deventer
et al.. 1990).
The sequential release o f TN F-a. IL.-1 and IL-6 is a common response to Gramnegative bacteria, such as Escherichia. Actinobacillus and Pasteurella species. Species
differences account for many variations to the cytokine cascade, but variations were also
due to the character and timing o f the stimulatory agent (Monshouwer. 1996). For
example, interferons are the main cytokine in the acute-phase response induced by viral
infection, because patients with confirmed viral infections have significantly increased
INF serum concentrations (Joklik. 1990). Endotoxins (lipopolysaccharide) or poly IC
are inflammatory stimuli that induce the cytokine cascade. Lipopolysaccharide induces
TNF-a. while poly IC is a potent IFN -a/p inducer.
Cytokines
Tumor Necrosis Factor
History
Tumor necrosis factor -a (TN F-a) can alter physiological and immunological
events as well as induce pathophysiological responses o f several disease conditions
(Myers & Murtaugh. 1995). Tumor necrosis factor has a wide spectrum of physiologic
functions; mediates hemorrhagic necrosis in tumors, wasting in chronic disease,
stimulates release of platelet activating factor, activates hepatocytes. increases IL-6
synthesis and recruits immune and non-immune cells (Edwards et al.. 1994). Usually,
tumor necrosis factor is released from macrophages and monocytes as a proximal-
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mediator before the release IL-1 and IL-6 in septic shock. Endotoxin increases serum
TNF-a concentrations by enhancing TNF-a gene transcription approximately 10-fold,
cellular TNF-a mRNA 100-fold and a 10.000-fold increase in the quantity o f protein
secreted from activated monocytes.
Early investigators observed that Trypanosoma hrucei infection caused a marked
hypertriglyceridemia along with anorexia and wasting diathesis. At first, the condition
was attributed to deficiency of lipoprotein lipase (Kawakami & Cerami. 1981; Rouzer
& Cerami. 1980). Production of the active factor was induced by endotoxin in sensitive
mice, but was not induced in endotoxin resistant mice. Serum from sensitive mice that
had been treated with endotoxin induced the wasting syndrome in resistant mice
(Kawakami & Cerami. 1981). This factor was called cachectin. In orally fed animals,
infusion o f cachectin/tumor necrosis factor-a caused weight loss and muscular wasting,
accompanied by anorexia (Matsui et al.. 1993). Despite muscle wasting, there were
gains in weight, protein and DNA contents of the viscera, but no significant metabolic
abnormalities. Oral feeding prevented loss of body weight, but cachectin-treated
animals had reduced nitrogen retention and carcass weight. By contrast, there were
gains in visceral protein concentrations, which in the liver was due to a marked
proliferation o f biliary epithelium. In addition, cachectin-treated animals receiving feed
developed hyperglycemia, hyperosmolality, diuresis, dehydration, azotemia and
cholestasis. In the absence o f the effects o f anorexia, cachectin reduced nitrogen
retention and caused metabolic and multisystem dysfunction, comparable with the
effects o f clinical sepsis.
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At the turn of the century, it was noted that some tumors underwent hemorrhagic
necrosis following streptococcal infection (Kawakami & Cerami. 1981). The necrosis
was caused by TN F-a and not a bacterial component. The serum factor inducing
hemorrhagic necrosis o f transplantable tumors (TNF) and the macrophage hormone
associated with cachexia in cancer and certain infectious diseases were shown to be the
same protein, cachectin (Mullin & Snock. 1990). Because an association may exist
between TNF-a and the cachectic state, the effect o f TN F-a on the permeability of
epithelial barriers was evaluated. Tumor necrosis factor was shown to affect the tight
junctional region between epithelial cells, lowered the transepithelial resistance and
potential difference and increased the flow of solute between cells and across the
epithelium. These effects were dose dependent, rapidly reversible and inhibited by a
monoclonal antibody to TNF-a. This suggested that the release o f TN F-a at various
sites throughout the body produced a general breakdown in the barrier function of an
epithelial cell sheet (Mullin & Snock, 1990). Furthermore, the breakdown of the
epithelial barrier may not only explain cachexia in cancer and chronic infections, but it
may also explain hemorrhagic necrosis of some tumors.
A selective inhibitor o f TNF-a synthesis is pentoxify lline (Strieter et al., 1988).
Pentoxifylline is a methylxanthine derivative that inhibits phosphodiesterases. The
subsequent increase in cAMP blocks accumulation o f TN F-a mRNA by decreasing the
rate o f transcription, but has no effect on transitional derepression (Han et al., 1990b:
Noel et al., 1990; Schonharting & Schade. 1989). Pentoxifylline has proven to be too
toxic for practical use in swine (Dr. Michael Myers, personal communication from Dr.
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Michael Murtaugh). Other methylxanthines suppress TNF-a synthesis: theophylline,
theobromide. isobutyl methylxanthine (Strieter et al., 1988). These compounds were
nearly as effective, but molar concentrations were 2 to 5 times greater than
pentoxifylline. Prostaglandin E2. misprostel. ciprofloxacin and phenylcyclopentenone
were other agents that increase cyclic AMP, inhibit accumulation o f T N F-a mRNA and
prevent TN F-a production in monocytes, macrophages and lymphocytes (Edwards et
al.. 1994: Kunkel et al., 1988: Mahatana et al., 1991). Inhibition o f TN F-a may impact
other cytokines, as TN F-a induces the production and release of IL-l and IL-6.
Dexamethasone and other glucocorticoids inhibit TN F-a mRNA accumulation
(Beutler et al., 1986; Han et al.. 1990b; Luedke & Cerami. 1990). Dexamethasone may
alter TN F-a mRNA concentrations by inhibiting early transduction o f proteins, but it
only inhibits T N F -a if present prior to endotoxin injection. Therefore, dexamethasone
is of limited benefit during septic shock.
Tumor necrosis factor and interleukin-1 in endotoxemia and sepsis
Tumor necrosis factor has immunological, hematopoeitic. cell differentiation,
reproduction, antiviral and endotoxic/septic shock effects (Myers & Murtaugh. 1995).
Tumor necrosis factor, in high doses, produces a variety o f systemic endotoxic/septic
shock effects to include; hemodynamic, pulmonary, metabolic and pathological events
(Tracey. 1991). Chronic TN F-a exposure leads to cachexia that was characterized by
weight loss, protein and lipid depletion and anorexia. Chronic TNF-a administration
directly affects the hypothalamus to induce fever and the release of corticotropinreleasing-factor (Martin & Tracey. 1991). Depletion of body fat. induction o f insulin
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resistance in adipocytes and decreased resting membrane potentials in myocytes are
direct effects (Goldblum et al.. 1989: Kiorpes et al.. 1990; Parrilo. 1993; Stephens et al..
1988a). Anabolic responses of the liver were indirect effects which reflected a cascade
of cytokine and hormone responses that persist for hours after the TNF-a blood
concentrations have dissipated (Nemerson. 1992). The effects of intravenous bolus
injections of T N F -a and IL -ip on hepatic mitochondrial energy metabolism were
investigated in rats (Shimahara et al.. 1995). The administration of TNF-a and IL-1 (3 in
rats induced a hypermetabolic state in hepatic mitochondrial energy metabolism, which
was a pattern similar to sepsis and presumably a compensatory reaction to the increased
energy consumption
Actinobacillus and Pasteurella species are Gram-negative pathogens that
produce respiratory bacterial infections in animals (Kiorpes et al.. 1990). Subsequently,
the lung becomes septic with increased vascular permeability, edema, injury' to
endothelial cells and death o f the animal (Goldblum et al.. 1989; Stephens et al..
1988a). Mortality after sepsis was directly related to the induction of TNF-a and a
tissue factor which was an inducible cell surface glycoprotein (Henry & Moore. 1988;
Levi et a l. 1993; Nemerson. 1992: Parrilo. 1993; Taylor et al. 1991). Tumor necrosis
factor may cause systemic hypotension and altered cell metabolism, while tissue factor
expression results in a local blood coagulation at the inflammatory site and
systemically. Coagulation activation occurs through the expression of tissue factor on
the cell membrane surface o f circulating monocytes and tissue macrophages. Tumor
necrosis factor may shift the balance between procoagulant and anticoagulant activities
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by initiating the tissue factor pathway of blood coagulation (Aderka, 1991). The most
severe consequence o f the cascade was disseminated intravascular coagulopathy and a
rapid progression to death (Hoffman et al., 1990: Thomson et al.. 1974: Vestweber et
al.. 1983). Tumor necrosis factor mediation o f lung injury was induced by LPS in
sheep, dogs, cattle, goats and pigs (Baarsch et al.. 1995; Egawa et al.. 1981: Eichacker
et al., 1991; Fukushima et al., 1992: Gerros et al.. 1993; van Miert. 1990: van Miert et
al.. 1992; Redl et al., 1990; van Miert et al.. 1992). Psuedomonas aeruginosa and
Actinobacillus pleuropneumoniae have both been used in pigs to induce acute lung
injury in studies designed to measure pulmonary alveolar macrophage cytokines, effect
o f pulmonary infection on pharmacokinetic parameters and pulmonary dysfunction and
metabolic acidosis associated with Gam-negative sepsis (Baarsch et al.. 1995:
Monshouwer et al.. 1995a.b: Windsor et al.. 1994).
Previous studies demonstrated that the administration of the cytokines IL-1 and
TNF to rats in a fasting state can produce many and. if not most, of the metabolic
alterations found in patients with sepsis and injury (Ling et al.. 1995). Consequently,
another study was designed to define the metabolic effects o f IL-l and TNF-a during a
fed state by continuous intravenous feeding for 20 hours and to characterize the unique
effects of IL-1 among other cytokines by employing the IL-1 receptor antagonist. IL-ra
(5 mg/kg). The effects were also explored during the endotoxemic condition induced by
infusion of 200 fig/kg o f endotoxin in rats. The results showed that during feeding IL-1
was responsible for the increase of glucose flux and plasma insulin, the development of
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insulin resistance and plasma zinc depression. In other words, IL-1 initiated conditions
that mimicked sepsis and injury that were similar to events in the fasting state.
The changes in energy expenditure have a more complex mechanism. The
results suggested that certain host responses to cytokines or endotoxin, related to protein
metabolism, differ between the fed and fasting states. These data may have clinical
relevance for the insulin-resistant state that develops during severe infection, because
IL-1 receptor antagonists may be used in conjunction with nutritional therapy to offer
additional advantages in the treatment o f these drastic metabolic disorders.
Cytokines can be produced within the nervous system by various cell types,
including astrocytes, which secrete them in response to pathological processes such as
viral infections (Yu et al.. 1995). Astrocytes were known to play an important role in
the homeostasis of the nervous system by contributing to the regulation o f local energy
metabolism. Tumor necrosis factor-a and IL -la markedly stimulate glucose uptake and
phosphorylation in primary cultures of neonatal murine astrocytes. The effects of TNFa and IL -la on glucose uptake and phosphorylation may be mediated by the
phospholipase A2 signal transduction pathway. These results demonstrated that TNF-a
and IL -la can fundamentally perturb the energy metabolism of astrocytes, possibly
impairing their ability to provide adequate energy substrates for neurons.
Interleukin-1
History
Three different investigators identified IL -I. The first described a pyrogenic
factor (endogenous pyrogen) that was produced by activated peritoneal exudate cells
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(Heyman & Beeson. 1949). The second investigator described a factor that was
synthesized from activated mononuclear phagocytes and acted as a co-stimulator of
thymocyte proliferation, termed lymphocyte activating factor (Gery & Waksman. 1972:
Gery et al.. 1971). The third investigator described a soluble mediator, leukocyte
endogenous mediator, that regulated the acute-phase response (Kampschmidt. 1984).
The three biological factors were identified and the identical factors were given the
name, "interleukin-1” (Dinarello. 1984; Kampschmidt. 1984). Additional work
revealed that IL-1 was produced by every nucleated cell type if not most cells had IL-1
receptors on their surface (Dower & Urdal, 1987). Monocytes and macrophages were
stimulated to produce IL-l by lipopolysaccharide. interferon-y (INF-y). muranyl
dipeptide, microorganisms, poly IC and complement 5a.
Interleukin-1 in inflammation and host defense
Interleukin-1 is a key promoter o f inflammation. There are two forms of
interleukin-1: IL -la and IL-1 p. In humans, there was a difference in the time frame that
the two forms are produced; the a form was produced early and then the cell switched
to producing the p form (Dr. Michael Myers, personal communication). Even though
there was only a 16 to 20% homology between the two forms, they both bound to the
same Type I receptor (Bomsztyk et al., 1989; Horuk et al., 1989). There was also
binding to Type II receptors, but without initiating biological activity. Hence. IL-1 type
II receptors are also termed decoy receptors since they have no biological effects (Dr.
Michael Myers, personal communication). Adherence o f leukocytes to endothelial cells
and the degradation o f cartilage have been examined in detail. In bovine and porcine
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domestic species, IL-1 and other cytokines activate endothelial cells to express surface
molecules that implement the adhesion and extravasation of IL-1 activated neutrophils
(Canning & Baker. 1990; Goodman et al., 1991; Johnston et al., 1992; Modat et al.,
1990; Sample & Czuprynski. 1991; Zimmerman et al.. 1992). Interleukin-1 stimulates
collengenase production and proteoglycan degradation by cartilage explants in vitro
(Buideetal.. 1992; Conquer et al.. 1992; Mauviel et al.. 1988; Mori et al.. 1989). The
influence o f IL-l on cartilage degradation may be an important part o f the inflammatory
process in arthritic joints (Lederer & Czuprynski. 1995). Lyme disease patients and
rheumatoid arthritis patients have increased production of IL-1. which further supports
the role o f IL-l as a biological mediator in the pathology of arthritis (Beck et al.. 1989;
Smith et al.. 1989).
Most o f the literature on IL-1 comes from studies on mice and human cells.
Veterinary researchers must extrapolate from these studies to a particular species
(Lederer & Czuprynski. 1995). There was limited literature available on the biological
effects of IL-1 in cattle, pigs and chickens (Lederer & Czuprynski. 1995). Interleukinl a and IL-1(3 are natural porcine isoforms (Huether et al.. 1993; Maliszewski et al.,
1990). These bind with similar high affinity to porcine chondrocytes and synovial
fibroblasts (Bird & Saklatvala. 1986,1987). Up-regulation of IL-(3 mRNA was observed
for LPS. phorbol myristate acetate and TN F-a (Huether et al.. 1993). Dexamethasone
and IL-4 down-regulated mRNA transcription (Huether et al.. 1993). Interferon alone
did not induce release o f IL-1 activity in porcine monocytes, but IL-1 was increased by
co-stimulation with LPS (Cllarieys et al.. 1990).
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Porcine and human IL-1 have been shown to modulate a host of biological
responses by porcine cells in vitro. Human IL-1 inhibited proteogylcan synthesis
without stimulating its degradation by porcine cartilage explants (Nietfeld et al.. 1990).
Porcine IL -la decreased collagen synthesis by human rheumatoid synovial cells
(Mauviel et al.. 1988). Interleukin-1 inhibited progesterone secretion and increased the
growth o f high density cultures o f granulosa cells from small or medium sized ovarian
follicles, but had no effect on mature granulosa cells (Fukuoka et al., 1989). Little is
published on the effects o f IL-1 on porcine leukocytes. It is known that human IL -la
induced natural killer (NK) cell lysis of tumor cell targets (Knoblock & Canning. 1992).
Interleukin-6
History
Interleukin-6 is a pleiotropic molecule with notable purposes in inflammation,
hemopoiesis and lymphocyte activation and differentiation (Richards el al.. 1995).
Rodent models o f inflammation have provided in vivo information on the function o f
IL-6. but little data was available in most food-producing animals. Most of the
investigators have reported work completed in human, rodent and swine systems.
The first observations o f IL-6 effects occurred in 1921 when inflamed patients
yielded blood samples with high erythrocyte sedimentation rates. Erythrocyte
sedimentation rates are still used today as non-specific markers of inflammation. The
increased erythrocyte sedimentation rate w'as due to elevation of serum liver proteins.
Some o f these proteins were acute-phase proteins such as fibrinogen. Interleukin-6 w as
largely responsible for the induction of these proteins from the liver. Early studies that
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sought to isolate and identify IL-1 were obscured by the probable contamination of
samples with IL-6 and the induction o f IL-6 in vivo by crude preparations o f IL-1. It
was later determined that IL-I induced fever and the production o f liver acute-phase
proteins in rat models o f inflammation (Kampschmidt & Upchurch. 1974:
Kampschmidt et al., 1982). When monocyte or macrophage products were examined, it
was shown that IL-1 and TNF-a were not fully active (Gauldie et al., 1987b; Koj et al..
1984; Perlmutter et al., 1986). A distinct cytokine . termed hepatocyte stimulation
factor (HSF). was identified which induced a full spectrum o f hepatic acute-phase
responses (Bauer et al.. 1984; Baumann et al.. 1987a.b: Darlington et al.. 1986:
Goldman & Liu. 1987: Koj et al.. 1984; Ritchie & Fuller. 1983; Woloski & Fuller.
1985). The IL-6 molecule was purified and cloned and was subsequently proven to be a
potent molecule for regulating hepatocyte responses (Gauldie et al.. 1987a: Hirano et
al.. 1986).
Acute-phase protein production
It was suggested that mediators responsible for serum acute-phase proteins were
released by leukocytes at sites of inflammation (Koj, 1974). These mediators acted
systemically on lymphocytes. The primary role o f IL-6 in vivo was to initiate the
hepatic inflammatory response. Interleukin-6 serum assays o f animals undergoing an
inflammatory response revealed a peak concentration o f IL-6 at 6-12 h before peak
concentrations of serum acute-phase proteins (Gauldie et al.. 1992; Jablons et al., 1989;
Nijsten el al.. 1987; Schreiber. 1987; Schreiber et al.. 1989). The 6 to 12 h time lag
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reflected the time required to synthesize and release cytokines into the systemic
circulation, interact with hepatic receptors and stimulate hepatic synthesis and secretion.
Treatment with a single low dose (80 to 800 ng) o f IL-1 24 h before a lethal
bacterial challenge o f granulocytopenic and normal mice enhanced non-specific
resistance (Vogels et al.. 1993). Interleukin-1 induced secretion o f acute-phase proteins,
liver proteins w hich possess several detoxifying effects. The role o f these proteins in
the IL-1-induced protection was investigated. Inhibition o f liver protein synthesis with
D-galactosamine completely inhibited the IL-1-induced synthesis o f acute-phase
proteins. D-galactosamine pretreatment abolished the protective effect o f IL-1 on
survival completely in neutropenic mice infected with Pseudomonas aeruginosa or
partially in non-neutropenic mice infected with Klebsiella pneumoniae. Pretreatment
with IL-6. a cytokine induced by IL-1. did not reproduce the protection offered after IL1 pretreatment, nor did it enhance or deteriorate the IL-1-enhanced resistance against
infection. A protective effect o f IL-1 via effects on glucose homeostasis during the
acute-phase response was investigated by comparing plasma glucose concentrations in
IL-1-treated mice and control mice before and during infection. Although glucose
concentrations in IL-1-pretreated mice were somewhat higher in the later stages o f
infection, no significant differences from concentrations in control mice were present
and the glucose concentrations in control and treated animals never fell to hypoglycemic
values. Interleukin-1-induced non-specific resistance was mediated neither by the
induction o f IL-6 nor by the effects o f IL-1 on glucose homeostasis. Acute-phase

35

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

proteins generated after IL-1 pretreatment seem to play a critical role in the IL-linduced protection to infection.
Immune effects
Interleukin-6 is a multifunctional cytokine whose circulating concentrations are.
under physiological conditions, below detection, but whose production was rapidly and
strongly induced by several pathological and inflammatory stimuli (Poli et al.. 1994).
Interleukin-6 has been implicated in a number o f cell functions connected to immunity
and hematopoiesis. Cells o f the immune system that were affected by IL-6 were: B
lymphocytes, helper T lymphocytes, cytokine T lymphocytes and NK cells (van Snick.
1990). In vitro. B lymphocytes require IL-6 for late stage differentiation o f B cells
(Muraguchi et al.. 1988). Interleukin-6 augmented secondary antibody responses in
vivo (Takatsuki et al.. 1988). Interleukin-6 played a major role in the development of
antigen specific humoral responses, but there were no supporting experiments in foodproducing animals. Interleukin 6 may also synergize with IL-1 to regulate the initial Tcell activation (van Snick. 1990). Lastly. IL-6 may increase the lysing activity of
natural killer cells (Luger et al.. 1989).
Interleukin-6 deficient mice were unable to mount a normal inflammatory
response to localized tissue damage generated by turpentine injection (Fattori et al..
1994). The induction o f acute-phase proteins was dramatically reduced, mice did not
lose body weight and only suffered from mild anorexia and hypoglycemia. In contrast,
when systemic inflammation was elicited through the injection of bacterial
lipopolysaccharide. these parameters were altered to the same extent both in wild-type
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and IL-6-deficient mice, demonstrating that under these conditions IL-6 function was
dispensable. Moreover, LPS-treated IL-6-deficient mice produce three times more
TNF-a than wild-type controls, suggesting that increased TN F-a production might be
one o f the compensatory mechanisms through which a normal response to LPS was
achieved in the absence o f IL-6. Different patterns o f cytokines were involved in
systemic and localized tissue damage which identified IL-6 as an essential mediator of
the inflammatory response to localized inflammation. Interleukin-6 may regulate
(locally) bone turnover and are essential for the bone loss caused by estrogen deficiency
in mice (Poli et al.. 1994).
Changes in the parameters o f specific and non-specific immunity after challenge
o f the immunized animals with Marburg virus were characterized (Ignat'ev et al.. 1994).
Mediators o f the immune response. TNF-a and rNF. were shown to play different roles
in the development o f the disease and "protection" o f animals. The survival rate o f the
immunized animals after the challenge with Marburg virus was determined by the
intensity and level o f the immune response after challenge rather than by the
concentrations o f post-vaccination immunity at the time o f the challenge.
Hematopoiesis
Interleukin-6 interacted with IL-3 to enhance stem cell differentiation (Wong &
Clark. 1988). Strong inducing effects on megakaryocyte colony formation were
impressive (Akira et al.. 1990; Kishimoto. 1989). Interleukin-6 and IL-11 may have a
use in supporting cancer patients, but high concentrations o f IL-6 cause pathological
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increases in proliferation o f hematopoietic myeloid cell lineage on multiple myeloma
and Castleman's disease (Akira et al., 1990; Zhang et al.. 1990).
Anti-inflammatorv mediators
The initiation o f the acute-phase response by IL-6 has been well characterized
(Bauman & Gauldie. 1990; Gauldie, 1991; Koj. 1985; Richards & Gauldie. 1995;
Travis & Salvesen, 1983). On the other hand. IL-6 has been shown to inhibit the release
o f pro-inflammatory cytokines IL-1 and TN F-a from monocytes in vitro (Aderka et al..
1989; Mancilla et al., 1990). In vivo. LPS induced inflammation in the rat lung was
reduced by IL-6 (Guo et al., 1992; Ulich et a l , 1991). Interleukin-6 also inhibited joint
inflammation in a collagen-induced arthritis model (Ikuta et al.. 1991). Tissue
inhibition of metalloproteinases-1 was enhanced by IL-6. The balance o f
metalloproteinases and tissue inhibitors of metalloproteinases-1 help govern the net
catabolism of connective tissue matrices in normal physiological processes and in
pathological conditions involving joints and lungs (Lotz & Gueme. 1991).
Other systemic functions o f IL-6 in inflammation include actions in the brain.
Interleukin-6 was shown to enhance ACTH production in vitro and to increase ACTH
in serum of rats (Perlstein et al., 1993; Woloski et al.. 1985). These ACTH effects
probably cause increases in glucocorticoids in serum after inflammatory stimuli.
Increased glucocorticoids may modulate numerous functions such as decreased cytokine
production, suppression o f lymphocyte responses and enhancement of regulation of
various acute-phase protein genes (Richards et al., 1995). In addition. IL-6 has also
been shown to increase body temperature (Akira et al.. I990a.b). Thus, IL-6 has a
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major role in several aspects o f the systemic inflammatory response. Analysis of these
activities in mice, rats and rabbits and correlation with IL-6 levels in humans, suggest
that similar activities o f IL-6 may occur in pigs, cattle and poultry in vivo. However,
this has not been determined.
Xenobiotic Immunomodulation by Cytokines
Cytokines in acute and chronic disease
Interleukin-1. IL-6 and T N F -a act synergisticallv to induce fever, initiate acutephase protein synthesis, activate neutrophil and macrophage antimicrobial activity,
decrease serum iron and zinc concentrations and induce tissue catabolism (Dinarello.
1986; Hardie & Kruse-Elliot. 1990; Le & Vileck. 1987; Whicher & Evans. 1990b).
These were beneficial events in the formation o f an effective inflammatory and immune
response to invading microorganisms and in tumor surveillance. The inflammatory
reaction was beneficial for humans when its effects were limited to the pathogens
(Hakim. 1993). The insufficiency o f a component o f the inflammatory reaction such as
the production o f reactive oxygen species (ROS). which was seen in chronic
granulomatous disease, leads to severe and recurrent bacterial infections. In other
situations, inflammatory reactions were deleterious because they were directed against
normal tissues instead, or in addition to. pathogens.
In some instances, the behavior o f the phagocytes was modified, because they
have been primed by inflammatory molecules such as TNF, LPS. interleukins or
interferons. Priming often led to a decreased speed o f locomotion o f the leukocytes
with an increased susceptibility to their stimuli. The combination o f these effects leads
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to a premature release by the phagocytes o f their killing and degradative factors.
Production o f ROS such as that seen during irradiation, drug metabolism, or ischemia
followed by reperfusion induced inflammatory reactions with a secondary amplification
o f ROS production. Acute ROS production can also lead to thrombosis, whereas
chronic ROS production induced a chronic inflammatory reaction o f the endothelium
with atherosclerosis as a possible consequence. Reactive oxygen species may either
positively or negatively control the activity of inflammatory molecules. The
multiplicity o f the cross reactions between ROS and inflammation suggests a search for
new therapeutic drugs that disconnect these two events.
In contrast, pro-inflammatory cytokines also have adverse effects in both acute
and chronic diseases (Dinarello. 1986: Hardie & Kruse-Elliot. 1990: Lahdevirta et al..
1988: Le & Vileck. 1987; Morris & Moore. 1991; Sprouse et al.. 1987; Whicher &
Evans. 1990b). Tumor necrosis factor and IL-1 were involved in the induction o f shock
associated with Gram-negative sepsis, trauma and bums (Dinarello. 1991; Eichacker et
al.. 1991: Hardie & Kruse-Elliot. 1990: Tracey & Cerami. 1989; Whicher & Evans.
1990b). Pathogenic sequellae associated with IL-1 and TNF-a release included
hypotension, depressed myocardial function, vascular leakage, microvascular
thrombosis, tissue neutrophilic infiltration and necrosis and multiple organ failure.
Chronic production o f pro-inflammatory cytokines caused cachexia found in
inflammatory and neoplastic disorders (Bistrian et al.. 1992; Cotran. 1987; Grunfeld &
Feingold. 1992: Le & Vileck. 1987; Tracy & Cerami. 1992). The cachexia was a result
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o f increased oxidation o f amino acids, muscle proteolysis and accelerated synthesis of
acute-phase proteins in the liver.
Tumor necrosis factor and IL-1 were also involved in tissue injury associated
with inflammation through interaction with neutrophils and endothelial cells. (Cotran.
1987; Le & Vileck, 1987; Ward. 1991 a.b). Both cytokines sustain the mobilization of
mature neutrophils from bone marrow and activate the neutrophils. Exposure of
endothelial cells to TNF-a or IL-1 induced expression o f leukocyte adhesion molecules
and contact between endothelial cells and neutrophils exposes endothelial cells to toxic
oxygen radicals and proteases. Tumor necrosis factor and IL-1 enhanced the
susceptibility of endothelial cells to injury by increasing concentrations of xanthine
oxidase and iron inducing the generation o f oxygen radicals and promoted conversion
into intracellular hydroxyl radicals. Tumor necrosis factor and IL-1 increased the
amount and surface expression o f tissue factor by endothelial cells. Tissue factor
expression promoted thrombus formation at the site of inflammation and may play a
role in disseminated intravascular coagulopathies during shock and sepsis.
Acute inflammation is a natural response to tissue injury during sepsis.
Excessive tissue destruction, shock, multiple organ failure and death are deleterious
effects caused by pro-inflammatory cytokines. Therapeutic regimes to limit
inflammatory responses may be life saving if accompanied by an antibiotic.
Approaches to limit inflammation include: inducing neutropenia, blocking neutrophil
migration from the blood, antioxidants, iron chelators, antiproteases, inhibitors or
antagonists o f IL-1 and TN F-a and inhibitors of IL-1 and TN F-a production, inhibitors
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o f cyclooygenase isozymes (COX-1 and COX-2) (Cotran. 1987; Landoni & Lees. 1996;
Le & Vileck, 1987; Ward, 191a.b). Therapeutics, such as ibuprofen. which prevent
effector cells from reaching the site o f inflammation or which inhibit synthesis o f proinflammatory cytokines have the most promise for prevention o f tissue injury
(Eichacker et al.. 1992; Mullen et al., 1993; Nacy et al.. 1990; Stephens et al.. 1988b).
Pro-inflammatory cytokines regulate local inflammatory reactions, but may also
gain access to the circulation and evoke systemic effects known as the acute-phase
response (van Miert, 1995). A study was performed to improve the understanding of
the pathophysiology o f pro-inflammatory cytokines in ruminants using TNF-a. IL -la /p
and INF-a/y (van Miert. 1995). The following aspects were perceived from this study:
a) cytokine therapy given before or just after microbial challenge induces in vivo
antimicrobial activity, cytokines potentiate in vivo antimicrobial activity o f antibiotics:
b) cytokines may act as biological response modifiers for enhancing specific immunity
to vaccines and c) cytokines may affect drug absorption, disposition and metabolite
formation in disease states.
Cytokine therapy in conjunction with antibiotics was further explored in a study
using Staphylococcus aureus (Sanchez et al.. 1994a.b). A bovine blood
polymorphonuclear neutrophil system was used to determine the ability of cytokines,
alone or in combination with various antibiotics, to enhance the intracellular killing of
Staphylococcus aureus sequestered within these phagocytes. Pretreatment of blood
polymorphonuclear neutrophils with human recombinant TN F-a. bovine macrophage
supernatant TN F-a. or human recombinant IL -ip enhanced the killing of S. aureus by
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the phagocytes compared with that o f untreated polymorphonuclear neutrophils. This
enhancement was dose-dependent and required 30 minutes o f contact between the
cytokine and the blood polymorphonuclear neutrophils. However, mammary gland
polymorphonuclear neutrophils, macrophages and blood monocytes showed no
enhanced killing activity following pretreatment with TNF. Pretreatment of
polymorphonuclear neutrophils with TNF-a and subsequent exposure to various
antibiotics after infection with S. aureus enhanced intracellular bacterial killing by
certain antibiotics, including paldimycin. rifampin and ciprofloxacin, but not antibiotics
that do not normally kill intracellular S. aureus. Cytokine therapy may be a useful
adjunct to antibiotic therapy in the treatment o f bovine staphylococcal infection and
mastitis.
Tumor necrosis factor plays a central role in the initiation of inflammation and
inhibitors of T N F-a production would be a logical choice as inhibitors o f inflammation
(Cavaillon & Cavaillon. 1990). Production o f T N F-a can be blocked at two
pharmacological sites. The first site, blocked by drugs such as dexamethasone and
cyclosporin A. halted pre-translational derepression without significantly inhibiting
transcription (Han et al.. 1990a: Trinchieri. 1991: Weinberg et al., 1992). Blocking at
the second site for compounds that increased cAMP. such as pentoxifylline,
prostaglandin E2. forskolin and dibutyrl cAMP. prevented translation o f TN F-a (Han et
al.. 1990a: Trinchieri. 1991). Increased concentrations o f cyclic AMP blocked
accumulation of T N F -a mRNA. as cyclic AMP caused a decrease in the rate of
transcription (Han et al., 1990a; Noel et al.. 1990). It had no effect on post-
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transcriptional control o f mRNA. The mechanism for this effect was not clearly
defined, but may involve the retention o f a necessary transcription factor (NF- k P) in the
cytoplasm due to the phosphorylation o f an associated inhibitor protein (I- k P).
Blocking TN F-a mRNA by increasing cAM P concentrations may require more than a
therapeutic dose o f pentoxifylline. A pharmacological dose of pentoxifylline had no
protective effects on the acute-phase response reactions induced by a pyrogenic dose of
Escherichia coli LPS (van Duin et al., 1995). However, both dexamethasone which
blocks arachadonic acid release and cyclosporin A have been reported to prevent IL-1
production (Cavaillon & Cavaillon. 1990).
Chlorpromazine (CPZ) inhibited T N F-a production and protected against
endotoxic shock in mice (Menzozzi et al.. 1994). The effect of pretreatment with CPZ
(4 mgdcg intraperitoneally 30 min before endotoxin) was compared with dexamethasone
(3 mg/kg) after induction o f endotoxin-induced cytokines (IL -la. IL6. IL-10 and TNF)
in the serum o f mice. The inhibitory effect o f CPZ and dexamethasone on serum and
spleen-associated TN F-a release was studied. Induction of IL-1 and IL-6 was inhibited
by dexamethasone but not by CPZ. Dexamethasone did not affect IL -10. while CPZ
potentiated its induction. Chlorpromazine also inhibited spleen-associated TN F-a
induction in LPS-treated mice, suggesting an effect on the synthesis o f TNF.
Chlorpromazine inhibited TN F-a induction by Gram-positive bacteria (heat-killed
Staphylococcus epidermidis) and by anti-CD3 monoclonal antibodies. Intraperitoneal
administration o f CPZ also inhibited the induction o f brain-associated T N F -a induced
by intra-cerebroventricular injection o f LPS. Therefore. CPZ was a more specific
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inhibitor o f T N F -a production than dexamethasone. In particular. CPZ increased the
induction o f IL -10. which is a "protective" cytokine known to inhibit LPS toxicity and
TNF-a production. Chlorpromazine inhibited TN F-a production in vivo, irrespective of
the TN F-a stimulus used to induce TNF. Finally, dexamethasone can potentiate TNF-a
production when administered 24 h before LPS which is called "rebound'’. CPZ did not
induce the "rebound” effect o f dexamethasone when administered 24 h before LPS but
it did inhibit T N F -a production after 24 h . Chlorpromazine has potent
immunomodulatory effects in vivo: it induces humoral autoimmunity in up to 50% of
patients, inhibits delayed-type hypersensitivity reactions and suppresses lethal immune
hyperactivation in animal models of septic shock (Tarazona et al.. 1995). In an in vivo
model o f acute superantigen-driven immune activation, CPZ independently downregulated the production o f various T cell-derived cytokines (IL-2. IFN-y. IL-4. TN F-a
and GM-CSF) and up-regulated the secretion o f IL-10. The mechanism by which CPZ
and related drugs enhance humoral autoimmune reactions, block cellular immune
responses and prevent lethal septic shock in vivo may explain the mechanism o f action
of CPZ in endotoxic shock.
The effect o f different inhibitors o f cytochrome P450 on TNF-a production can
repress TN F-a production (Fantuzzi et al.. 1993). Metyrapone and SKF525A (100 and
50 mg/kg, i.p.. respectively) suppressed serum TN F-a induced by co-treatment with
LPS. (2.5 micrograms/mouse). Inhibition was independent of endogenous
corticosteroids since it was also observed in adrenalectomized mice. In vitro production
of TNF-a by endotoxin-stimulated human monocytes was also inhibited by metyrapone
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and SKF525A. Since lipoxygenase (LO) inhibitors also block T N F -a production and
metyrapone was reported to inhibit LO. it was suggested that inhibition by metyrapone
and SKF525A might be due to inhibition of either LO or a cytochrome P450 implicated
in the oxidation o f endogenous substrates involved in the inflammatory response.
Glucocorticoids
Dexamethasone and other glucocorticoids inhibited T N F-a mRNA
accumulation (Beutler et al.. 1986; Han et al.. 1990b; Luedke et al., 1990).
Dexamethasone was believed to alter TN F-a mRNA levels by inhibiting early
transduction proteins. This may explain why dexamethasone inhibited TNF-a
production only if present prior to administration of endotoxin. It also explains why
dexamethasone was o f limited benefit during septic shock. Thalidomide also
destabilized TNF-a mRNA and reduced its half-life from approximately 30 to 17 min.
The effect o f thalidomide was selective for TNF-a (Moreira et al., 1993). Its
mechanism of action was distinct from those o f the glucocorticoids and pentoxifylline,
thus accounting for the synergistic effects of these drugs.
Glucocorticoids acts both at the transcriptional and post-transcriptional level to
inhibit TNF-a synthesis (Han et al.. 1990a; Trinchieri. 1991). Endotoxin induced TNFa gene expression was associated with an increase in NF-kB nuclear factors binding kB
motifs. Tumor necrosis factor action was mediated through receptor signaling
pathways, as microinjection o f T N F-a into the cell has no effect (Niitsu et al.. 1985).
Tumor necrosis factor rapidly induced production of diacylglycerol (DAG) from
membrane phospholipids as a result o f activation of a phosphatidylcholine-specific
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phospholipase C (PC-PLC) following binding to the type I receptor. Diacylglycerol
formation did not result in changes in cellular Ca~+ or inositol trisphosphate (Shutze et
al.. 1991). Diacylglycerol produced by PC-PLC resulted in the activation o f two
additional signal pathways, protein kinase C (PK.C) and acidic sphingomyelinase which
breaks down cellular sphingomyelin to produce ceramide (Schutze et al.. 1992). Protein
kinase C triggered the activation of the proto-oncogenes c-myc. c-fos and c-jun.
The sphingomyelin/ceramide pathway functions to activate NF-kB. Activation
o f NF-kB resulted when the inhibitory subunit I-kB was released from the cytoplasmic
complex containing the p50 and p65 (rel A) subunits. This dimer was then translocated
to the nucleus. Ceramide produced from neutral sphingomyelinase also may activate
NF-kB (Yang et al.. 1993). Neutral sphingomyelin (SM) was directly activated by the
TNF-a receptor (Kim et al.. 1991). Neutral SM broke down membrane sphingomyelin
to ceramide. which activated a membrane-bound. 97 kDa-protein kinase. This activated
kinase then phosphorvlated substrates containing the m otif X-Ser/Thr-Pro-X which was
the consensus sequence for the action o f mitogen-activated protein (MAP) kinases.
Tumor necrosis factor binding resulted in the phosphory lation o f 42- and 44-kDa MAP
kinases (Vietor et al.. 1993: Raines et al.. 1993). Tumor necrosis factor activation of
the MAP kinases are responsible for production o f arachidonic acid through the
activation o f both a secreted phospholipase A2 (sPLA2) and a cellular phospholipase
A2 (cPLA 2 ) (Lin et al.. 1993: Hoek et al.. 1993). Arachidonic acid metabolites play a
role in the induction o f c-fos and cell cytotoxicity (Jones et al.. 1993: Chang et al..
1992; Reid et al.. 1991).
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Glucocorticoids strongly inhibited translational derepression of TN F-a (Han et
al.. 1990a). A highly conserved region in the 3* untranslated mRNA region may be
responsible for post-translational control. The 3' untranslated region contains the
(UUAU)n sequence common to many cytokine mRNAs. which may regulate messenger
RNA stability (Jongeneel, 1992). Stimuli that induced NF-kB translocation to the
nucleus and binding to the promoter region were potent inducers o f TNF. Endotoxin
was a strong inducer o f NF-kB in macrophages and phorbol mvristate acetate (PMA).
the classic inducer o f protein kinase C activity and TN F-a itself, also elicited the
appearance o f NF-kB in the nucleus. Various transactivator viral proteins, such as the
Taxi gene o f HTLV-I. activated the TNF-a promoter through the NF-kB enhancer
element (Albrecht et al.. 1992). These observations showed that the activation o f NFkB

was a major route by which TN F-a expression was induced in target cells. Since

NF-kB was a universal transcription factor and was activated by numerous conditions,
including bacterial products, viruses and their products, cytokines, mitogens and
physical and oxidative stresses, it was not surprising that expression of TNF-a has been
implicated in many physiological and pathophysiological processes (Baeuerle &
Henkel, 1994).
Another mechanism o f TN F-a suppression may be through lipocortin induced
inhibition o f phospholipase A2 (Goulding & Guyre. 1992). Many of the anti
inflammatory effects o f glucocorticoids were dependent on lipocortin 1 synthesis.
Lipocortin 1 is a calcium binding protein in the annexin family. Lipocortin inhibited
phopholipase A2 which resulted in decreased production o f platelet activating factor.
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leukotrienes and prostaglandins (Fradin et al., 1988). The binding of lipocortin to
neutrophils and monocytes reduced chemotaxis and attenuated the release o f oxygen
radicals and eicosanoids (Goulding & Guyre. 1992).
Efficacy of glucocorticoids in endotoxic shock
Synthetic glucocorticoids, such as dexamethasone and non-steriodal anti
inflammatory drugs, such as phenylbutazone, are often used as immunosuppressors in
veterinary practice (Bertini et al.. 1989; Edwards et al.. 1994). The scope o f treatment
extends from mild allergic reactions to septic shock. Glucocorticoids inhibit TN F-a
mRNA transcription and prevent translation when corticosteroids were administered
prior to LPS administration. A lag time is needed for blocking mRNA transcription and
translation. Cytokines. TN F-a in particular, may contribute to inflammation through
eicosanoid activation. Arachidonic acid metabolites seem to function as secondary
messengers to escalate the inflammatory processes. Pretreatment with the
cyclooxygenase inhibitor, ibuprofen. and other non-steriodal anti-inflammatory agents
prior to endotoxin exposure may dampen cytokine-mediated prostaglandin responses.
At the same time, negative feedback inhibition of cytokine production by prostaglandins
is also blocked. The specific actions of these therapeutic steroids and non-steroids on
cytokine mediated alteration in cytochrome P450 metabolism of antibiotics was
discovered in the present decade. Efficacy of the veterinary immunomodulators in
domestic animals has often been assumed, because o f extrapolation from human and rat
data (Myers & Kawalek. 1995).
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Dexamethasone attenuation of experimental endotoxin-induced acute respiratory
failure in pigs has been evaluated (Olson et al., 1988). Dexamethasone (5 mg/kg) was
given intravenously 18 and 1 hour before administration o f endotoxin. The
hemodynamic alterations attributed to endotoxin infusion were attenuated and
leukotriene B4 was blocked (Weiss. 1995). These preliminary data suggested that
modulation of inflammatory cytokines may be beneficial in attenuating acute infectious
pneumonia and septic and endotoxic shock. Perhaps combinations of drugs, such as a
phosphodiesterase inhibitor and a cvclooxygenase and/or lipoxygenase inhibitor may
prove to be effective.
Cytochrome P450 Subfamilies and Isozymes
Rat
The following cytochrome P450s subfamilies have been identified in the rat: IA.
11A. IIB, IIC. IID. HE. IIG. Ill A. IVA. IVB. IVF. VII. XIA. XIB. XVII. XIX and XXVII
(Nelson et al., 1993). Analysis o f interspecies differences o f P450 primary sequence
showed a strong evolutionary conservation of the mammalian IA genes (Wrighton &
Stevens. 1992). In the rat. IA1 was constitutively expressed at low levels in the liver
and in extrahepatic tissues, such as the lung (Ryan & Levin. 1990). After treatment
with polycyclic aromatic hydrocarbons (PAH), such as 3-methylcholanthrene. IA1
concentrations were increased by induction. The second gene of the P450IA subfamily
vvas IA2. which plays a major role in the rat with the bioactivation of a multitude of
carcinogens and mutagens (Guengerich. 1988: Nebert et al.. 1987).
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The P450IIA subfamily has been extensively studied in the rat. This subfamily
had three members (Gonzalez. 1988; Nebert et al.. 1991). The IIA1 isozyme was the
most extensively studied and was originally referred to as testosterone 7a-hydroxylase
(Ryan et al.. 1979). The second rat form was IIA2. Although it was highly related to
IA1 by amino acid sequence, it did not demonstrate the same degree of specificity with
respect to testosterone hydroxylation (Arlotto et al.. 1989). Furthermore. IIA1 and IIA2
were not expressed similarly in the untreated rat and were not induced by PAH (Arlotto
et al.. 1989: Ryan & Levin. 1990; Ryan et al.. 1979). The third rat IIA subfamily
member . IIA3 was expressed exclusively in the lung, where the concentrations of
mRNA encoding IIA3 were induced by 3-methylcholanthrene (Kimura et al.. 1989).
The P450I1B6 subfamily were the major forms o f P450 induced by
phenobarbital and the most widely studied in humans (Adesnik & Atchison. 1985: Ryan
& Levin. 1990). Phenobarbital induced IIB1 and IIB2 in the rat. where only IIB2 was
expressed in untreated rats (Adesnik & Atchison. 1985: Ryan & Levin. 1990). The
substrate specificity o f these two forms overlap, but the activity of IIB1 is greater than
IIB2 for the majority o f substrates (Guengerich et al.. 1982; Ryan & Levin. 1990).
Most o f the P450IIC subfamily was composed o f a large number of forms that
were historically referred to as the constitutive P450s (Ryan & Levin. 1990). This
designation includes most o f the rat forms that were expressed in a gender-specific
manner. As of 1992. seven rat IIC genes had been identified.
The HE subfamily is a very important metabolic system in regards to toxicology.
In the rat. the HE subfamily contains only one member. IIE 1 (Nerbert et al.. 1991).
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This P450 was unusual, because it was induced by many common small organic
molecules (Wrighton & Stevens, 1992). Furthermore. IIE2 often catalyzed the
conversion of numerous low molecular weight agents to metabolites that were more
chemically reactive than the parent compound. Therefore. IIE2 was first isolated as the
low Km N-nitrosodimethylamine N-demethylase. which was induced after treatment
with pvrazole, acetone, isoniazid, ketone, isopropanol and ethanol (Patten et al., 1986;
Ryan et al., 1985). Rat IIE1 was also induced by physiological status, such as fasting,
diabetes and obesity that result in accumulation of acetone or ketones. It has been
demonstrated that rat HE 1 was responsible for the metabolic activation o f a large
number o f halogenated toxins to include: carbon tetrachloride, enflurane. alcohols. Nnitrosodimethylamine. aniline, benzene, acetone and acetominophen.
The final P450 subfamily involved in hepatic drug metabolism is the IIIA
subfamily. The various members o f this subfamily have been widely studied, because
they were shown to be responsible for the metabolism o f clinically and toxicologically
important agents. The IIIA subfamily is inducible by steroids, macrolide antibiotics,
imidazole antifungals. clotrimazole and phenobarbital (Bachmann et al. 1992; Gonzalez.
1988: Watkins. 1990). Two genes were identified in the rat. IIIA 1 and IIIA2 (Hardwick
et al.. 1983; Gonzalez et al., 1986). However, it is important to know that various
purification procedures and immunochemical characterizations indicate that three or
four proteins may be present in the P450III family (Halpert. 1988: Hostetler et al., 1987:
Graves et al.. 1987). It was found that rat III Al was induced by glucocorticoids, such
as dexamethasone and was not expressed in untreated adult rats (Gonzalez et al.. 1986;
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Wright & Paine. 1994) On the other hand. IIIA2 was not induced by glucocorticoids
and was expressed only in adult male rats. Finally, both IIIA 1 and IIIA2 were induced
by phenobarbital (Gonzalez et al., 1986). These forms of rat P450 were specifically
responsible for erythromycin N-demethylation. steroid 6p-hydroxylation and the
formation o f a stable metabolic intermediate complex with triacetyloleandomycin
(Wrighton et al.. 1985; Sonderfan et al., 1987). The stable metabolic intermediate
complex with triacetyloleandomycin inhibited IIIA1 and IIIA2. Hepatocytes from
female rats lack P450IIIA2 (Fau et al., 1994). Hepatotoxicity due to flutamide. an
androgen, was lower in female rats than in male rats. Flutamide led to the covalent
binding o f reactive electrophilic metabolites in male rat hepatocyte proteins. The
female rat did not produce reactive electrophilic metabolites which resulted in lower
covalent binding to proteins. In a like manner, male rats had reduced covalent binding
and lactate dehydrogenase release from hepatocytes after piperonyl butoxide. a P450
inhibitor, administration. The toxicity in male rats was increased by P-naphthoflavone
which induces P450IA. It was concluded that flutamide was toxic to rat hepatocytes as
a result o f the P450-mediated (IIIA and IA) formation of electrophilic metabolites. To
date, much less is known about the regulation o f expression or substrate specificity o f
other rat IIIA subfamily members, as compared to humans.
Swine
The following cytochrome P450 families and subfamilies have been identified in
the pig: XIA1. XVII and XXIA1 (Nelson et al., 1993). Compared to the rat. swine
P450 subfamilies and isozymes have not been extensively studied (Axen et al., 1994).
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Therefore, there is very little published information concerning substrates, inducers and
inhibitors. A small number o f studies have appeared in the literature and seem to deal
primarily with the P450IIIA subfamily. One o f these studies investigated the
simultaneous use of the antibiotic, tiamulin, with certain ionophoric antibiotics
(monensin. salinomycin) which may give rise to a toxic interaction in pigs and poultry
(Witkamp et al.. 1994). The effects of tiamulin on hepatic cytochrome P450 activities
in vitro were tested using pig liver microsomes. When tiamulin was added to the
incubation medium, the N-demethvlation rate o f ethylmorphine and the hydroxylation
of testosterone at the 60- and 1 la-positions was strongly inhibited. Tiamulin inhibited
these activities more than SKF525A or cimetidine. but less than ketoconazole. The
microsomal N-demethylation rate o f erythromycin and the hydroxylation o f testosterone
at the 20-position were inhibited to a lesser degree, whereas the ethoxyresorufin-Odeethylation. aniline hydroxylation and testosterone hydroxylations at the 15a- and
150-positions were not affected by tiamulin. Complexation by tiamulin o f cytochrome
P450 resulting in a loss o f CO-binding capacity was not demonstrated. Thus, it was
suggested that a selective inhibition o f cytochrome P450 enzymes was present in pigs,
probably those belonging to the P450IIIA subfamily. The mechanism o f this interaction
was unclear. However, interactions between tiamulin and those veterinary drugs or
endogenous compounds which undergo oxidative metabolism by P450 enzymes must
be considered.
A second study involving P450IIIA was conducted (Monshouwer et al.. 1995b).
The effect o f APP infection on both Phase I (oxidative) and Phase II (conjugative)
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microsomal enzyme activities was investigated in castrated male conventional pigs.
After 24 h. Actinobacillus pleuropneumoniae infection resulted in a significant
suppression o f 33% or more o f all oxidative enzyme activities determined. After 40 h .
the activities were still suppressed, but did not differ from the results after 24 h . On the
contrary, all glucuronosyltransferase activities measured were not affected by APP
infection after both 24 and 40 h . To further clarify the mechanism of the suppression of
oxidative enzyme activities, analysis o f mRNA were conducted by dot-blot analysis
using a human cytochrome P450IIIA4 cDNA probe. The results indicated that APP
infection suppressed oxidative enzyme activities. The reduction in cytochrome
P450IIIA activity, specific for 6a-hydroxylation o f testosterone, was postulated to be at
a pre-translational level, as measured by a decrease in the amount o f mRNA.
In another study, a cytochrome P450XXVII catalyzing la-hydroxylation of 25hydroxyvitamin D3 was purified from pig liver mitochondria (Axen et al.. 1994). It
also catalyzed 27-hydroxylation o f 25-hydroxy vitamin D3 and 25-hydroxyIation of
vitamin D3. The ratio between the la -. 27- and 25-hydroxylase activities remained
essentially constant during the purification. This was an example of a constitutive P450
subfamily in porcine liver.
Cytokine Mechanism of Action on Cytochrome P450
Interferons
Interferon induction was thought to be the most likely suppresser of P450.
because all agents that induce INF. such as the antiviral drug tilorone. depressed mixedfunction oxidase (Leeson et al.. 1976: Renton & Mannering. 1976b). The down
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regulating effect o f 12 different INF inducing agents on P450 content and reactions
supported this hypothesis. Tilorone, Mengo RNA virus. Escherichia coli
lipopolysaccharide. B. pertussis vaccine, hepatic RNA, poly IC and statolon. from a
fungal mycophage. were tested. In addition to the interferons, these agents induced the
production and release o f several other cytokines: IL-1, IL-6 and TNF-a.
Testing of purified and hybrid interferons in mice showed that there was a
relationship between INF concentrations and changes in P450 activity and
concentrations (Ghezzi et al., 1986a.b). Interferons administered in vivo inhibited
microsomal metabolism, in vitro, o f benzo(a)pyrene. hexobarbital, 7-ethoxycoumarin.
benzamphetamine and zoxazolamine (Ghezzi et al.. 1986a.b.c). Murine in vivo and
human in vitro studies showed increased hexobarbital sleep-times and decreased
metabolism of antipyrine. p-nitroanisole. theophylline. 16P hydroxylation of
androstenedione and acetominophen (Craig et al.. 1989a; Franklin & Finkle. 1986;
Moochhala & Lee. 1991; Moore et al.. 1983;Okuno. 1990; Smith et al.. 1983; Taylor et
al.. 1985).
Interferon influenced constitutive P450 expression both at the steady state
mRNA and P450 apo-protein biosynthesis level (Craig et al.. 1990). Messenger RNA
concentrations were depressed 6-8 h after exposure to INF and reached maximum
suppression at 24 h post-treatment. Cytochrome P450 apo-protein did not diminish
until 8-12 h post-treatment. Reduced P450 mRNA mirrored decreased concentrations
o f hepatic P450 protein (Craig et al.. 1990; Morgan, 1989.1991; Stanley et al.. 1991).
In a more recent rat study, the response o f constitutive enzymes activities to down-
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regulation of INF was not influenced by any o f the induction protocol using
polyinsonoic acid-polycytidylic acid (Anari et al., 1995). The interferon inducers
depressed the constitutive and induced activities o f ethoxyresorufin O-deethylase.
benzyl-oxyresorufin O-dealkylase and p-nitrophenol hydroxyalse at all concentrations
of induction. Cytochrome P450 induction did not invariably confer resistance to
interferon-medicated down-regulation of the enzymes. Furthermore, the mechanism of
induction did not determine the response to INF. It was concluded that species and
duration or level o f induction were the major influences on the observed response of
P450 enzymes to INF down-regulation.
Interleukin-1, interleukin-6 and tumor necrosis factor-a
Interleukin-1. IL-6 and TNF-a are cytokines produced during an inflammatory
response, including endotoxin challenge (Bertini et al.. 1988.1989: Myers & Kawalek.
1995). Interferons. TN F-a and IL-6 all down-regulated P450 by affecting hepatic P450
concentrations and activity. Interferons are potent blockers o f P450 synthesis, but
definitive proof is lacking that interferons are the primary agents: they may even
enhance degradation o f P450s. Heat-stable LPS induced serum factor could also
depress P450 after heat-inactivation of all interferons (Egawa et al.. 1981). It was
decided that the heat-stable factor was not interferon which led to the discovery o f other
blockers of P450 synthesis. Dextran sulfate induced production o f a factor that
decreased hepatic P450 concentrations and inhibited in vitro aminopvrine and benzo(a)-pyrene metabolism (Peterson & Renton, 1986). The serum samples from the
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animals contained no detectable INF. The serum factor could have been a combination
o f IL-1. IL-6 and T N F -a (Myers & Kawalek, 1995).
More recent research suggests that IL-6 may have an inhibitory effect on
cytochrome P450IIIA and may alter drug metabolism (Liao et al., 1996). Cyclosporine
is a drug used to prevent rejection o f transplanted organs and is metabolized by
P450IIIA. Thus, the inhibitory effect o f IL-6 may alter cyclosporine concentrations
which, in turn, may increase its adverse effects, such as nephrotoxicity. Interleukin-6
was administered in vivo to rats, resulting in decreased steady state concentrations of
mRNA and apoprotein for P450 IIC12. microsomal ethylmorphine-N-demethvlase and
ethoxycoumarin-O-deethylase activities (Williams et al., 1991; Wright & Morgan.
1991).
IL-1 also depressed P450 by inhibiting gene expression (Myers & Murtaugh.
1995). Ethyoxycoumarin-O-deethylase activity decreased in microsomes from mice
treated in vivo with IL-1. but did not affect activity when added to microsomes from
untreated animals. In a study to compare cytokines, cultured rat hepatocytes were used
to measure the relative activities of human IL-6, IL-1 a and -P and INF-y (Clark et al..
1995. 1996). These cytokines were used to inhibit phenobarbital and/or 3methylcholanthrene induction of cytochrome P450IIB1. P450IIB2. P450IA1 and
P450IA2. All cytokines produced a concentration-dependent inhibition of
phenobarbital induction o f benzyloxyresorufin O-dealkylase activity. All cytokines
were less effective in inhibiting the 3-methylchoIanthrene induction of ethoxyresorufin
O-dealkylase. These results suggested that inducible isoforms of P450 differ in their
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susceptibility to regulation by cytokines. Cytokines possess differential activity to
inhibit the induction o f P450 isoforms, where IL-1 P and IL-6 were the most effective.
The mechanism for the inhibition o f drug-metabolizing enzymes by IL-1p was
investigated (Ferrari et al.. 1993a). Interleukin-1 treatment on various drugmetabolizing enzymes in male and female rats induced both cytochrome P450IIIA1
activity and protein in females. In males. IL-1 repressed P450IIIA2 activity without
decreasing the protein. Cytochrome P450IA1 activity was impaired in males, but was
retained after dexamethasone pretreatment. Interleukin-1 did not change P450IIB1/2
activity and protein, but counteracted their induction by dexamethasone. Uridine
diphospho-glucuronosyltransferase. P450IA2 (bilirubin), activity and its induction by
dexamethasone were not affected by IL-1 treatment. Both P450IIC11 and epoxide
hydrolase activities were repressed by IL-1 treatment, as well as dexamethasone
treatment. The incongruity between the variations o f the activities and the protein of
P450IIIA2 suggested a post-translational regulation. Interleukin-1 treatment mimics
glucocorticoid effects for P450IIC11. IIIA 1 and for microsomal epoxide hydrolase, but
not for P450IA1 and IIB1/2. Cytochrome P450IA1 was impaired in males, but its
activity was restored after dexamethasone pretreatment. Both P450IIC11 and epoxide
hydrolase activities were repressed by IL-1 treatment, but were not altered by
dexamethasone.
In a study using rat hepatocytes in primary culture. IL -1P strongly inhibited
basal ethoxyresorufin O-deethylase and pentoxyresorufin O-deethylase activities and
fully blocked their induction by pentobarbital in a dose-dependent relationship while IL-
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6 only slightly antagonized pentobarbital-induced pentoxyresorufin activity (AbdelRazzak et al., 1995). This demonstrated that IL-1 (3 can suppress basal P450 activities,
as well as pentobarbital-inducible expression o f five cytochrome P450 mRNA's in
cultured hepatocytes. A previous experiment provided the first demonstration that
various cytokines act directly on human hepatocytes to affect expression o f major P450
genes and that a wide range o f responses can be observed among the enzymes for a
given cytokine, suggesting that different regulatory mechanisms may be involved
(Abdel-Razzak et al., 1993).
Interleukin-1 triggered the down-regulation o f several hepatic cytochrome P450
gene products, but the cellular signaling pathways involved are not known (Chen et al..
1995). The role o f sphingomyelin hydrolysis to ceramide in the suppression of
P450IIC11. a major constitutive form of cytochrome P450. by IL-1 was examined.
Treatment of rat hepatocytes cultured on matrigel with IL -la caused a rapid turnover of
sphingomyelin and an increase in cellular ceramide. with no change in cellular
phosphatidylcholine. The ceramide was composed mainly o f a D-erythro-sphingosine
backbone, suggesting that it was derived from sphingolipid hydrolysis rather than from
increased de novo synthesis. Treatment o f the cells with either N-acetyl-D-erythrosphingosine (C2-ceramide) or bacterial sphingomyelinase suppressed the expression of
P450IIC11 and induced the expression of the interleukin-1-responsive a,-acid
glycoprotein mRNA. In contrast, the acute-phase gene p-fibrinogen. which was
induced by IL-6 but not by IL-1. did not respond to C2-ceramide. N-Acetyl-D-erythrosphinganine mimicked the effect of C2-ceramide on P450IIC11. but not on a,-acid
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glycoprotein expression. These results were consistent with a role for ceramide or a
related sphingolipid in mediating the down-regulation of P450IIC11. the induction of
a r acid glycoprotein and perhaps other cellular effects of IL -1 in hepatocytes.
Interleukin-1 is known to repress a number o f hepatic drug-metabolizing
enzymes in rats and humans (Parmentier et al.. 1993). The effect o f interleukin-ip on
lauric acid 12-hydroxylase (IVA family) was studied in cultured fetal rat hepatocytes
after clofibric acid induction. Dexamethasone was used as an agent promoting
differentiation and long-term maintenance o f active hepatocytes. Dexamethasone and
clofibric acid in combination allowed maximal (13.5-fold) induction o f IVA 1. Lauric
acid 12-hydroxylase activity was found to increase with time in culture. Interleukin-ip
adversely affected P450IVA clofibric acid-induced activity, totally eliminating the
effect of induction at doses exceeding 5 ng/ml. This repression was dose-dependent.
The mechanism by which interleukin-ip prevents the development o f cytochrome
P450IVA activity was unclear.
The cytokine. T N F -a . is a primary inflammatory' mediator after liver injury.
Several cytokines impair the regulation of cytochrome P450 genes in liver, but the
specificity o f these effects remains unclear (Nadin et al.. 1995). Tumor necrosis factora depressed ethoxycoumarin-O-deethylase activity and the steady state concentrations
of mRNA and apo-proteins for P450IIC12 and IID6 (Bertini et al.. 1988; Chen et al.,
1992; Wright & Morgan, 1991). Microsomal ethylmorphine-N-demethylase and
ethoxycoumarin-O-deethylase (P450 IIC12) were inhibited by exogenous IL-6 in rats.
Messenger RNA steady state concentrations were depressed along with decreased apo-
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protein (Williams et a l, 1991; Wright & Morgan. 1991). The effects o f recombinant
murine TN F-a on the expression o f specific constitutive P450s in male rat liver was
investigated (Nadin et al.. 1995). Tumor necrosis factor-a down-regulated P450IIC11
and IIIA2 in male rat liver at a pre-translational level, whereas two other constitutive
P450s. IIA 1 and IIC6, seem refractory to TNF-a. Thus, impaired P450 regulation by
T N F-a resembled the combined effects of autologous interferons on IIIA2 and
interleukins on IIC11.
Inhibition o f cytochrome P450 was not limited to hepatic microsomes but can
occur in other tissues, such as Leydig cells (Li et al.. 1995). Testosterone biosynthesis
in Leydig cells depended on the action o f 17 a-hydroxylase/C 17-20 Ivase cytochrome
P450 (P450cl7). which was encoded by the C ypl7 gene. Tumor necrosis factor-a
inhibits cAMP-stimulated testosterone production in mouse Leydig cells. The
inhibition o f testosterone production was parallel to the inhibition o f P450cl7
messenger RNA and protein concentrations. Tumor necrosis factor-a stimulated PK.C
a-translocation was further demonstrated by indirect immunofluorescence assay.
Phorbol myristic acid, a known activator of protein kinase C and TN F-a a had a similar
inhibitory effect on P450cl7 expression, testosterone production and P450XVII
activity.
Dexamethasone is a well known inhibitor o f T N F-a production when given
shortly before lipopolysaccharide (Fantuzzi et al., 1995). However, dexamethasone
may potentiate TNF-a production when administered 24-48 h before LPS. This may be
due to induction o f P450IIIA. which was known to produce nitric oxide (NO). This
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suggests that P450IIlA-generated NO might be involved in T N F-a induction. Nitric
oxide is becoming more recognized as a signaling molecule in many organs, although
its role in the liver remains to be fully elucidated (Milboume & Bygrave. 1995). Liver
cells produced NO in response to a variety o f stimuli including infection with
Corynebacterium parvum. LPS and cytokines. Within the liver. NO modulated some
fundamental intracellular functions such as protein synthesis, mitochondrial electron
transport and components o f the citric acid cycle. Drug metabolism and blood storage
may be other intracellular roles o f nitric oxide. Additionally. NO acts to protect the
liver from immunological damage in models of hepatic inflammation. Inflammatory
stimulation of the liver led to the induction of nitric oxide (NO) biosynthesis (Stadler et
al.. 1994). The interference o f NO with specific P450-dependent metabolic pathways
was investigated, because NO binds to the catalytic heme moiety o f cytochromes
P450IA. The results indicated that inhibition o f NO biosynthesis in patients suffering
from systemic inflammatory response syndromes may help to restore biotransformation
capacity o f the liver.
Although nitric oxide synthetase (NOS) is a cytochrome P450-like hemoprotein
with additional sequence homology to cytochrome P450 reductase, the role of the
cytochrome P450 system in cytokine-mediated NO synthesis is unknown (Kuo et al..
1995). Inhibition o f P450IIIA activity was associated with a concentration-dependent
decrease in cytokine-mediated NO production. Concentrations o f NOS mRNA and
protein were not altered. The NOS enzyme assay was notable for stable concentrations
of intermediate. N-OH-L-arginine and decreased production o f the final end product. L-
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citrulline. Cytochrome P450IIIA isoform may play a post-translational role in cytokinemediated NO synthesis in this model of isolated rat hepatocytes in primary culture. Rat
liver microsomes catalyzed the oxidative denitration o f N omega-hydroxy-L-arginine
(NOHA) by hydrogenated nicotinamide adenine dinuleotide phosphate (NADPH) and
0 2 with formation of citrulline and nitrogen oxides like NO and N 0 2- (Boucher et al..
1992). Classical inhibitors o f NO-synthetases. like N omega-methyi-and N omeganitro-arginine. failed to inhibit the microsomal oxidation o f NOHA to citrulline and
N 0 2-. On the contrary, classical inhibitors of hepatic cytochromes P450 like CO,
miconazole, dihydroergotamine and troleandomycin. strongly inhibited this
monooxygenase reaction. Oxygenation o f NOHA by NADPH and 0 2 with formation of
citrulline and NO can be efficiently catalyzed by cytochromes P450, including the IIIA
subfamily.
Endotoxin and infection effects on drug metabolism
Endotoxin
Active infection with bacterial proliferation was not necessary for changes in
drug biotransformation. Heat-killed or formalin-fixed Corynebacterium parvum and
bacillus Calmette-Guerin, an immunomodulator. depresses hepatic P450 drug
metabolism (Farquar et al.. 1976: Soyka et al.. 1976). Endotoxin from other Gramnegative and positive bacterial cell walls are potent inhibitors o f hepatic mixed-function
oxidase (Azri & Renton, 1987; Gorodischer et al., 1976; Lavicky et al.. 1988; Sasaki et
al., 1984; Sonawane et al., 1982; Stanley et al., 1988; Williams & Szentivanyi. 1983:
Yoshida et al., 1982). Escherichia coli. Bordatella pertussis, diphtheria toxoid and
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tetanus toxoid all contain cell wall endotoxins that alter P450 activity (Ashner et al.,
1992.1993; Fantuzzi et al., I994a.b). Pertussis toxin was a necessary component for the
sustained effects o f diphtheria-tetanus-pertussis vaccine on hepatic drug metabolism
which suggested a role for INF-y in this process (Ashner et al.. 1993). Bacterial
endotoxin such as Escherichia coli or B. pertussis endotoxin decreased P450 activities
in mice (Fantuzzi et al., 1994b; Sasaki et al.. 1984). Endotoxin treated rats experienced
a dramatic decrease in steady state concentrations o f P450IIC12 mRNA and apo-protein
(Morgan. 1989). The mechanism for these effects was thought to be suppression of
cytochrome P450 activity and concentrations by TNF. interleukins, interferons and
other cytokines (Myers & Kawalek. 1995). The common theme that emerges from the
preceding studies was that infections, whether viral, bacterial, or parasitic, all depressed
P450-mediated metabolism. The next question was how were these vastly different
agents all affected by the mixed-function oxidase system? In a series o f papers, it was
shown that both poly IC and tilorone decreased the levels o f enzymatically-active P450.
cytochrome b5 and 5-aminoIevulinic acid synthetase (ALA-S) (El Azhary &
Mannering, 1979). Conversely, heme oxygenase activity increased following treatment
with poly IC. 6-Aminolevulinic acid synthetase was the rate-limiting enzyme
controlling heme biosynthesis, whereas heme oxygenase degrades heme (Tephley et al.,
1973; Maines. 1988). Administration of interferon inducers such as poly IC and
tilorone seemed to simultaneously decrease heme synthesis and increase heme
degradation.
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Functional P450 consists o f both the P450 apoprotein and the heme moiety with
independent synthesis o f both components. Either component could be the target of the
interferon-inducing agents. The turnover rate o f the heme moiety had a biphasic
pattern, indicating that different P450 molecules have different turnover rates (Levin &
Kuntzman. 1969). Poly IC and tilorone increased the turnover rate o f short-lived P450
molecules, but did not affect the long-lived variants (El Azhary et al., 1980). However,
a transient increase in heme ievels was also noted. This suggested, but did not prove,
that the ultimate target w as the synthesis of the P450 apoprotein.
Xanthine oxidase had been proposed as being another mechanism for the
depression o f P450 levels and was observed after animals were treated with interferon
or interferon inducers (M yers & Kawalek. 1995). Added support for this hypothesis
came from studies showing an inverse relationship between production of interferon and
depression o f P450 protein levels and P450-mediated enzymatic activity (Singh et al..
1982). Strains o f mice that produced high levels o f interferon had low levels of P450
following challenge with Newcastle disease virus, whereas mouse strains that produced
lower levels of interferon exhibited a small effect on P450 concentrations. The
differences in P450 levels between these two strains o f mice correlated to
ethylmorphine-/V-demethylase activity and high interferon-producing strains exhibiting
the lowest levels o f enzymatic activity. The induction o f xanthine oxidase paralleled the
levels o f interferon produced (Deloria et al., 1983). High interferon-producing mice had
levels o f xanthine oxidase that were higher than those found in mice producing lower
levels o f interferon. The inhibiting effect on P450 levels and its monooxygenase
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activity was greatest in high interferon-producing mice (Deloria et al.. 1983).
Formation o f lipid peroxides (Ali et al., 1985) has also been proposed as one possible
mechanism to explain the decrease in the P450 levels following interferon induction.
However, inhibiting lipid peroxidation failed to prevent poly 1C induced P450 loss
(Mannering et al.. 1989).
Additional studies revealed that incubation with free radical scavengers
superoxide dismutase and iV-acetylcysteine protected the P450 enzymes from the effects
o f added xanthine oxidase (Ghezzi et al.. 1985). In vivo treatment with allopurinol. an
xanthine oxidase inhibitor, or iV-acetylcysteine canceled the effect o f poly IC on both
P450 and xanthine oxidase. However, while allopurinol protected against the effects of
poly IC. it also decreased the basal concentrations o f P450 and xanthine oxidase.
Although there were effects o f xanthine oxidase on P450 levels, there was no significant
effect on P450-mediated ethoxycoumarin O-deethvlase activity (Ghezzi et al.. 1985).
Chickens cannot form xanthine oxidase and it was shown that polv IC treatment of
chickens did not affect P450 levels (Moochhala & Renton. 1991). Nonetheless,
brooder-raised chickens may have very low levels o f P450-mediated enzymatic activity
when compared with pen-raised birds (Dr. Joseph Kaw'alek. unpublished). Using
animals with such low activity would minimize any changes in P450 concentrations that
may have been affected in these chickens. In addition, they could not show a protective
role for the free radical scavenger iV-acetylcysteine, or that added xanthine oxidase
affected the in vitro activity o f liver microsomes.
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The above results were subsequently contradicted using mice, rats and hamsters
(Reiners et al., 1990; Cribb & Renton. 1993). While no one group showed a role for
xanthine oxidase, an earlier study had been designed to feed diets containing tungstate
to inactivate xanthine oxidase in mice (Mannering et al., 1988). In the tungstate study,
a role for either xanthine oxidase or lipid peroxides in the poly IC mediated decrease in
hepatic P450 was not discovered. Therefore, it was concluded that induction of
xanthine oxidase and reduction in P450 content were coincidental and not causally
related. Based on these observations, the decreases in P450 and its related activities
were probably not a consequence of xanthine oxidase activity in rodents (Reiners et al..
1990; Cribb & Renton. 1993).
In a more recent in vivo study using pigs instead of rodents, multiple intravenous
(i.v.) doses of LPS (17 pg/kg) induced a mild acute-phase response in swine within 2 h
o f the first injection (Monshouwer et al.. 1996a). Antipvrine plasma clearance was
decreased in the LPS treated pigs (control: 8.5±0.8; LPS: 2.2±0.7 ml/min/kg) and
decreased ethoxyresorufin O-deethylase. caffeine, 3-demethylase and testosterone 6Phydroxylase activities which corresponded to P450IA1. P450IA2 and P450IIIA
respectively, in rats. The P450IA and P450IIIA apoprotein concentrations were also
decreased. The results suggested that the effect on cytochrome P450 was relatively
non-selective in the pig and affects several P450 isozymes. High systemic
concentrations o f TN F-a and IL-6 were associated with decreased antipvrine clearance
in LPS treated pigs. Microsomal 1-naphthol glucuronosyl transferase activity was not
altered in LPS treated pigs.
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Endotoxin elicits a broad, non-specific cascade o f events in vivo. a variety of
potent mediators and cytokines were secreted, primarily, by activated cytokines and
monocytes (Kielian & Blecha, 1995) The over-production o f these effector molecules,
such as IL-1 and TN F-a. contributed to the pathophysiology o f endotoxic shock.
Cellular recognition o f LPS involved several different molecules, including a cluster o f
differentiation antigen. CD 14. A thorough understanding of the interaction of LPS with
cells o f the immune system is necessary before effective preventative or therapeutic
measures can be designed and tested to limit the host response to endotoxin. The CD 14
antigens function as a receptor for lipopolysaccharide binding protein complexes
(Kielian et al.. 1995). Lipopolysaccharide has a varying effects on CD14 expression in
vitro which required that the evaluation o f CD14 expression in response to LPS with a
fully differentiated macrophage phenotype, the porcine alveolar macrophage. The
investigators found that LPS activation of porcine alveolar macrophages for 24 h
increased CD14-like receptor expression. The degree o f CD14-like up-regulation was
related to LPS concentration. However, activation did not require the presence of serum
at concentrations o f LPS.
Infection
Infection from viral, bacterial, or parasitic sources depressed drug metabolizing
activity of diseased animals (Myers & Kawalek. 1995). Pharmacokinetic changes were
often overlooked when drug toxicity or decreased efficacy occur during an infection,
especially in veterinary medicine. Influenza infections altered the metabolism of
theophylline and cytomegalovirus increased the toxicity o f parathion. but not all viral
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vaccines affected cytochrome P450 (Fisher et al.. 1981; Selgrade et al.. 1984). Both
heat-killed and formalin-fixed infection with Corynebacterium parvitm in rats and mice
decreased hepatic P450-mediated drug biotransformation (Farquar et al.. 1983: Soyka et
al., 1976). Malaria-infected rats have exhibited decreased ability to metabolize aniline,
ethylmorphine,/7-nitroanisole and hexobarbital (McCarthy et al.. 1970). Plasmodium
berghei were irradiated and injected into mice (Song et al.. 1995). There were
significant decreases in mouse hepatic cytochrome P450 and benzo(a)pyrene
hydroxylase activity, but no effect on N-demethylase activity. Antipvrine and
metronidazole were administered as a cocktail to young male Wistar rats to investigate
the effect o f malaria infection due to the rodent parasite Plasmodium berghei and
Escherichia coli endotoxin-induced fever on the metabolism o f the two compounds in
vivo (Kokwaro et al.. 1993). Malaria infection had no effect on clearance o f antipyrine
or on formation clearance o f any o f its metabolites. However, the clearance of
metronidazole was reduced by approximately 20% compared with controls as a result o f
decreased formation o f hydroxymetronidazole. Fever decreased clearance o f both
antipyrine and metronidazole by approximately 36% and 23%, respectively. These
results demonstrated that both malaria infection and fever influenced P450-dependent
drug metabolism and the effects seen were isozyme-selective Parasitic infection with
Fasciola hepatica or viral infection with influenza A and B, poliovirus, as
cytomegalovirus depressed mixed-function oxidase activity (Chang et al., 1978;
Descotes & Evreux. 1986; Descotes et al.. 1985; Kraemer & McClain. 1981; Kraemer
et al.. 1982; Maffei et al., 1981; Renton, 1981; Selgrade et al.. 1984). In mice infected
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with Fasciola hepatica. there was a loss o f respiratory control in isolated liver
mitochondria at 4 weeks post-infection (Somerville et al.. 1995). A similar time course
was demonstrated for a reduction in hepatic microsomal cytochrome P450 content. In
another parasitic study using Schistosoma mansoni. the intensity o f infection determined
alterations in hepatic drug metabolism, as indicated by measuring zoxazolamine
paralysis times (Naik & Hasler. 1995).
The A. pleuropneumoniae infection model was well characterized and has
become a standard respiratory disease model in pigs (Baarsch et al., 1995: Kamp & van
Leengoed, 1989). Hepatic microsomes. in vitro. from APP infected pigs were used to
determine enzyme activities for the model substrates: aniline-hydroxylation.
ethoxyresorufin O-deethylation. pentoxyresorufin O-depentylation and testosteronehydroxylation at the 20. 60. 1la . 15a and 150 positions (Monshouwer et al., 1995b).
All oxidative enzyme activities were depressed by 33% twenty four hours after infection
and indicated that the depression was not selective. UDP-glucuronosyltransferase
activities were not affected. The dot blots showed a reduction in total mRNA in two
infected pigs, but this study was somewhat lacking in experimental design. The human
cytochrome P450IIIA4 cDNA probe was used to detect mRNA in a mixture of mRNA
on the dot blot. There was no control for the possibility that the IIIA4 cDNA probe
might cross-react with mRNA in other P450 subfamilies, resulting in a false positive.
Additionally, only two control and two treated pigs were used, which makes statistical
analysis difficult.
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In a subsequent experiment, the investigator attempted to verify in vitro findings
by performing an in vivo pharmacokinetic experiment with APP infected pigs using
model drugs (Monshouwer et al.. 1995a). The plasma clearance of antipyrine and
caffeine represented a decrease in oxidative drug metabolism and differed greatly from
the infected pigs compared to the controls (72% and 68%. respectively). The effect of
the infection on the glucuronidation of paracetamol was minimal in infected pigs (39%
depression). The clearance o f indocyanine green and creatinine were unaffected which
indicates normal hepatic blood flow and renal excretion. Antipyrine. caffeine and
paracetamol were negligibly bound to plasma proteins so it was unlikely that the
decrease in clearance was from changes in protein binding. Cytochrome P450 enzymes
responsible for the reduction of oxidative metabolism were not pursued, but the results
suggested non-selective action in vivo. The possible mechanism for decreased
paracetamol disposition was not clear, because glucuronosyl activity was not suppressed
by the infection.
Actinobacillus Pleuropneumoniae
History
Actinobacillus pleuropneumoniae is the most common causative agent o f swine
pleuropneumonia, a highly contagious and sometimes fatal, respiratory tract disease of
pigs known as porcine pleuropneumonia (Nicolet. 1994). The disease was first reported
in 1957 and was followed by worldwide reports of APP outbreaks in commercial swine
herds (Fedorka-Cray et al.. 1993a; Pattison et al., 1957). Morbidity approaches 100%
with 50% mortality, 55% increase in the feed conversion ratio and a 40% decrease in
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average daily gain (Mackinnon. 1993). In controlled studies o f swine infected with A.
pleuropneumoniae, 60% died 18 to 56 h after exposure (Kung et al., 1993a.b). Control
and prevention measures for porcine pleuropneumonia were often ineffective, because
o f the complex nature o f the disease (Fedorka-Cray et al.. 1993a: Maclnnes &
Rosendal. 1982; Sebunya & Saunders. 1983). Subsequently, pork producers have
suffered great economic loss.
Actinobacillus pleuropneumoniae is a facultative anaerobe that is non-spore
forming, encapsulated, nonmotile. Gram-negative pleomorphic coccobacillus (Kilian &
Biberstein. 1984). Biochemical characteristics o f the organism include: urease positive:
able to ferment mannitol. xylose and ribose; with variable fermentation o f lactose
(Kilian & Biberstein. 1984; Nicolet. 1994). A rough to smooth morphologic transition
may occur after passage in artificial medium. (Fedorka-Cray et al.. 1993a; Gunnarsson.
1979). Colonies exhibit P hemolysis on blood agar plates, but some isolates were non
hemolytic (Kamp & van Leengoed. 1989; Morrison et al., 1985; Sebunya & Saunders.
1983). Some field isolates have been identified with fimbria by negative staining
(Utrera& Pijoan. 1991).
Actinobacillus pleuropneumoniae was originally believed to be Haemophilus
parahaemolyticus. because o f the requirement o f nicotinamide adenine dinucleotide
(NAD) for growth (Biberstein et al., 1977; Kilian & Biberstein, 1984; Niven &
Levesque. 1988). In 1978. distinguishing biochemical and cultural characteristics were
identified between porcine and human strains and a new strain, Haemophilus
pleuropneumoniae, was named (Kilian et al., 1978). In 1983, DNA hybridization was
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performed between Haemophilus pleuropneumoniae and Haemophilus influenza and the
percent binding indicated no measurable relationship (Pohl et al., 1983). The DNA
hybridization and phenotypic characteristics did indicate that Haemophilus
pleuropneumoniae was closely related to Actinobacillus lignieresi. The Haemophilus
pleuropneumoniae was transferred to the genus Actinobacillus with 2 biovars: a V
factor biovar 1 dependent on nicotinamide adenine dinucleotide and a V factor
independent biovar 2. The two strains were very similar except for the NAD
requirement and morbidity in biovar 2 induced pleuropneumonia was less than the
morbidity caused by strains o f biovar 1 (Kilian et al.. 1978).
Epidemiology
Only pigs are known to be naturally susceptible to Actinobacillus
pleuropneumoniae (Fedorka-Cray et al.. 1993a). The organism has not been found in
rodents, birds, or humans and does not persist in the environment (Fedorka-Cray et al..
1993a; Nicolet. 1994). Serotypes 1. 5 and 7 are frequently found in the United States
and are common in the Midwest; serotypes 3. 4. 8 and 9 are infrequently found
(Fedorka-Cray et al.. 1993a; Sebunya & Saunders. 1983). Serotypes 1. 2. 3 5 and 7 are
common in Canada and serotypes 1, 2, 5. 7 and 9 are common in Europe (Rapp et al..
1985; Rosendal & Boyd, 1982; Sanford & Josephson. 1981; Schultz et al.. 1983). In a
recent study, bronchoalveolar lavage was performed in 128 pigs from five fattening
units showing acute pneumonia, subclinical pneumonia and chronic purulent pneumonia
(Tapner et al., 1996). Using cultural methods. APP could only be isolated from six
samples. In contrast, there were frequent positive reactions to APP antigens with
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immunofluorescence microscopy. Thus, immunofluorescence was a better screening
method.
Occurrence of swine pleuropneumonia in previously non-infected herds can be
linked to introduction o f asymptomatic carrier pigs (Greenway. 1981). Chronically
infected pigs that are asymptomatic may develop signs o f the disease during transport
(Greenway. 1981). Actinobacillus pleuropneumoniae is spread by direct contact or by
aerosol transmission (Fedorka-Cray et al., 1993a). Nasal secretions can contain 109
colony forming units/milliter (CFU/ml) which quickly spreads the disease between pigs
(Rosendal & Mitchell. 1982). Stress factors of overcrowding, transportation and abrupt
temperature changes also increased the incidence of the disease (Sebunya et al., 1983b).
The increased susceptibility to APP can be predicted by the absence o f toxinneutralizing antibodies to haemolysin and cytotoxin (Cruijsen et al.. 1995a.b). Autumn
through early spring is the period o f greatest incidence o f APP (Fedorka-Cray et al..
1993a.: Sebunya et al., 1983b).
Intense industrialization o f pork production has been suggested as contributing
to the rapid rise of APP infected herds (Fedorka-Cray et al., 1993a). Pigs older than 12
weeks o f age are the most vulnerable and immunologically naive herds are the most
severely affected (Sebunya et al., 1982.1983b: Shope. 1964). A recovered pig can
remain an asymptomatic carrier for months and provide low exposure o f APP to the
herd. This allows the herd to establish a level of immunity that decreases the incidence
o f new and acute infections. Chronically infected herds have some individuals that
remain seronegative. Seronegative sows did not pass on colostral immunity to suckling
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piglets and the offspring will remain susceptible to infection. Piglets become vulnerable
when exposed to crowding and poor ventilation (Fedorka-Cray et al.. 1993a: Sebunya et
al.. 1982).
Signs, pathology and lesions
Actinobacillus pleuropneumoniae infection can cause death within 12 h after
exposure (Fedorka-Cray et al., 1993a). Clinical signs include: anorexia, fever, severe
respiratory distress, cyanosis, coughing and dyspnea. Discharge of blood tinged foam
from the nose and mouth is common in acutely infected pigs (Fedorka-Cray et al..
1993a). The severity of the disease is influenced by the virulence of the strain, size of
inoculum, protective immunity and stress (Greenway. 1981; Rosendal. 1985; Sebunya
et al.. 1983b; Shope. 1964; Jacobsen et al., 1996).
The disease can occur in the peracute. acute, subacute or chronic form (FedorkaCray et al.. 1993a: Nicolet. 1994: Udeze et al., 1987). In the peracute form, death
occurs within 24 to 36 hours. Sudden death in piglets without previous clinical signs
has been reported (Fedorka-Cray et al.. 1993a; Sebunya et al.. 1983b; Shope, 1964).
The acute form may progress from severe clinical disease to death within a few days or
it may resolve into the chronic form depending on the severity of lung lesions and
response to antibiotic therapy (Fedorka-Cray et al., 1993a; Nicolet. 1994) In the early
stages o f the disease, common microscopic changes included pulmonary necrosis,
hemorrhage, neutrophil infiltration, macrophage and platelet activation, vascular
thrombosis, widespread edema and fibrinous exudate (Bertram. 1985. 1986. 1988:
Liggett & Harrison. 1987). Following the acute response to APP infection, macrophage
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infiltration, marked fibroplasia around areas o f necrosis and fibrinous pieuritis were
characteristic in later stages of the disease (Hani et al.. 1973). Antibiotic therapy was
efficient only in the initial phase of the disease, when there was the best chance to
reduce mortality (Nicolet. 1994). Actinobacillus pleuropneumoniae was susceptible to
(3-lactams, mainly penicillin and cephalosporins: chloramphenicol: cotrimoxazole: and
tetracyclines, but resistance has developed to ampicillin. streptomycin, sulfonamides,
tetracyclines, chloramphenicol, tiamulin and a combination of lincomycin and
spectinomycin (Anderson & Williams, 1990; Gilbride & Rosendal. 1984; Hsu. 1990:
Vaillancourt et al.. 1988). Resistance was most frequently seen in serotypes 1 .3 .5 and
7. Presently, the quinolone derivatives or the semisynthetic cephalosporin, ceftiofur
sodium, have been shown to be very effective after experimental challenge with APP
(Kobisch et al.. 1990; Stephano et al.. 1990).
Gross lesions common in acute APP infections consisted of serofibrinous
pieuritis and fibrinous and necrotizing hemorrhagic pneumonia (Sebunya et al.. 1983a).
Lesions were usually distributed bilaterally in the caudal lobes o f the lungs (Sebunya et
al.. 1983a). In chronic infections, fibrinous pieuritis and necrotic foci that very in size
were evident. The necrotic foci, in recovered animals, serve as a nidus o f infection for
months and infected animals were considered to be carriers (Fedorka-Cray et al..
1993a).
Sequential studies have been conducted to record histological lesions caused by
Actinobacillus pleuropneumoniae infection (Liggett & Harrison, 1987). Neutrophil
infiltration and fibrinous exudate are present in the early stages o f the disease (Bertram,
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1988). Bacteria occur as individual cells or groups throughout the exudate (FedorkaCray et al., 1993a). Coagulative necrosis was evident 12 to 18 h after infection in areas
o f concentrated suppuration (Liggett & Harrison. 1987). Macrophage infiltration and
areas o f marked fibroplasia were evident around necrotic tissue as the disease
progressed (Bertram, 1988). Neutrophils occurring in various stages o f degradation
suggested that vascular damage may be mediated by neutrophil degeneration and release
of lysomal contents (Liggett & Harrison. 1987). Sequestration o f necrotic pulmonary
tissue and development o f pleural adhesions were common sequellae to the acute
response (Bertram. 1988: Fedorka-Cray et al.. 1993a). Complete healing, locally
extensive areas of fibroplasia, or liquefactive necrosis may result after survival o f acute
infections (Bertram. 1988).
Virulence factors
Capsule
Some of the 12 identified serotypes o f APP cause more severe disease than
others (Brandreth & Smith. 1987: Fedorka-Cray et al., 1994: Jensen & Bertram. 1986:
Rosendal & Boyd. 1985). Inoculation with as few as 10,000 virulent bacteria can cause
death in 12 hours and 100 bacteria caused lung abscesses in swine (Perry et al., 1990).
Virulence factors on the cell surface or secreted by the bacteria were responsible for the
disease process.
The structure and chemical composition o f the 12 APP serotypes have been
described (Fedorka-Cray et al., 1994). Capsules consist o f polymers of two or three
sugars or amino acids, techoic acid polymers linked by phosphate diester bonds or
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oligosaccharide polymers linked by phosphate bonds (Fedorka-Cray et al.. 1994). The
presence o f phosphate or carboxylic acid creates a negative charge on the capsule and
was important for the evasion o f APP cells from phagocytic cells. Serotype specificity
o f APP was attributed to capsular antigens (Inzana. 1991; Inzana & Mathison. 1987).
The capsule protected the bacterium from host defenses, such as opsonization
and phagocytosis and complement mediated killing by classic and alternate pathways
(Inzana. 1991). However, not all encapsulated strains have been shown to be virulent
(Jacques et al.. 1988a: Jensen & Bertram. 1986: Rosendal & Boyd. 1985). Capsule
deficient mutants of APP serotypes 1 and 5 were less virulent in pigs than their
encapsulated parent strains (Inzana et al.. 1988: Rosendal & Maclnnes. 1990). Injection
o f capsular material alone neither produced disease nor pulmonary lesions nor disease in
pigs (Fenwick et al.. 1986c). Purified capsule produced a poor antibody response, but
conjugation with protein improved immunogenicity and gave partial protection to
pleuropneumonia caused by APP (Inzana. 1990: Inzana et al.. 1988). Passive transfer of
non-specific capsular antiserum to swine provided a level o f protection similar to
immunization with killed bacteria (Inzana et al.. 1988). Other virulence factors
accounted for the variation in virulence. The presence of lipopolysaccharides and
exotoxins were known to vary between A. pleuropneumoniae serotypes and strains
(Byrd & Kadis. 1989; Frey & Nicolet. 1990: Kamp & van Leengoed. 1989). Adhesins.
hemagglutinins, fimbriae and pili. played an unknown role in the pathogenesis of APP
(Fedorka-Cray et al.. 1994).
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Subsequently, to explore the attachment of APP to mucosal surfaces, an
investigator endobronchially inoculated seven pigs with APP serotype 1 and the pigs
developed subacute necrotizing pleuropneumonia (Narita et al., 1995). When the pigs
were treated with high doses o f atropine (0.25 mg/kg) and xylacaine spray using a
bronchoscope, mucus secretion was suppressed along with ciliary activity. The animals
showed severe pleuropneumonia and two treated pigs died within 36 h after inoculating
320 CFU/2ml of APP serotype 1. The findings suggested that the attachment of APP to
the mucosal surfaces may be a critical in the pathogenesis o f pneumonic lesions.
Lipopolysaccharide
Lipopolysaccharide is a macromolecule that is part o f the outer membrane of
Gram-negative bacteria (Stanier. 1976). Lipopolvsaccharides are composed of a
complex lipid material, lipid A. which is attached to the core polysaccharide. The core
is comprised o f sugars, including 2-keto-3-deoxyoctonate. attached to O-specific side
chains. The O-specific side chains protrude out from the cell surface of the bacterium
and endow strain specific antigenic properties on certain Gram-negative bacteria. Ospecific side chains have repeating units that convey a phenotypic characteristic of
smooth, side chains present, or rough, side chains absent. Each strain shares a common
core O antigen within each serotype. Serotype 5 can have both partially rough and
smooth strains, because the length of the side chain can vary (Altman et al.. 1990; Frey
& Nicolet. 1990). Serotype specific and cross reactive epitopes in the LPS have been
identified for APP (Fenwick & Osbum. 1986).
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Lipopolysaccharides have similar structures among the Gram-negative bacteria
and similar biological effects have been inferred (Fenwick. 1990). Lipopolysaccharide
induced the release of pro-inflammatory cytokine mediators. The mediators activate
various cells to include macrophages and neutrophils which played a primary role in
acute inflammation. Purified APP lipopolysaccharide induced non-necrotizing
pneumonia with neutrophil infiltration (Udeze et al.. 1987). The deleterious effect of
LPS was inflammation and not the associated necrotic lesion development (Idris et al..
1992; Udeze et al.. 1987). Necrotic lesion development seems to depend on the
presence o f exotoxins that lyse neutrophils and release toxic substances that severely
damaged tissue.
Supporting evidence for the involvement of endotoxin with A.
pleuropneumoniae virulence was demonstrated in a study using pigs vaccinated with the
J5 bacterin from a mutant o f Escherichia coli 0111: B4 (Udeze et al.. 1987). The
vaccinated pigs survived Actinobacillus pleuropneumoniae infection challenge, whereas
four of the five control non-vaccinated animals died following infection with APP.
Antibodies against lipid A and possibly to core antigens o f LPS. may have a protective
effect against septicemia and death caused by pleuropneumonia infections (Udeze et al..
1987). J5 protection against septicemia and death in porcine pleuropneumonia was
indirect evidence that APP endotoxin contributed to pathogenicity. Lipopolysaccharide
isolated from A. pleuropneumoniae induced a pulmonary lesion and the severity of the
lesion may be a function o f the composition of the LPS molecule. The heat stable
endotoxin and the heat labile extracellular hemolysins act in concert to produce lung
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lesions. Endotoxin alone did not induce the full array of lung lesions observed in the
acute form o f natural and experimental infections. Lipopolysaccharide and exotoxins
may act together as virulence factors in mediating the disease process (Fenwick &
Osbum. 1986; Fenwick et al., 1986a.b). Hemolysin and cytotoxin may also contribute
to the pathogenesis o f lung lesions (Udeze et al., 1987).
Another virulence factor may be the affinity o f APP endotoxin for porcine
respiratory tract secretions (Belanger et al., 1994). The affinity for a crude preparation
o f porcine respiratory tract mucus o f isolates of the Pasteurellaceae family
{Actinobacillus. Haemophilus and Pasteurella spp.) and o f some unrelated Gramnegative bacteria was examined. To identify the receptors recognized by the
lipopolysaccharidic adhesin o f APP. affinity chromatography was used. Two
proteinaceous bands (10 and 11 kDA) were recovered. This suggested that two lowmolecular-mass proteins present in porcine respiratory tract secretions bind APP
endotoxin. In a latter study. LPS from all APP isolates tested, bound pig hemoglobin
and lipid A was involved in this binding (Belanger et al.. 1995). Some APP isolates
were able to use hemoglobin for growth. This indicated that binding o f hemoglobin to
LPS might represent an important means by which APP acquires iron in vivo from
hemoglobin released from erythrocytes Iysed by the action o f its hemolysins. Two
outer-membrane proteins were involved in the uptake of iron from transferrin by certain
Gram-negative bacteria, including Actinobacillus pleuropneumoniae. transferrinbinding proteins 1 and 2 (Daban et al., 1996).
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Recently. 40 and 48 (kDa) outer membrane proteins have been identified from
Actinobacillus pleuropneumoniae. serotype 5 (Bunka et al. 1996; Cruz et al.. 1996).
Vaccine prepared from the outer membrane o f serotype 5 provided protective immunity
in swine challenged with either serotype 5 or serotype 1. The outer membrane protein
was common to all 12 capsular serotypes o f APP. but was not present in the outer
membranes o f related species of Gram-negative swine pathogens. It was inconclusive
whether or not antibodies to the 48 kDa outer membrane antigen contribute to crossprotective immunity to control porcine pleuropneumonia caused by APP. Live non
capsulated mutants o f A. pleuropneumoniae may provide safe and cost-effective
protection against swine pleuropneumonia (Inzana et a l. 1993). These observations
support the possibility that non-capsulated mutants o f other encapsulated, toxinproducing bacteria may also prove to be efficacious live-vaccine candidates.
Bacterins for Actinobacillus pleuropneumoniae have proven to be ineffective
(Fedorka-Cray et al., 1993b). Current bacterins may provide only partial protection in
swine following infection APP. Vaccination failure o f whole cell bacterins has been
attributed to antigenic variation within a capsular serotype, due to antigenic variation
within LPS (Jolie et al., 1995). This lack o f cross-protection, within a capsular subtypes
1A and IB. provides partial explanation for vaccination failures observed under field
conditions. The efficacy of a cell-free concentrate from mid-log phase growth cultures
of APP serotype 1 to four commercial bacterins were compared (Fedorka-Cray et al.
1993b). This cell-free preparation contained carbohydrate, endotoxin and protein and
had hemolytic and cytotoxic activity. Similar, but not identical, responses were
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observed when antisera generated against the bacterins was used. This study indicated
that an acellular vaccine, containing multiple virulence factors, can provide complete
protection from mortality and significantly reduced morbidity to homologous challenge
(Fedorka-Cray et al., 1993b). Swine were protected by a subunit vaccine that did not
create unacceptable tissue reaction at the immunization site after challenge with APP.
serotype 1 (Walker et al.. 1995).
A study in mice used specific monoclonal antibodies (MoAbs) to Actinobacillus
pleuropneumoniae serotypes 1 and 2 which recognized serotype-specific antigens (Saze
et al.. 1994: Oishi et al., 1993). It was revealed that the two serotype-specific MoAbs
H I-18 and H22-7 recognized O-polysaccharides o f the lipopolysaccharide from APP
serotypes 1 and 2. respectively. These results showed that LPS from APP bacterial cells
was one o f the structural substances in the serotype-specific antigens and an important
component as one o f the antigens protecting against the homologous serotype strain.
The combined vaccine o f serotypes 1. 2 and 5 from APP was tested for its ability to
confer protection in pigs (Oishi et al., 1995). Clinical signs o f pleuropneumonia were
not observed after intratracheal challenge with A. pleuropneumoniae.
Exotoxins
Bacterial exotoxins are soluble proteins secreted by live organisms (Rutter.
1988). Toxin release contributed to the disease process, especially for organisms
infecting mucosal surfaces (Shewin. 1988). The presence o f exotoxins was
demonstrated by administering sterile culture supernatants o f APP to pigs (FedorkaCray et al.. 1994). Pulmonary lesions were similar to those found in natural infections.
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Lung lesions were produced by all o f the exotoxins, except one. PTX/ClvIII. which was
not essential for the pathogenicity o f the organism (Fedorka-Cray et al., 1994). In an
attempt to gain insight into the events that take place during APP infection, the effects
o f bacterial toxicity on porcine neutrophil functions and viability was evaluated (Udeze
et al.. 1992). Incubation o f phagocytes with opsonized APP resulted in phagocylic
uptake o f less than or equal to 4%. At the same bacterium-to-phagocyte ratio, levels o f
lactate dehydrogenase activity of 74 and 81% were detected in the extracellular medium
after 1.5 and 3 h o f incubation, respectively. Furthermore, the ingested bacteria were
not killed by the phagocytes. These effects were ascribed to hemolysin produced by the
bacteria, because the presence of hemolysin-neutralizing antibody prevented overt
cellular damage, significantly increased phagocytic uptake and resulted in an
approximately 10-fold decrease in the number o f ingested bacteria. Cytolytic doses o f
isolated hemolysin caused dose-related loss of cell viability, diminished bactericidal
activity o f toxin-treated phagocytes for Escherichia coli and decreased the ability o f the
phagocytes to undergo a respiratory burst upon stimulation with phorbol myristic
acetate. In contrast, sublytic doses of the hemolysin activated the phagocytes and
caused them to respond to phorbol myristic acetate with increased generation o f
superoxide anion. Heated (100 degrees C. 5 min) hemolysin preparations did not
produce similar effects and it was concluded that the observed effects were not due to
contaminating endotoxin. The data indicated that APP hemolysin was a potent
antiphagocytic virulence factor by virtue o f its leukocidal activity.
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Two hemolytic and cytolytic toxins (Hly/Clyl and Hly/CIyll) were believed to
be important in disease progression and are related to the repeat toxin (RTX) family of
exotoxins o f other Gram-negative microorganisms. These toxins include the leukotoxin
in Pasteurella haemolytica. the exotoxin in A. sais and the a hemolysin produced by
some strains o f Escherichia coli (Devenish et al.. 1989: Lian et al., 1989). The derived
amino acid sequence o f Hlyl showed 42% homology with the hemolysin of
Actinobacillus pleuropneumoniae serotype 5. 41% homology with the leukotoxin o f
Pasteurella haemolytica and 56% homology with the Escherichia coli a-hemolysin
(Frey et a i. 1991). The 13 glycine-rich repeats and three hydrophobic areas o f the Hlyl
sequence show more similarity to the E. coli a-hem olysin than to either the APP
serotype 5 hemolysin or the leukotoxin. while the last two were more similar to each
other. Two types o f RTX hemolysins, therefore, seem to be present in APP. one (Hlvl)
resembling the a-hem olysin and a second more closely related to the leukotoxin.

The

structural gene encoding Actinobacilluspleuropneumoniae-RTX-toxin I (ApxIA) was
cloned from serotype 10. as a major hemolytic and cytolytic toxin of the organism (Nagi
et al.. 1993a). The gene from serotype 10 was 98% identical to that from serotype 1 at
both the DNA and amino acid levels. Results of DNA sequencing showed serotypes 1.
9 and 11 to be the original form of the ApxIA gene and the allelic variant was found in
serotypes 5a. 5b and 10. The gene products, ApxIA proteins, have different secondary
structures at the carboxyl terminal region. Using the AppA gene encoding
Actinobacillus pleuropneumoniae-KYX-toxm II (ApxII) as a probe, it was demonstrated
by Southern hybridization that AppA-sequence was present in all 12 serotypes except
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10 (Nagi et al., 1993b). After DNA sequencing, this region was determined to be part
of the HlylA gene that encoded a 105 kDa hemolysin (Apxl). The presence of the low
homology region was evident in serotype 10 compared to the AppA gene locus (HlylA)
found in serotypes 1, 5a. 5b. 9 and 11 which all had strong hemolytic activity with
sheep red blood cells and were highly virulent in mice. This suggested that Apxl may
be associated with the virulence phenotype of the organism. Another investigator
proposed a new and uniform designation for the App-RTX-toxins consisting of
hemolysins, cytolysins, pleurotoxins and their genes (Frey et al.. 1993). The
designation o f Apxl. Actinobacillus pleuropneumoniae RTX-toxin I. was proposed for
serotypes 1. 5a. 5b. 9. 10 and 11, which was previously named hemolysin I (Hlyl) or
cytolysin I (Clyl). This protein was shown to be strongly hemolytic and cytotoxic
towards pig alveolar macrophages and neutrophils. The genes o f the Apxl operon
would have the designations: ApxIC. ApxIA. ApxIB and ApxID for the activator, the
structural gene and the two secretion genes respectively. The designation of ApxII was
proposed for the RTX-toxin which was produced by all serotypes except 10 and was
previously named APP. HlvII. Clyll or Cyt. This protein is weakly hemolytic and
moderately cytotoxic. The genes of the ApxII operon would have the designations of
ApxIIC for the activator gene and ApxIIA for the structural toxin gene. In the ApxII
operon. no genes for secretion proteins have been found. Secretion o f ApxII seemed to
occur via the products o f the secretion genes ApxIB and ApxID o f the Apxl operon.
The designation. ApxIII. was proposed for the non-hemolytic RTX-toxin of the
reference strains for serotypes 2. 3. 4. 6 and 8. which was previously named cytolysin
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Ill (Clylll). pleurotoxin (Ptx). or macrophage toxin. The previous studies and toxin
designations were corroborated by another study where structural analysis demonstrated
that intact Apxl operons, consisting o f the four contiguous genes. ApxICABD, were
present in serotypes 1. 5. 9. 10 and 11 (Jansen et al., 1993a). However, Apxl operons
with a major deletion in the ApxICA genes were present in serotypes 2. 4, 6 . 7, 8 and
12; serotype 3 did not contain Apxl operon sequences. All Apxl operons were
transcriptionally active despite the partial deletion o f the operon in some serotypes.
Next, the APP RTX-toxin III gene (ApxIII) was cloned (Jensen et al., 1993b). Two
genes. ApxIIIC and ApxIIIA. coded for proteins ApxIIIC and ApxIIIA. respectively,
which were 53 and 50% identical to the prototypic RTX proteins HlyC and HlyA o f E.
coli. It was assumed that the ApxIIIA gene coded for the structural RTX-toxin and that
the ApxIIIC gene coded for its activator. In addition, it was found that ApxIII could be
secreted from E. coli by the heterologous RTX transporter proteins. HlyB and HlyD.
The deduced amino acid sequence o f ApxIIIA was 50% identical to that of ApxIA and
41% identical to that of ApxIIA. Beside Apxl and ApxII. ApxIII was determined to be
the third RTX toxin produced by A. pleuropneumoniae.
The virulence of the RTX hemolysins (Apxl and ApxII) of the swine pathogen
Actinobacillus pleuropneumoniae was investigated using hemolysin-deficient mutants
(Tascon et al.. 1994). Two types o f haemolysin mutants with single insertions of the
transposon were obtained from a serotype I strain producing both Apxl and ApxII. One
presented a complete loss o f hemolytic activity because o f the absence o f Apxl and
ApxII production. The other displayed weaker hemolysis than the wild type and
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produced only ApxII. In the non-hemolytic mutant, the transposon had inserted in
ApxIB. a gene involved in the exportation o f Apxl and ApxII toxins. The weakly
hemolytic mutant resulted from the disruption o f the structural gene for Apxl. Both
mutations in the Apxl operon were associated with a significant loss o f virulence for
mice and pigs, demonstrating that hemolysins were involved in APP pathogenicity. The
non-hemolytic mutant was non-pathogenic and the weakly hemolytic mutant retained
some virulence for pigs, suggesting that both Apxl and ApxII were needed for full
virulence.
Actinobacillus pleuropneumoniae strains that secrete three different exotoxins
(Apxl. ApxII and ApxIII) have been implicated in the etiology o f porcine
pleuropneumonia (Chang et al.. 1993). To understand the role o f these toxins in the
pathogenesis of this disease, the hemolysin gene (ApxII )was cloned, which encodes a
110-kDa polypeptide with hemolytic and cytotoxic activity. To clone the third toxin
gene (ApxIII). a new genomic library using APP serotype 2 chromosomal DNA was
constructed. A series o f five overlapping recombinant phage clones carrying the gene
(ApxIII) for this 120-kDa antigen were identified using a DNA probe containing
sequences from the Pasteurella haemolytica IktBD genes. Sequence analysis of a
region o f the cloned DNA revealed four open reading frames encoding proteins with
predicted masses of 20.4, 112.5. 80.3 and 54.7 kDa. These genes, designated ApxIIC.
ApxIIIA. ApxIIIB and ApxIIID. respectively, were similar in sequence to the RTX
(repeat o f toxin) toxin family. The toxin produced by the cloned gene kills BL-3 cells
and was not hemolytic in vitro. Mutants of Actinobacillus pleuropneumoniae serotype
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1 that were devoid of RTX toxins did not activate or kill porcine neutrophils (Jansen et
a i, 1995; van de-Kerkhof et al... 1996). The Actinobacillus pleuropneumoniae RTXtoxins Apxl. ApxII and ApxIII were important virulence factors o f this swine pathogen
and emphasized the importance o f Apxl and ApxII in pathogenesis. The Apx toxins
may be deleterious to defense cells o f the host, enabling the bacterium to infect the host.
The hemolytic RTX toxins o f 27 isolates of APP representing all serovars have
been isolated in Australia (Tarigan et a i, 1994.1996). The quantity o f protein secreted
by these isolates was not significantly different between serovars. Hemolytic activity
was detected only in the unconcentrated supernatants from cultures o f serovar 1 and 5
isolates. Hemolytic activity in supernatants o f serovar 2. 3 and 7 isolates was detected
only after the supernatants were concentrated. The hemolytic activity o f the culture
supernatant depended on the type of composition o f media and adaptability of the
bacteria to in vitro culture. A low number o f in vivo passage after several in vitro
passages cultures of APP characterized by waxy colonies, produced significantly
weaker hemolytic activity than initial APP.
Non-Swiss albino (CF1) male mice were used as a model to study the
pathological effects of specific toxic components o f APP on the respiratory system
(Idris, et al., 1993). Mice were divided into five groups of ten each and were inoculated
by the intranasal route with whole-cell APP serotype 1. cell-free culture supernatant
fluid (CFCSF) containing hemolysin protein, purified lipopolysaccharide. heat-treated
CFCSF. or PBS solution. Pulmonary lesions were evaluated at 6 and 12 h after
inoculation. Mice inoculated with whole cells. CFCSF and LPS developed severe
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purulent bronchiolitis and alveolitis. Focal pulmonary necrosis was also observed in
these three groups but was most consistent in the CFCSF-inoculated mice.
Ultrastructurally. lungs from mice inoculated with whole cells, LPS and CFCSF were
characterized by severe degenerative changes in type I and type II pneumocytes.
Alveolar spaces contained cellular debris and fibrin. Endothelial cells were swollen and
selected pulmonary capillaries were occluded with platelets and fibrin. Infiltrating
neutrophils were often swollen, vacuolated and degranulated. Although inoculation
with relatively large numbers of APP were required to kill mice, the mouse lung was
quite sensitive to the toxic components produced by these bacteria. The elaboration of
these two toxic components by APP may be responsible for the characteristic
pulmonary inflammatory and necrotic lesions observed in infected swine.
Fluoroquinolones
Biotransformation
The predominant site of fluoroquinolone biotransformation is the piperazine ring
(Figures 1.1 and 1.2). (Neu. 1989. 1992). The oxoquinolones represent the major
metabolites o f ciprofloxacin, enoxacin and norfloxacin (Lode et al.. 1990). It has been
postulated that fluoroquinolones producing 4-oxo metabolites were stereochemically
similar to theophylline or caffeine and inhibit methylxanthine metabolism (Robson,
1992: Sakar et a i. 1990; Staib et a i, 1989; Fuhr et al.. 1992,1993). The potential for
interaction with theophylline was not identical for all gyrase inhibitors (Sorgel &
Kinzig, 1993). Enoxacin is the strongest inhibitor of theophylline and caffeine
metabolism, followed by tosufloxacin. ciprofloxacin and pefloxacin. Fleroxacin.
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ofloxacin, rufloxacin and sparfloxacin have none or negligible effects. A likely
mechanism for this interaction is the inhibition o f subsets o f the cytochrome P450
enzyme. Piperazine ring-cleaved compounds and naphthyridine nuclei were shown to
be most active inhibitors o f cytochrome P450IA2 (Figure 1.1). The effect of various
substituents was also tested, leading to an equation that predicted inhibition o f 3caffeine 3-demethylation. Piperazine ring-cleaved compounds were more inhibitory
than parent compounds and a nitrogen at position 4 or 7, respectively, reduced or
increased inhibitory activity. Data on interactions o f rifampin and cyclosporine with
gyrase inhibitors were conflicting. Rifampin increased the clearance of fleroxacin but
did not change the elimination half-life significantly. Although norfloxacin may
interfere with metabolism o f the S enantiomer o f warfarin, fleroxacin did not affect
pharmacokinetic parameters of either the R or S enantiomer or the anticoagulant
response.
Ciprofloxacin is the main metabolite o f enrofloxacin resulting from ethyl
dealkylation at the para nitrogen on the piperazinyl ring (Figure 1.2) (Outman &
Nightingale. 1989). Desethylene-ciprofloxacin ( Ml ) resulted from dealkylation of the
ethyl group from the piperazinyl ring. Sulfo-ciprofloxacin (M2) was produced when the
para nitrogen on the piperazinyl ring was sulfated. Oxo-ciprofloxacin (M3) occurred
with the oxidation o f the ortho position in relation to the para nitrogen on the 3' carbon
of the piperazinyl ring. Formyl-ciprofloxacin (M4) was formed by an aldehyde group
on the para nitrogen o f the piperazinyl ring.
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Figure 1.1. The basic structure of the quinolones relates to the inhibition of
methylxanthine metabolism. The N-C=N-C-N-C moiety is found in pipemidic acid and
enoxacin. but not lomefloxacin or enrofloxacin.
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Flavin-containing monooxvgenase
Usually, flavin-containing monooxygenases catalyze the formation of N-oxides
from tertiary aliphatic amines like the 4-methvl-1-piperazinyl gyrase inhibitors (Sorgel.
1989). Like the cytochrome P450's. flavin-containing monooxygenases are oxidative
enzymes involved in Phase I biotransformations and can be referred to as mixedfiinction amine oxidases (Sipes & Gandolfi. 1991). The FAD-flavoprotein is present in
the endoplasmic reticulum and is capable of oxidizing nucleophilic nitrogen using
NADPH and oxygen. Flavin-containing monoxvgenase competes with the cytochrome
P450 system in the oxidation o f amines, where FMO activity is high in humans and
pigs, but low in rats. Tertiary amines are converted to amine oxides, secondary amines
are converted to hydroxyl amines and nitrones and primary amines are converted to
hydroxy lam ines and oximes. The catalytic mechanism for flavin-containing
monoxvgenase is known in some detail for porcine liver (Poulsen & Ziegler. 1979:
Beaty & Ballou. 1980. 1981 a.b). The flavin-containing monooxygenases are not under
the same regulatory control as cytochrome P450's (Sipes & Gandolfi. 1991). While
P450's can be induced by phenobarbital and 3-methylcholanthrene. FMO was
repressed. Steroid sex hormones seem to regulate FMO enzymes with testosterone
decreasing and progesterone increasing the cellular concentrations. Unlike P450's.
xenobiotic substrates were not oxygenated for the reduction of flavin by NADPH or for
the reaction o f dioxygen with the reduced flavin (Poulsen & Ziegler. 1979: Beaty &
Ballou. 1980. 1981 a.b). The key to FMO catalytic activity was the 4 a hydroperoxyflavin intermediate and was formed by the reaction o f oxygen with
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reduced flavin. The 4a-hydroperoxvflavin intermediate was stable, which was a feature
unique to this type o f monoxvgenase. The hydroperoxyflavin was also the oxygenating
intermediate and oxygen was transferred from the hydroperoxyflavin to the substrate.
The oxygenation reaction was identical in a model mechanism with similar products to
the oxidation o f nucleophiles by synthetic protein-free N-5-alkyI. 4a-hydroperoxyflavin
(Ziegler. 1988). There was no evidence for intermediates during oxygen transfer in
either the porcine model or enzymatic reactions. This suggested that activation of
substrate was not required and explains the nature of products formed and for the broad
range o f xenobiotics oxygenated by flavo-protein monooxygenases. Therefore, only
xenobiotics with electron-rich centers can serve as substrates. However, the substrate
must gain access to the enzyme-bound hydroperoxyflavin. Hydroperoxyflavin was
common to all forms o f the enzyme, so it was evident that steric differences in access
may be responsible for differences in substrate specificity.
Substrate specificity o f the enzyme-bound oxygenating intermediate should be
limited to organic nitrogen compounds with functional groups that are readily oxidized
by organic peroxides (Ziegler. 1988). Hydroperoxyflavin was not a strong oxidant for
the attack of nitrogen atoms in amides, carbamides. imines. nitrones. oximes.
isocynates, nitriles. or heterocyclic aromatic amines (Poulsen & Ziegler. 1979; Beaty &
Ballou. 1980. 1981a,b). Amines, hydroxylamines. hydrazines and sulfur functional
groups were more susceptible to oxidation and xenobiotics containing these groups
were suitable substrates. Amine functional groups are quite common in alkaloids and
synthetic drugs which makes the number of substrates in this category very large. Most
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all lipophillic acyclic (nortryptyline. promazine) or cyclic (perazine, nicotine) secondary
and tertiary amines, respectively, tested were substrates. Flavin-containing
monoxvgenase had a loose specificity for amines and precise fit into the catalytic cavity
was not essential for biotransformation of substrates. Subsequently, the enzyme
catalyzes both acyclic and cyclic amines with equal efficiency.
The piperazinyl ring on enrofloxacin has two tertiary nitrogens (Figure 1.2).
The most likely position for N-oxidation and dealkylation by FMO would be the
nitrogen at the para position, possibly because there would be less steric hindrance. The
metabolism o f enrofloxacin by FMO is supported by work with tertiary amines related
to brompheniramine, an antihistamine (Cashman et al.. 1993). The metabolism of
racemic, (D)- and (L)-brompheniramine was studied in microsomes and with highly
purified FMO from porcine liver. The main metabolite was the metabolite containing
aliphatic nitrogen N-oxide. but some N-demethylation was observed. Furthermore,
brompheniramine was extensively N-oxygenated by the highly purified FMO from hog
liver. N-oxygenation o f bromapheniramine was enantioselective in both microsomes
and highly purified FMO. The Km for N-oxygenation o f (D)-brompheniramine was
markedly lower than the Km for (L)-brompheniramine. (D)- and (L)-zimeldine were
less conformationally flexible model compounds o f brompheniramine and both
compounds were found to be steroselectively N-oxygenated by the highly purified FMO
from hog liver. The results suggested that (D)-brompheniramine and (L)-zimeldine
have the aliphatic tertiary amine nitrogen atom and aromatic ring center at a defined
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distance and geometry and were more efficiently N-oxygenated than their respective
isomers.
Antimicrobial mechanism of action
The primary target o f quinolone activity in prokaryotic cells was DNA gyrase
(Vance-Bryan et al., 1990). This enzyme, a type II topoisomerases. was required for
DNA replication, transcription o f certain operons. repair and recombination. In vitro.
the quinolones inhibit gyrase mediated DNA supercoiling and promote double stranded
DNA breakage at specific sites. New details o f the molecular interactions of quinolones
with their target DNA gyrase and DNA have come from the nucleotide sequences of the
gyrA genes from resistant mutants of Escherichia coli and wild-type strains of other
bacteria and studies o f gyrase A tryptic fragments (Hooper & Wolfson 1991). The
importance o f an amino-terminal domain in quinolone action was supported by
observations o f alterations in DNA super-twisting that were associated with altered
quinolone susceptibility, possibly by indirect effects on DNA gyrase expression.
Specific binding o f relevant concentrations of norfloxacin to a complex of DNA gyrase
and DNA in the presence o f ATP. the cooperativity o f DNA binding and the crystalline
structure of nalidixic acid led to a model in which quinolones bind cooperatively to a
pocket o f single-strand DNA created by DNA gyrase. Quinolones vary in their relative
activity against DNA gyrase and its eukaryotic homolog. topoisomerase II. The action
o f the fluoroquinolones on the eukaryotic enzyme was associated with genotoxicity.
Inhibition of bacterial DNA synthesis by quinolones may correlate with minimum
inhibitory concentrations (MICs) in some species, but comparisons of drug
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accumulation and inhibition o f DNA synthesis in permeabilized cells among species
have been difficult to interpret. In addition to interaction with DNA gyrase. the specific
factors necessary for bacterial killing by quinolones include oxygen and new protein
synthesis.
Pharmacokinetic characteristics
The fluoroquinolones are characterized by a large volume o f distribution, which
is reflected by good tissue penetration and long biological half-life in dogs, pigs and
humans (Greene & Budberg. 1993; Kung et al.. 1993a.b; Lode et al.. 1990; Vancutsem
et al.. 1990). The gastrointestinal absorption in mammals is rapid and substantial; the
duration of action is long and the excretion mainly through the kidney (Vancutsem et
al.. 1990). Their adverse effects were not severe when compared to the beneficial
features fluoroquinolones exhibit. The targets for adverse effects are: central nervous
system, urinary tract. DNA (genotoxicity). skin (phototoxicity), reproductive, digestive
tract and the juvenile cartilage (Takayama et al.. 1995; Vancutsem et al.. 1990). Neither
blood concentration nor pH affected low serum protein binding (Greene & Budberg.
1993; Kung et al.. 1993a.b; Lode et al.. 1990). Low serum protein binding promoted
rapid elimination by renal and extrarenal mechanisms with high total and renal
clearances. There was transluminal enteric excretion as well as nephron tubular
secretion (Wolfson & Hooper. 1991: Vance-Bryan et al.. 1990). The transluminal
elimination of ciprofloxacin implied that the drug was eliminated across the intestinal
wall without significant biliary elimination (<1%) (Bergan. 1989). In fact, transluminal
elimination compensates for loss o f renal elimination. All fluoroquinolones, except
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pefloxacin and enrofloxacin. undergo limited metabolism (Wolfson & Hooper. 1991:
Vance-Bryan et a l. 1990). Water solubility promotes excellent bioavailability and
rapid distribution. In humans, pharmacokinetic characteristics include a large volume
o f distribution for fluoroquinolones (1.74 to 5.0 L/kg), a two compartment model after
oral dosing and a three compartment model after i.v. dosing (Lode et a l. 1990). The
two peripheral compartments consist of one with a rapidly equilibrating high clearance
rate and the other slowly equilibrating with a slow clearance rate that prolongs the halflife (Lode et a l. 1990).
The large volume o f distribution is not counterbalanced by rapid elimination of
quinolones for most species. In pigs, the half-life is 6 to 8 h for the elimination of
ciprofloxacin, which is much slower than other reported half lives (Kung et a l.
1993a.b). Ciprofloxacin may have potential clinical use in veterinary medicine, because
o f its breadth and intensity o f activity against Gram-negative pathogens and no cross
resistance with P-Iactams or aminoglycosides occurs (Nouws et a l. 1988). Pigs were
administered an i.v. injection o f 3.06 mg/kg of ciprofloxacin. The volume o f
distribution, elimination half-life and total clearance were: 3.83 L/kg. 2.57 h and 17.3
ml/min/kg respectively. Twenty four hours after i.v. dosing, the urinary drug
concentration in pigs was 8.9 pg/ml and plasma protein binding for ciprofloxacin in
pigs was 23.6 %. The renal clearance of ciprofloxacin was 10 times higher than the
creatinine clearance and indicated a predominately tubular secretion pattern o f the drug.
Urinary recovery for pigs following i.v. administration was 47.9%. No glucuronide
conjugates o f ciprofloxacin or its metabolites (M, or M2) were detected in the plasma or
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urine o f the pigs (Nouws et al., 1988). The low protein binding o f ciprofloxacin was
attributed to interference o f fatty acids in the drug binding by albumin or fewer binding
sites on albumin and a i-acid glycoprotein (Belpaire. 1986).
The relationship o f the physicochemical properties o f gyrase inhibitors to their
hepatic and renal elimination pathways was analyzed (Sorgel & Kinzig, 1993). Luminal
fluid concentrations o f gyrase inhibitors were affected by an active process and
inhibited by agents, such as probenecid, that inhibit tubular secretion o f anions (Bergan.
1989; Sorgel & Kinzig. 1993). Probenecid may inhibit base transport in the proximal
tubule and inhibit quinolone transport as well. Available evidence suggested that all
gyrase inhibitors were secreted as anions by the proximal tubules. Cimetidine. which is
cationic at physiologic pH. inhibited base transport in the proximal tubule and inhibit
base transport o f gyrase inhibitors. Reabsorption also affected tubular concentrations.
The N4'-methylated derivatives were the most lipophilic and addition or removal of the
methyl group can. but did not always, affect reabsorption. The data indicated that all
gyrase inhibitors undergo tubular secretion as either acids or bases and that some also
were significantly reabsorbed. Hepatic handling and resultant excretion o f metabolites
were also influenced by the presence or absence of N4'-methylation. A step in the
hepatic handling o f N4'-methylated gyrase inhibitors that leads to N4'-oxidation has not
yet been found in rufloxacin.
Enrofloxacin in veterinary medicine
In the USA. approved use o f enrofloxacin is limited to dogs; approval for use in
food-animals is currently being sought for several fluoroquinolones (Greene &
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Budberg, 1993: Vancutsem et al., 1990). even though extra-label use of other approved
fluoroquinolones has been banned by the U.S. Food and Drug Administration. The
activities o f danofloxacin. a novel fluoroquinolone and two other antimicrobials were
determined in vitro against field isolates o f seven Mycoplasma species o f veterinary
importance isolated from cattle, swine and poultry in five European countries (Cooper
et al., 1993; Giles et al., 1991; McGuirk et a i. 1992). It was concluded that
danofloxacin is highly active in vitro for the antibiotic control of all of the Mycoplasma
species tested and thus showed great potential for the treatment o f respiratory and other
infections caused by Mycoplasma species in cattle, pigs and poultry. Marbofloxacin is a
new fluoroquinolone that was developed exclusively for veterinary use (Spreng et ai.
1995) Marbofloxaicn showed a broad spectrum of activity for the treatment o f Gramnegative and Gram-positive bacterial diseases in dogs and cats. The post-antibiotic
effect durations were found to be almost equal to the durations of enrofloxacin and
ciprofloxacin. Marbofloxacin has been recently approved in 1997 in the United
Kingdom for salmonellosis and colibacillosis in cattle (Dr. Michael Myers, personal
communication).
Enrofloxacin is available in some countries as a injectable for parenteral use and
as a food additive (Greene & Budberg. 1993). Enrofloxacin is the first antibacterial of
this family to be available to veterinary medicine in the United States (Vancutsem et al..
1990). In swine, quinolones are effective for treating difficult respiratory diseases:
mycoplasmal pneumonia and arthritis; enteric infections such as diarrhea o f suckling,
weaning or fattening pigs (coli diarrhea); septicemia caused by pathogenic Escherichia
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coli (edema disease) or Salmonella spp.; mastitis-metritis-agaiactia and urinary tract
infections (Vancutsem et al., 1990; Wendt. & Sobestiansky 1995). Enrofloxacin is
effective for the control of diseases caused by Escherichia coli and Haemophilus.
Mycoplasma, Pasteurella, Eubacterium suis, Actinobacillus suis, Actinomyces
pyogenes, Corynebacterium pseudotuberculosis. Erysipelothrix rhusiopathiae.
Haemophilus pctrasuis, Haemophilus somnus, Pasteurella haemolytica, Pasteurella
multocida, Rhodococcus equi. Streptococcus equi. Streptococcus suis. Streptococcus
zooepidemicus and Salmonella spp in the United States (Hariharan et al., 1995; Prescott
& Yielding. 1990; Vancutsem et al., 1990; Wendt. & Sobestiansky 1995).
Streptococcus suis types 1 and 2 were most commonly isolated via direct swabbing of
palatine tonsils of healthy nursery pigs on 35 farms throughout the United States (Dee et
al.. 1993). All isolates o f Streptococcus suis were susceptible to enrofloxacin. 97% of
the isolates were susceptible to ceftiofur and 94% were susceptible to ampicillin.
However, only 80% o f the isolates were susceptible to penicillin and only 18% were
susceptible to tetracycline.
While vaccine protection has not been rewarding for the control o f porcine
pleuropneumonia caused by APP. antimicrobial therapy has proven to be effective .
Treatment for infection usually lasts 8 to 10 days in swine using quinolones. In
controlled studies of swine infected with APP, 60% of the pigs died 18 to 56 h after
experimental inoculation (Glawischnig et al., 1989; Schroder. 1989). Enrofloxacin was
administered intramuscularly for 3 days at 2.5 to 5 mg/kg beginning 8 h post-infection
or 5 mg/kg starting 12 h post-infection. Clinical improvement began 12 h after therapy
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was initiated and recovery was facilitated in all treated animals (Bauditz. 1987;
Stephano et al.. 1987).
In a recent study, the pharmacokinetic parameters o f enrofloxacin in clinically
normal dogs and mice and drug pharmacodynamics in neutropenic mice with
Escherichia coli or Staphylococcal spp. infections were investigated (Meinen et al..
1995; Walker et al.. 1992). Enrofloxacin dosages ranged from 0.78 to 50 mg/kg of
body weight in dogs and 6.25 to 200 mg/kg in mice. It was determined that
enrofloxacin total dose rather than the dose frequency was significant in determining
drug efficacy. Pharmacokinetic parameters were analyzed by multivariate stepwise
linear regression analysis. The calculations revealed that the area under the
concentration-time curve was more important than the time above minimum inhibitory
concentration. So. enrofloxacin killing of Escherichia coli and Staphylococcus was
plasma concentration-dependent and not time-dependent.
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CHAPTER II
INFECTION M ODEL
Introduction
Previous experiments by other investigators were designed to demonstrate
efficacy and pharmacokinetic changes using non-infected animals. However, animals
may have altered drug disposition and clearance when infected with pathogenic
organisms. The infectious disease may alter the drug pharmacokinetic changes and
efficacy studies often do not examine drug pharmacokinetic parameters. Therefore,
evidence o f a potential problem will not be detected. Few studies have explored the
possibility o f drastically increased toxicity or reduced efficacy in domestic animals to
the same extent as rodent and human studies (Monshouwer. 1996: Monshouwer et al..
1995a.b. 1996a.b: Myers & Kawalek. 1995: Pijpers et al.. 1990.1991: Short. 1986:
Short et al.. 1986). Endotoxin has been shown to reduce the elimination rate of
antipyrine and trimethoprim in swine and decreased the total clearance o f tiliazad
mesylate in beef calves (Ladefoged, 1979: Rose et al.. 1993).
Target animal safety problems could arise in the drug development and approval
process whereby therapeutic doses are actually toxic in the infected animal (Ladefoged.
1979: Rose et al.. 1993). Conversely, increased rate o f clearance could indicate a need
for more frequent dosing. Doses that were previously efficacious may not be sufficient
to treat an infected animal. Human food safety is a concern. However, increased drug
clearance and decreased half-life in food animals would result in decreased residue
concentrations that are well below tolerance concentrations and withdrawal times.
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The goal o f the infection study was 1) to characterize pharmacokinetic changes
associated with APP infection in swine after receiving enrofloxacin and 2) to evaluate
the pulmonary infection model compared to the endotoxin model and 3) to characterize
the systemic level o f cytokines that may be associated with pharmacokinetic changes.
Plasma concentrations of IL-6 were determined from 0 to 72 h after infection. Plasma
concentrations o f IL -ip were determined for 0. 2, 6 and 12 h after infection. Plasma
concentrations o f enrofloxacin and ciprofloxacin were determined for pharmacokinetic
analysis from 24 to 72 h after infection. Urine enrofloxacin and ciprofloxacin were also
measured and normalized with urine creatinine concentrations for samples collected 48
and 72 h after infection. Gross necropsies were performed on all pigs which included
lung weights and tissues collection for histopathology.
Materials and Methods
Animal management
The experiment consisted of 24 crossbred. Landrace x Yorkshire, castrated pigs
that were procured from a local vendor. All o f the pigs were weighed prior to
intravenous catheterization and were within a 25 to 35 kg weight range. Housing
consisted o f a heated building with a concrete floor and all animals were fed 3 kg/day
from a single batch o f a commercial corn-based ration without antibiotics. The pigs had
been fed a commercial ration that was medicated with tylosin before procurement. All
pigs were examined upon arrival and were clinically healthy at the start o f the study.
All procedures were approved by the Food and Drug Administration, Center for
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Veterinary Medicine, Office o f Research. Institutional Animal Care and Use
Committee.
Experimental design
The design consisted o f a 2 x 2 factorial o f treatments groups (Table 2.1).
Actinobacillus pleuropneumoniae (gift from Dr. Michael P. Murtaugh. University of
Minnesota. St. Paul. Minnesota) was one treatment. The second treatment was
dexamethasone (0.5 mg/kg, Phoenix Pharmaceuticals. St. Joseph. Missouri). The
bacteria were administered bv endotrachael infusion at zero hour into two o f the four
groups as a comparison to endotoxin that was administered by i.v. bolus in the next
experiment. Intranasal inoculation in previous studies had resulted in a low infection
rate while endotrachael inoculation produced a 100% infection rate. Four groups of six
pigs were intravenously catheterized and placed in stainless steel metabolism cages over
a one month period. Two groups were procured at a time and one group was placed in
metabolism cages for four days followed by the second group. This process was
repeated with another two groups of pigs. The Actinobacillus pleuropneumoniae was
administered as a single endotrachael infusion to two groups while the other two groups
received a sham saline infusion (Table 2.1). One infected group and one sham group
received i.v. dexamethasone at -18 h . 0 h and 12 h . A bolus dose of 5 mg/kg
enrofloxacin (Baytril . Bayer, Shawnee Mission. Kansas) was administered
intravenously 24 h after saline or bacterial infusion to all four groups o f pigs.
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Table 2.1. Experimental design for the Actinobacillus pleuropneumoniae infection
study.
Treatment

Sham Infection

Infection

Sham Infection

Infection

No Dexamethasone

No Dexamethasone

Sham Infection

Infection

Dexamethasone

Dexamethasone

No Dexamethasone

Dexamethasone
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Bacteria
Animals were endobronchially inoculated with Actinobacillus
pleuropneumoniae serotype 1. strain L91-2. a field strain isolated from an outbreak in
Iowa(Baarsch et. a i . 1995: van Leengoed et. al.. 1987. 1989. 1990). The virulence of
strain L91-2 was reduced by serial in vitro passage on solid growth media. Single
colonies were passaged four times or until atypical morphology was evident. Colonies
were creamier in appearance and two to three times larger and had a more rapid growth
rate compared to non-passed microorganisms.
Logarithmically growing bacteria were employed to prepare inocula for the pigs.
Cultures o f APP bacteria were grown on agar plates from frozen stock (-70°C) that had
been preserved in broth culture and 80% glycerol. The agar media consisted of 43
grams of Casm an's agar (Difco Laboratories, Detroit. Michigan) dissolved in 1000 ml
o f water and autoclaved for 20 minutes. The media was allowed to cool to 50°C and 50
ml of heat inactivated horse serum was added. After the addition of 2 ml (5 g/L) of
sterile NAD (Sigma. St. Louis. Missouri) the agar was poured into sterile plates. After
incubating at 37°C for 12 hours, a single colony wras picked from the Casm an's plate
and inoculated into 3% tryptic soy broth (Difco Laboratories. Detroit. Michigan)
containing 1% NZ amine (Sigma, St. Louis. Missouri), 0.1% yeast extract and 0.001%
NAD and incubated at 37°C for 4-6 h while shaking at 215 rpm. The NAD was added
to the broth after autoclaving and just before inoculation o f the bacteria.
The cells were washed with 5% bovine serum albumin (BSA) in phosphate
buffered saline (PBS. pH 7.4) after centrifugation at 1500g for 10 minutes. The washed
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cells were diluted to 0.4 optical density (550 run) which corresponded to approximately
2.0 x 10 CFU/ml. Viable cell-counts before inoculation were confirmed by plating on
Casman's agar and reading the plate counts on the day following endobronchial
inoculation. The cells were further diluted in PBS-BSA to about 2 x 104 CFU/ml. Six
milliliters o f the 2 x 104 CFU/ml bacterial inoculum was delivered through a rigid
polypropylene tubing (1 m x 1 mm I.D.) into the bronchial lumen using a 12 ml syringe.
Air was flushed into the polypropylene tubing after the inoculation of the bacteria.
Non-infected animals received 6 ml o f PBS-BSA.
Blood collection
A cranial vena cava catheter was implanted in each animal 24 h prior to bacterial
inoculation or saline inoculation. Plastic tubing (0.6 mm I.D. x 1 m) was inserted
through a 14 gauge (14 cm in length) stainless steel cannula (Brocht et al.. 1989; van
Leengoed et al.. 1987). The animals were restrained without anesthesia while inserting
the cannula 2.5 cm lateral to the point of the sternum at a 45° angle. The catheter was
secured at the point o f skin penetration with surgical silk. The end of the catheter was
extended to the back o f the neck and protected with 15 cm of Elastikon2' (Johnson &
S)
Johnson. Raritan. New' Jersey) and two rolls of Vetrap (3M Animal Care. St. Paul.
Minnesota). A 19 gauge tubing adapter (Becton/Dickson. Sandy. Utah) was inserted
into the end of the catheter and fitted with an injection cap (Becton/Dickson, Sandy.
Utah).
Blood samples were collected through a saline-heparin lock (10 units/ml. Sigma.
St. Louis, Missouri) in order to measure plasma concentrations o f enrofloxacin.
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ciprofloxacin (Sigma, St. Louis. Missouri) IL-6 and TNF-a. Cytokine blood samples
were collected in heparin tubes (Monovette. Sarstedt, Germany) at 0. 1. 2. 3,4, 6. 8, 10.
12.24, 36. 48. 60 and 72 h after sham infection or infection. High-performance liquid
chromatography (HPLC) samples were also drawn in heparin tubes at 0. 0.25. 0.5. 1. 2.
3, 4. 6, 8, 12. 24, 30 and 48 h after i.v. administration o f enrofloxacin at 24 h post
infection or sham infection. The samples were placed on ice before transporting to the
laboratory and centrifuged (Jouan CR 412. Winchester. Virginia) at 1500g for 10
minutes. The centrifuged plasma was harvested and aliquoted for storage at -70°C.
Pharmacokinetic analysis
Plasma sample preparation
Plasma samples were analyzed for enrofloxacin and ciprofloxacin by mixing 100
pi of sample with 300 pi o f a 2: 1 mixture of 0.05 N sodium hydroxide (Sigma. St.
Louis. Missouri) and acetonitrile (HPLC grade. Burdick & Jackson. Muskegon.
Michigan) containing 333 pg/L o f pipemidic acid (Tyczkowska et al.. 1994). The final
internal standard concentration o f the fortified samples was 250 ng/ml pipemidic acid.
After vortexing for 10-15 seconds, a 200 pi aliquot was placed in a 30.000 molecular
weight cut-off microfilter (Microcon 30®. Millipore. Burlington. Massachusetts) and
centrifuged (Eppendorf 5402. Brinkman Instruments, Westbury, New York) at 14.000g
in a 45° fixed-angle rotar for 1 h . Approximately 150 pi was recovered and placed in
tapered glass sample vials (Sulpelco. Bellefonte. Pennsylvania). Ten microliters o f the
clear ultrafiltrate was injected into the liquid chromatograph.
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Urine sample preparation
Urine samples were collected 24 h after infection or sham infection and at 0. 24
and 48 hours after enrofloxacin administration. The urine samples were aliquoted into
cryovials and stored at -70°C. After thawing at room temperature, sample dilution was
accomplished by adding 100 pi o f the sample to 400 pi o f diluent (2: 1 mixture of 0.05
N. sodium hydroxide and acetonitrile) in siliconized microcentrifuge tubes (Costar,
Cambridge, Massachusetts) and mixed by vortexing. A 50 pi aliquot was taken from
the 1:4 urine dilution and added to a sample vial containing 950 pi o f the following
mixture: 750 pi o f 0.05 N sodium hydroxide and acetonitrile (2: 1): 200 pi o f distilled
water with 263 pg/L o f pipemidic acid. The pipemidic acid had been added from a 5
mg/L stock solution that was diluted with the 2: 1 mixture o f 0.05 N sodium hydroxide
and acetonitrile. The pipemidic acid, water and sodium hydroxide/acetonitrile were
mixed in a single batch prior to addition to the sample vial. The final urine dilution in
the sample vial was 1: 99 after mixing the 50 pi of the 1:4 diluted urine to the 950 pi of
internal standard, water and 2: 1 mixture of 0.5 N sodium hydroxide/acetonitrile. The 2
ml glass sample vials (Sulpelco. Bellefonte, Pennsylvania) were placed in the HPLC for
10 pi injections.
Urine creatinine
Urine creatinine was used to normalize the urine concentrations o f enrofloxacin
and ciprofloxacin (Palmisano et. al.. 1995). This approach avoided the need to collect
and measure the volume o f 24 hour urine samples, because o f the occasional
contamination with drinking water or accidental loss of a portion of the 24 hour urine
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sample. Urine creatinine was assayed using a Urine Creatinine Kit (Sigma, St. Louis,
Missouri). The urine samples were first diluted ten to thirty times with water. Working
standard dilutions were prepared by diluting 150 mg/L stock standard with water
resulting in a standard curve consisting o f 0. 25. 50, 75. 100 and 150 mg/L. Sample and
standards were prepared in triplicate by adding 30 pi to 300 pi o f alkaline picrate
solution into each well o f a microplate including the standard curve wells on each plate.
The plates were mixed for 30 seconds and let stand at room temperature for 10 minutes.
The plates were read at 500 nm using a microplate spectrophotometer (Spectra Max
250. Molecular Devices. Sunnyvale. California)
The standard curve on each of the four test plates was linear, "y" (absorbance)
versus “c" (concentration. mg/L): y=0.007 c + 0.221. R=0.9995; y=0.007 c + 0.189,
R=0.9995; y=0.007 c + 0.191. R=1.0: and y=0.007 c + 0.185. R=0.9995. The
coefficient o f variation was less than 7% and 10% for the standar ds and samples,
respectively.
Recovery of the internal and external standards
Pooled pig plasma from an unrelated study was used to explore recovery of
ciprofloxacin and enrofloxacin. Ten serial dilutions (1: 1) o f ciprofloxacin and
enrofloxacin were prepared in the range o f 313 pg/L to 80 mg/L using water. The final
concentrations o f the 10 standards ranged from 15.6 pg/L to 4 mg/L after adding 50 pi
of each stock standard to 950 pi of pooled pig plasma. The fortified plasma samples
were analyzed for enrofloxacin and ciprofloxacin by mixing 100 pi of the fortified
plasma with 300 pi o f a diluent consisting of: a 2: 1 mixture o f 0.05 N sodium

113

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

hydroxide and acetonitrile with 333 pg/L pipemidic acid as the internal standard
(Tyczkowska et al.. 1994). The final internal standard concentration o f the fortified
samples was 250 pg/L pipemidic acid. After vortexing for 10-15 seconds, a 250 pi
aliquot was placed in a 30.000 molecular weight cut-off microfilter and centrifuged at
14.000g in a 45° fixed-angle rotary for lh. Approximately, 200 pi of the ultrafiltrate
was recovered and placed in tapered glass sample vials. Ten microliters o f the clear
ultrafiltrate was injected into the liquid chromatograph Average analyte recovery from
five replicates at each o f the 10 concentrations ranged from 91% to 104% for pipemidic
acid. 94% to 107% for ciprofloxacin and 94% to 106% for enrofloxacin. The plasma
peak height counts were compared to the average o f five replicates of aqueous internal
standard and external standards that were prepared in water without microfiltration. The
coefficients o f variation for each of the 10 concentration recoveries ranged from 1.9% to
11% for the percent o f recovery of pipemidic acid, ciprofloxacin and enrofloxacin.
Aqueous standard curves for plasma
Aqueous standard curves for plasma were constructed by first preparing
enrofloxacin and ciprofloxacin working standards consisting o f eleven dilutions: 0.
0.156. 0.313. 0.625. 1.25. 2.5. 5.0. 10.0. 20. 40 and 80 mg/L. Each working standard
was diluted 20 times to final concentrations ofO, 0.0078. 0.0156. 0.0313. 0.0625. 0.125,
0.25, 0.5. 1. 2 and 4 mg/L. for enrofloxacin and ciprofloxacin. The final dilution for
HPLC analysis was prepared by adding 50 pi o f working standard to 950 pi o f the
following mixture: 750 pi o f 0.05 N sodium hydroxide and acetonitrile (2: 1); 200 pi of
distilled water with 263 pg/L of pipemidic acid. The pipemidic acid had been added
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from a 5 mg/L stock solution that was diluted with the 2: 1 mixture o f 0.05 N sodium
hydroxide and acetonitrile. The pipemidic acid, water and sodium
hydroxide/acetonitrile were mixed in a single batch prior to addition to the sample vial.
The final internal standard concentration o f the standards and fortified samples was 250
ng/ml of pipemidic acid. The standards were not filtered through the 30.000 molecular
weight cut-off filters.
The linearity o f the response, "y" (ratio of peak height counts) versus ”c '
(concentration. mg/L) were tested over eight standard solutions. The typical response
standard curves for plasma samples were linear as represented by the equations: y=12.8
c + 0.135. R=0.9995 for enrofloxacin; and y=10.2 c - 0.323. R=0.9984 for
ciprofloxacin. Five replicates of each o f the 10 standard concentrations (7.8 pg/L to 4
mg/L) for ciprofloxacin and enrofloxacin yielded coefficients o f variation ranging from
2% to 6% for ciprofloxacin and 0.8% to 13% for enrofloxacin.
Aqueous standard curves for urine
Aqueous standard curves for urine were constructed by first preparing
desethylene-ciprofloxacin. enrofloxacin and ciprofloxacin stock standards.
Desethylene-ciprofloxacin stock standard (6.25 mg/L) was diluted (1 :1 ) into the
enrofloxacin and ciprofloxacin stock standard (20 mg/L). Working standards were
prepared by simultaneous 1:1 serial dilutions of the three standards in the stock solution.
The working standards concentrations were: 0. 0.0244. 0.0488. 0.0975. 0.195. 0.39.
0.78. 1.56 and 3.13 mg/L for desethylene-ciprofloxacin and corresponding dilutions: 0.
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0.078. 0.156. 0.313. 0.625, 1.25. 2.5, 5.0 and 10.0 mg/L o f enrofloxacin and
ciprofloxacin.
Each working standard was diluted 20 times with 0.05 N sodium
hydroxide/acetonitrile (2:1) to final concentrations o f 0. 3.9. 7.8. 15.6. 31.3. 62.5. 125.
250 and 500 pg/L, for enrofloxacin and ciprofloxacin and 0. 1.22. 2.44. 4.88. 9.75. 19.5.
39. 78 and 156 pg/L. for desethylene-ciprofloxacin. The final solution for HPLC
analysis was prepared by adding 50 pi o f working standard to 950 pi o f the following
mixture: 750 ul o f 0.05 N sodium hydroxide and acetonitrile (2: 1): 200 pi o f distilled
water with 263 pg/L of pipemidic acid. The pipemidic acid had been added from a 5
mg/L stock solution that was diluted with the 2: 1 mixture o f 0.05 N sodium hydroxide
and acetonitrile. The pipemidic acid, water and sodium hydroxide/acetonitrile were
mixed in a single batch prior to addition to the sample vial. The final internal standard
concentration o f the standards and fortified samples was 250 ng/ml o f pipemidic acid.
The internal standard, water and sodium hydroxide/acetonitrile were mixed in a single
batch prior to addition to the sample vial. The standards were not filtered through the
30.000 molecular weight cut-off filters.
The linearity o f the response, "v” (ratio of peak height counts using the internal
standard, pipemidic acid) versus concentration, "c” (mgT. for desethyleneciprofloxacin, ciprofloxacin and enrofloxacin) were tested over eight standard dilutions.
The typical response standard curves for urine samples were linear as represented by the
equations: y=16.0 c - 0.0379. R=0.9997 for enrofloxacin; y=l 1.8 c + 0.00253.
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R=0.9997 for ciprofloxacin; and y=123 c + 0.0434, R=0.9997 for desethyleneciprofloxacin.
Five replicates o f each of the 8 concentrations (3.9 - 500 pg/L for ciprofloxacin
and enrofloxacin and 1.22 - 156 pg/L for desethylene-ciprofloxacin) o f standard yielded
coefficients o f variation ranging from 0.7% to 2.9% for desethylene-ciprofloxacin, 2%
to 11 % for ciprofloxacin and 1% to 9% for enrofloxacin. respectively. The minimum
detection concentrations for pipemidic acid, ciprofloxacin, enrofloxacin. and
desethylene-ciprofloxacin were 33. 10. 12 and 1 ng/ml, respectively. The actual
minimum detection level was 40, 49 and 4 ng/ml for ciprofloxacin, enrofloxacin and
desethylene-ciprofloxacin. respectively because of a four-fold plasma dilution. The
actual minimum detection limit for urine was 200. 240 and 20 ng/ml for ciprofloxacin,
enrofloxacin and desethylene-ciprofloxacin. respectively because o f a 20-fold urine
dilution. The minimum detection limit was based on a signal-to-noise ratio of 3.
High-performance liquid chromatography
Ten microliters injections o f samples and standards were loaded into a
Rheodvne injector valve using a an autosampler that was incorporated into the liquid
chromatograph (Perkin Elmer Integral 4000. Perkin Elmer. Norwalk, Connecticut). The
column was a reverse phase C-18 column with dimensions of 250 mm c 3.2 mm and a 5
pM particle size protected by a guard column (Primasphere^. Phenomenex, Torrance.
California). The mobile phase for the plasma samples consisted o f 19% acetonitrile and
81% 0.15 M citric acid (Sigma. St. Louis. Missouri) with a flow rate o f 0.5 ml/min with
a 10 minute run time for plasma. The mobile phase for the urine samples consisted of
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18% acetonitrile and 82% 0.15 M citric acid with a flow rate o f 0.5 ml/min with a 14
minute run time. The UV detector was set at 280 nm and the fluorescence detector (LS4, Perkin Elmer. Norwalk, Connecticut) settings were 276 nm and 450 nm for excitation
and emission, respectively. The peak height data was integrated by Turbochrom9
(Version 4.2. Perkin Elmer-Nelson, San Jose. California). The resulting plasma
concentrations were then subjected to nonlinear regression analysis using a
noncompartmental model (WinNonlin Version 1.1. Apex, North Carolina).
Interleukin-6 bioassay
Interleukin-6 assay was performed as previously described using the murine IL6 dependent 7TD1 cell line (ATCC No. CRL 1851. Rockville. Maryland) to assay the
swine plasma (Myers et al.. 1992). The cells were grown in Ultraculture media (500
ml. Bio-Whittaker. Walkersville, Maryland) with supplements o f HEPES (5 ml. 1 M.
Sigma. St. Louis. Missouri), gentamicin (1 ml. 50 mg/ml. Bio-Whittaker. Walkersville,
Maryland), sodium bicarbonate (5 ml. 7.5%. Sigma. St. Louis. Missouri), fungizone (2
ml. 250 mg/ml, GIBCO, Grand Island, New York) and glutamine (10.3 ml. 200 mM.
Sigma. St. Louis. Missouri). The media was further supplemented with 10 units of IL6/mI and 50 pM o f 2-mercaptoethanol to maintain the cells.
The cells were washed three times in assay media that did not contain IL-6. A
standard curve was prepared for each 96-well microplate (Costar. Cambridge.
Massachusetts). A standard curve (33.3, 25, 10. 5. 3.33. 2.5. 1 and 0 units per/ml) was
prepared for each microplate by dilutions. Specific activity o f the human IL-6 standard
o

was 1.375 x 10 units/mg o f protein. The samples were diluted 1: 39 with assay media
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and 100 pi o f the diluted sample or standard was added, in duplicate, to the appropriate
wells. The 7TD1 cells were diluted with assay media to a concentration o f 2-10 cells x
104 cells/ml and 100 pi o f cells was added to each well of the microplate. The plates
were incubated for 68 hour at 37°C in 5% C 0 2. Four hours before termination. 20 pi of
Alamar blue dye (Alamar Biosciences, Sacramento, California) was added to each well
and the plate was incubated at 37°C for 4 hours. The activity of the IL-6 was assessed
by use of a fluorometer (Cytofluor 2350. Millipore. New Bedford. Massachusetts) with
settings o f 530 nm excitation and 590 nm emission.
The standard curve was plotted as a log-logit transformation using Cytocalc
(Millipore. New Bedford. Massachusetts). The log-logit transformations gave 12 linear
response curves. ”y" (absorbance) versus "c" (concentration, pg/ml). for each plate:
y = l.57 c - 5.34. R=0.95; v=l.49 c - 5.12. R=0.94; y=1.41 c - 4.82. R=0.91; y = l.50 c 4.95. R=0.92; y=1.38 c - 4.70. R=0.91: y=1.40 c - 4.76. R=0.90; v=1.27 c -4.45.
R=0.98; y=l .44 c - 4.98. R=0.99; y=l .38 c -4.72. R=0.99; v=1.45 c -5.05. R=0.98:
y=l .33 c - 4.63. R=0.98 and y=1.38 c - 4.81. R=0.99. The sample values were
interpolated from the standard curve on each o f the microplates and the data was plotted
using SigmaPlot (Version 3.0. Jandel Scientific. San Rafael. California).
Interleukin-ip ELISA assay
Microplates that were coated with mouse monoclonal antibody to IL -1p
(Interleukin-ip ELISA Test K.it. Genzyme Diagnostics. Cambridge, Massachusetts)
were used to measure IL-1P in pig plasma at 0, 2. 6 and 12 hours. A 100 pi aliquot of
standard or sample was added to each well in duplicate. A standard curve was prepared
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to include 0. 4. 64. 256, 512 and 1024 pg/ml o f IL -1p using polypropylene culture
tubes. The serial dilutions o f the standards were accomplished with sample diluent that
was supplied in the kit and were mixed by vortexing. The undiluted plasma was added
directly to the test wells.
The test wells were covered with plate sealer and incubated for 30 minutes at
37°C to allow IL -1P to bind with the monoclonal antibody. The liquid was aspirated
from the test wells after incubation. The wells were washed five times with wash
reagent followed by aspiration after each wash. After the last wash, the plates were
blotted with paper towels to remove excess liquid. Reconstituted IL-1P rabbit
polyclonal antibody (100 pi) was added to each well. The plates were covered with
plate sealer and incubated for 30 minutes at 37°C. The test wells were washed and
aspirated five times and 100 pi o f IL-1(3 conjugate (peroxidase anti-rabbit IgG reagent)
was added to each well. The plates were incubated for 15 minutes at 37°C and washed
five times.
Finally. 100 pi o f peroxidase substrate and chromagen (tetramethylbenzidine)
reagent was added to each well and the plates were incubated for 30 minutes at room
temperature. A blue color was produced in the presence o f the peroxide enzyme. The
color reaction was stopped by the addition o f acid (50 pi) which changes the blue color
to yellow. The intensity o f the yellow color was directly proportional to the amount of
IL-ip present in the sample or standard. The plates were read at 450 nm absorbance on
a microplate spectrophotometer (Spectra Max 250. Molecular Devices. Sunnyvale.
California) within 30 minutes after stopping the reaction. A standard curve was plotted
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using Softmax Pro (Version 1.2, Molecular Devices. Sunnyvale. California) and the
plasma sample concentrations of IL-ip were interpolated from the standard curve on
each plate. The response curves of the standard dilutions were nonlinear, "y”
(absorbance) versus "c” (concentration, pg/ml): y=0.12 + 0.006 c - (2.5 x 10-6)c\
R=0.9995 and y=0.175 + 0.009 c - (5 x 10-6)c2. R=0.9995.
Health observations, necropsies and histopathology
Health observations were made during the entire study period of 4 days. Gross
necropsies were performed on all animals in the infection study. The pigs were
euthanized with Euthasol® which contained sodium pentobarbital (Delmarva
Laboratories. Inc.. Bristol. Tennessee). Brain and spinal cord were not examined. Fresh
liver (100 to 200 grams) was collected and frozen at -80°C if required to perform
Northern or Western blots. Lung weights and gross necropsy observations were
recorded on a necropsy form. The color, texture, location and size o f gross lesions were
also noted on the necropsy form. After trimming the trachea from the lung at the level
o f the cranial bronchi the lung was weighed before sampling for histopathology.
The following tissues (1-2 mm thick up to 4 x 4 cm) were collected for
histopathology: right bronchial lymph node, middle mediastinal lymph node, mesenteric
lymph node, lung, two sections of heart from the left ventricle and septum, three
sections o f liver from different lobes, one section o f the middle region of the spleen and
one section o f each kidney. The lungs were covered with a paper towel during fixation
in the specimen jar. If gross abnormalities were observed in other organs or tissues, a
sample was collected for histopathology. The tissues were placed in a 4 L specimen jar
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containing 10% buffered formalin. pH 7.4. (Sigma. St. Louis. Missouri) in a 1: 20 ratio
o f tissues to formalin. The tissues were allowed to fix in the formalin for 24 hours and
the spent formalin was decanted and replaced with fresh formalin. The tissues were
allowed to completely fix for at least one week before transporting to the Department of
Veterinary Pathology. College of Veterinary Medicine. Louisiana State University,
Baton Rouge. Louisiana for processing and microscopic examination. The tissues were
sealed and shipped to Louisiana State University in whirl pack plastic bags with a
minimum of formalin. Selected tissues were processed by routine methods for light
microscopy.
Statistics
Pharmacokinetic parameters, urine enrofloxacin and ciprofloxacin
concentrations. IL -1 and IL-6 plasma concentrations and lung weights were analyzed by
Two-Way ANOVA. General Linear Model, using SigmaStat. Version 2.0 and
SigmaPlot. Version 3.0 (Jandel Scientific. San Rafael. California). Pharmacokinetic
parameters that were statistically analyzed were: : Area Under Curve. 0 h to last
sample. (AUCq.*

pg h /L); Area Under Curve. 0 h to infinity. ( A U C , p g h /L);

Mean Residence Time, (MRT. h ); Terminal half-life. (t1/2 h ); Total Body Clearance
(Cltot. L/hr/kg); Volume o f Distribution at Steady State (Vss. L/kg) and Volume of
Distribution o f the elimination phase (Vp, L/kg)) and Elimination Rate Constant (p.
1/h). Bacterial infection and dexamethasone treatments were the main effects with
infection by dexamethasone as the interaction. Two-way ANOVA was performed after
ranking the raw data, P<0.01. except for the comparison of total urine creatinine.
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ciprofloxacin and enrofloxacin. Urine for the control and dexamethasone groups was
collected and the volume measured, but urine volumes for the infected and infecteddexamethasone groups were not measured. AH pairwise multiple comparisons were
made using the Student-Newman-Keuls test with P<0.01. except for total urine
creatinine, ciprofloxacin and enrofloxacin which was done using the t-Test. P<0.01.
after ranking the raw data.
Results
Animal observations and pathology
The infected pigs became lethargic and dyspnic within 2 hours after inoculation
with Actinobacillus pleuropneumoniae. Three infected pigs vomited and all infected
pigs were anorectic. After 24 hours, the infected pigs were still depressed but ate some
of their ration. Breathing was labored in all of the infected pigs until the time of
necropsy. In contrast, all o f the non-infected pigs were eating and drinking and did not
exhibit labored breathing after sham inoculation.
Five of the non-infected pigs showed focal to extensive areas of hemorrhage and
the lesions were raised above the surface of the lung. The remaining 7 non-infected
pigs had normal lungs (Figure 2.1). Gross pathology observations in all of the infected
pigs included fibrinous pleuropneumonia with necrosis and hemorrhage in a focal to
multifocal pattern (Figure 2.2). The pulmonary lesions were raised above the surface
and observed predominately on the right lung in the middle and caudal lobes. The rank
means o f the lung/body weight (g/kg) ratio of the infected pigs was increased and
significantly different (P O .O l) from the non-infected pigs (Table 2.2; Figure 2.3).
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Histopathology o f the non-infected pigs revealed slight to moderate, chronic
interstitial pneumonia that was not indicative o f Actinobacillus pleuropneumoniae
infection (Figure 2.4). The infected pigs had necrotizing extensive, severe,
fibrinopurulent pneumonia with edema and fibrinopurulent pleuritis (Figures 2.5 and
2.6). One o f the infected pigs died within 24 hours after inoculation. The cytokine
results were analyzed for this pig. but not the pharmacokinetic changes because plasma
samples were not collected. The gross and microscopic lesions in the infected pigs were
compatible with Actinobacillus pleuropneumoniae infection. Lung cultures o f the
infected and non-infected pigs on agar plates provided only isolates that were
contaminants instead o f the characteristic Actinobacillus pleuropneumoniae colonies.
Enrofloxacin administration at 24 h after infection may have prevented the recovery of
viable bacteria from the lung..
Plasma interleukin-6
Plasma interleukin-6 concentrations were elevated and significantly different in
the non-infected pigs versus the infected pigs based on area under the curve form 0 to
72 h (P O .O l) (Table 2.3; Figures 2.7 and 2.8). Comparison o f the infected group
versus infected-dexamethasone group was not significantly different (P O .O l) (Figure
2.8). Control group and dexamethasone group interleukin-6 concentrations remained at
baseline over the 72 h period (Figure 2.7).
Plasma interleukin-1
Plasma interleukin-1 concentrations were not statistically different among the four
treatment groups in the endotoxin study. The IL -1 plasma concentrations of
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STUDY 318.14 PIG 27
12/7/95
GROUP I NON-INFECTED
NO DEXAMETHASONE

Figure 2.1. Dorsal view o f the trachea, heart and lungs o f a control pig (non-infected.
no-dexamethasone).
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STUDY 318.14 PIG 1 11/8/95
GROUP III INFECTED
NO DEXAMETHASONE

Figure 2.2. Dorsal view o f the trachea, heart and lung in an infected pig (nodexamethasone). The gross lesion (5 x 6 cm) on the right caudal lung lobe (arrow)
described as necrotizing fibrinopurulent pneumonia that is consistent with
Actinobacillus pleuropneumoniae infection.
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Table 2.2. Lung/body weight (g/kg) ratios in control, dexamethasone. infected and
infected-dexamethasone treatment groups.

LW/BW (g/kg)
(min-max)

Control

Dexamethasone

Infected

InfectedDexamethasone

8.49

8.82

12.3

12.7

(7.41-9.44)

(7.58-20.3)

(10.3-14.7)

(9.5-16.7)

The lungs weights were normalized with body weights.
LW/BW; the ratio o f the lung weight/total body weight.
Values are raw data medians and (min-max) represents the range o f raw data within a
group.
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Figure 2.3. Rank means±SD o f iung/body weight ratios in control, infected,
dexamethasone and infected-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare non-infected pigs with infected pigs, (n= 12) (Two-way analysis of
variance performed after ranking the raw data. P O .O l).
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Figure 2.4. Photomicrograph of a normal section o f lung from a control pig with slight,
chronic interstitial pneumonia.
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Figure 2.5. Photomicrograph o f a section o f lung from an infected pig with necrotizing,
fibrinopurulent pneumonia.
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Figure 2.6. Photomicrograph o f a section o f lung from an infected pig with necrotizing,
fibrinopurulent pneumonia with alveolar edema, bronchitis and bronchopneumonia.
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control, dexamethasone, endotoxin and endotoxin-dexamethasone groups remained at
baseline levels over the 12 h period after endotoxin administration.
Plasma enrofloxacin pharmacokinetic changes
Area under the curve
The rank means o f no-dexamethasone pigs versus dexamethasone treated pigs
were significantly different for both area under the curve for zero to infinity AUC(inf)
and area under the curve from zero to the last measured time point AUC(last) (Table
2.4: Figure 2.9). The no-dexamethasone pigs rank means were greater (P O .O l) than the
dexamethasone treated pigs rank means (Figure 2.10). The ratio o f AUC(last) to
AUC(inf) was lower for the control group compared to the dexamethasone. infected and
infected-dexamethasone groups, 0.76, 0.82. 0.86 and 0.91 respectively (Figure 2.11).
This is expected, because the control group has a longer half-life than the other three
treatment groups which increases the percentage of the AUC from the last measured
time point to infinity within the area of AUC(inf) (Table 2.4: Figures 2.10 and 2.11).
The larger area under the curve from the last measured time point to infinity in the noninfected and infected pigs should not bias pharmacokinetic calculations because the last
measured time point at 36 and 48 h are above the 0.05 mg/L limit of detection for
plasma enrofloxacin and the elimination phase was determined over four time points
from a beginning time point of 3 to 12 h to an ending time point of 36 to 48 h.
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Clearance, volume o f distribution, mean residence time, half-life and elimination rate
constant
Clearance was significantly greater (P O .O l) for the dexamethasone treated pigs
compared to the no-dexamethasone pigs (Table 2.5: Figure 2.12). Volume of
distribution based on the elimination phase (Vp) and volume o f distribution at steady
state (Vss) were both significantly less (P O .O l) for the infected pigs compared to the
non-infected pigs (Table 2.5: Figures 2.13 and 2.14). Mean residence time and half-life
were significantly less ( P O .0 1) for the infected pigs compared to non-infected pigs
(Table 2.5: Figure 2.15). The elimination rate constant (P) was significantly greater
(P O .O l) for the dexamethasone treated pigs compared to the no-dexamethasone pigs
(Table 2.5). The elimination rate constant (P) was also significantly greater (P O .0 1)
for the infected pigs compared to the non-infected pigs (Table 2.5).
Urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios
Ciprofloxacin and enrofloxacin were both detected in the 24 and 48 h urine samples
(Tables 2.6 and 2.7). The ciprofloxacin and enrofloxacin peaks did not appear in the 0 h
blank sample (Figure 2.16). Ciprofloxacin was the only metabolite that was measured
in the urine of the infection study pigs (Figure 2.16). The four other possible lesser
metabolites were oxo-ciprofloxacin. desethylene-ciprofloxacin. oxo-enrofloxacin and
desethylene-enrofloxacin (Figure 2.17). Oxo-enrofloxacin is a suspect peak found in
the urine o f a control pig between the pipemidic acid and ciprofloxacin at about 7
minutes retention time in the infection study (Figures 2.16 and 2.17). The oxoenrofloxacin suspect peak corresponded to a peak detected in a separate analysis using a
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Figure 2.7. Mean plasma concentration o f interleukin-6 collected at 0, 1. 2. 3. 4. 6. 8,
10. 12. 24. 36. 48, 60. and 72 hours after infection or sham infection.
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Table 2.3. Area under the curv e for plasm a interleukin-6 in pigs.

AUC0_>72 hr
(units/ml x h)

Control

Dexamethasone

Infected

InfectedDexamethasone

32.3

38.6

467

1158

(0-340.1)

(0-335.6)

(2.11-946.7)

(39.27-6014.9)

(min-max)
A U C o ^ hr: area under the curve from 0 to 72 h.
Values are raw data medians and (min-max) represents the range o f raw data within a
group.
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Figure 2.8. Rank m eans o f area under the curve for plasm a interleukin-6.
Values with identical superscripts are not significantly different. P< 0.01.
*\B
w
Used to compare non-infected pigs with infected pigs. (n=12) (Two-way analysis of
variance performed after ranking the raw data. P<0.01).
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Figure 2.9. Semilogrithmic plot o f mean plasma concentrations o f enrofloxacin
measured at 0. 0.25. 0.5. 1. 2, 3, 4, 6, 8. 12. 24. 36. and 48 h after i.v. enrofloxacin (5
mg/kg BW) administration and 24 h after infection or sham infection.
139

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 2.4. Area under the curve (mg/L x h) for plasma enrofloxacin in control,
dexamethasone. infected and infected-dexamethasone treatment groups.
Area Under the
Curve

Control

Dexamethasone

Infected

InfectedDexamethasone

AUC(inf)

31.1

19.5

31.1

14.2

(min-max)

(21.3-32.2)

(12.2-27.1)

(23.1-45.0)

(11.3-32.4)

AUC(last)

22.8

14.8

28.3

13.0

(min-max)

(17.1-25.3)

(10.4-22.8)

(19.9-34.5)

(10.4-26.7)

(mg/L x h)

AUC(inf) area under the curve from zero to infinity
AUC(last). area under the curve from zero to the last measured hour.
Values are raw data medians and (min-max) represents the range o f raw data within a
group.
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Figure 2.10. Rank means±SD o f area under the curve for plasma enrofloxacin in
control, infected, dexamethasone and infected-dexamethasone treatment groups.
AUC(inf) area under the curve from zero to infinity.
AUC(last). area under the curve from zero to the last measured hour.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs for
AUC(inf) (n—12) (Two-way analysis of variance performed after ranking the raw data.
PO .O l).
^Used to compare no-dexamethasone pigs with dexamethasone treated pigs for
AUC(last) (n=12) (Two-way analysis of variance performed after ranking the raw data.
P<0.01).
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Figure 2.11. Means o f area under the curve ratios for plasma enrofloxacin in control,
infected, dexamethasone and infected-dexamethasone treatment groups.
AUC(inf). area under the curve from zero to infinity.
AUC(Iast), area under the curve from zero to the last measured hour.
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Table 2.5. Plasma pharmacokinetic parameters of enrofloxacin in control, infected, dexamethasone and infected-dexamethasone
treatment groups.

-t-/|
C

Pharmacokinetic
Parameters

Control

Dexamethasone

Infected

lnfected-Dexamethasone

C \„ (L/h/kg)

0.161

0.259

0.161

0.359

(min-max)

(0.155-0.234)

(0.185-0.409)

(0.111-0.216)

(0.154-0.443)

V ptfA g)

5.47

7.75

3.20

5.13

(min-max)

(4.25-6.73)

(4.32-9.52)

(2.59-4.71)

(3.50-6.42)

V«(L/kg)

5.52

7.61

3.04

4.85

(min-max)

(4.33-6.89)

(4.40-8.60)

(2.60-4.84))

(3.33-5.97)

MRTinr(h)
(min-max)

31.3
(26,1-44.2)

24.2
(20.5-36.9)

21.2
(18.5-30.1)

13.6
(11.3-27.3)

l i/2 (h)
(min-max)

21.4
(17.7-29.9)

17.2
(15.9-25.8)

14.6

10.2

(12.8-19.2)

(8.25-19.1)

P ( 1/h)
(min-max)

0.0360“a

0.0516bA

0.0560aU

0.0679bH

(0.0261-0.0414)

(0.0318-0.0744)

(0.0472-0.0706)

(0.0369-0.0840)

Cll01, total body clearance; V() volume of distribution based on the terminal phase; Vss, volume of distribution at steady state; MR r il)t,
mean residence time from zero to infinity; t1/2, half-life of the terminal phase and |), elimination rate constant.
Values are raw data medians and (min-max) represents the range of raw data within a group.
Values with identical superscripts are not significantly different, P< 0.01.
,lbUsed to compare the no-dexamethasone pigs with the dexamethasone treated pigs after ranking the data (n= 12) ( Two-way analysis of
variance performed after ranking the raw data, P<0.01).
AHUsed to compare the non-inlected pigs with the infected pigs after ranking the data (n=12) ('Two-way analysis of variance performed
after ranking the raw data, P<0.01).

Figure 2.12. Rank means±SD of clearance for plasma enrofloxacin in control, infected,
dexamethasone and infected-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=12)
(Two-way analysis of variance performed after ranking the raw data. P O .O l).
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Figure 2.13. Rank means±SD for volume of distribution o f the elimination phase for
plasma enrofloxacin in control, infected, dexamethasone and infected-dexamethasone
treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
Used to compare non-infected pigs with infected pigs. (n=12) (Two-way analysis o f
variance performed after ranking the raw data, P<0.01).
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Figure 2.14. Rank means±SD of volume of distribution at steady state for plasma
enrofloxacin in control, infected, dexamethasone and infected-dexamethasone treatment
groups.
Values with identical superscripts are not significantly different, P< 0.01.
Used to compare non-infected pigs with infected pigs (n=l2) (Two-way analysis of
variance performed after ranking the raw data. P<0.01).
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Figure 2.15. Rank means±SD o f mean residence time (MRT) and half-life (tt/2) for
plasma enrofloxacin in control, infected, dexamethasone and infected-dexamethasone
treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
ABUsed to compare non-infected pigs with infected pigs for mean residence time (h)
(n=12) (Two-way analysis o f variance performed after ranking the raw data, P O .O l).
CD
"
w
Used to compare non-infected pigs with infected pigs for half-life (h) (n=12) (Twoway analysis o f variance performed after ranking the raw data. P O .O l).
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internal standard (pipemidic acid); 0 h urine sample; and 48 h urine samples in a control
pig.
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Figure 2.17. Enrofloxacin and the major metabolite, ciprofloxacin, with four minor
metabolites.
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Table 2.6. Total urine creatinine, enrofloxacin and ciprofloxacin in control and
dexamethasone treatment groups for the infection study.
Dexamethasone

24 h Creat (mg)

510a

OO
o
00

Control

(min-max)

(139-962)

(336-1037)

48 h Creat (mg)

1204a

1002a

(min-max)

(798-1417)

(459-1044)

24 h Enro (mg)

10.7°

13.5°

(min-max)

(6.64-14.3)

(8.28-17.7)

48 h Enro (mg)

8.46c

4.45d

(min-max)

(5.08-19.0)

(2.91-6.12)

24 h Cipro (mg)

11.0e

9.92°

(min-max)

(4.24-12.9)

(7.50-23.6)

48 h Cipro (mg)

8.45c

3.45f

(min-max)

(4.74-11.1)

(3.04-6.53)

Creat (mg), total urine creatinine: Enro (mg), total urine enrofloxacin: and Cipro (mg),
total urine ciprofloxacin.
Values are raw data medians and (min-max) represents the range of raw data within a
group.
Values with identical superscripts are not significantly different. P< 0.01.
“Used to compare the control group with the dexamethasone group for total urine
creatinine at 24 and 48 h (n=6) (t Test after ranking the raw' data. P O .O l).
cdUsed to compare the control group with the dexamethasone group for total urine
enrofloxacin at 24 and 48 h (n=6) (t Test after ranking the raw data. P O .O l).
ctUsed to compare the control group with the dexamethasone group for total urine
ciprofloxacin at 24 and 48 h (n=6) (t Test after ranking the raw data, P O .O l).
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Table 2.7. Urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios in control,
infected, dexamethasone and infected-dexamethasone treatment groups.
Control

Dexamethasone

Infected

InfectedDexamethasone

24 h
Enro/Creat
(pg/mg)

22.5

16.5

18.2

14.7

(min-max)

(14.1-47.8)

(14.5-28.4)

(11.5-25.8)

(7.28-32.0)

8.58

4.75

9.17

3.81

(5.71-27.9)

(2.80-6.33)

(4.89-15.1)

(0.828-5.05)

18.5

19.3

20.4

13.1

(10.8-47.5)

(7.24-29.5)

(7.54-24.7)

(9.17-16.9)

7.52

4.46

10.8

6.41

(5.32-47.6)

(0.575-6.69)

(4.27-14.2)

(1.11-9.69)

48 h
Enro/Creat
(pg/mg)
(min-max)
24 h
Cipro/Creat
(pg/mg)
(min-max)
48 h
Cipro/Creat
(pg/mg)
(min-max)

Enro/Creat (pg/mg). ratio o f urine ciprofloxacin to urine creatinine.
Cipro/Creat (pg/mg), ratio o f urine enrofloxacin to urine creatinine.
Values are raw data medians and (min-max) represents the range of raw data within a
group.
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Figure 2.18. Rank means±SD o f urine enrofloxacin/creatinine ratios in control,
infected, dexamethasone and infected-dexamethasone treatment groups at 24. and 48 h
after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01.
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and noninfected pigs with infected pigs at 24 h (n= 12) (Two-way analysis of variance
performed after ranking the raw data. P<0.01).
cdUsed to compare no-dexamethasone pigs with dexamethasone treated pigs at 48 h
(n=12) (Two-way analysis o f variance performed after ranking the raw data. P O .O l)
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Figure 2.19. Rank means±SD of urine ciprofloxacin/creatinine (pg/mg) ratios in
control, infected, dexamethasone and infected-dexamethasone treatment groups at 24
and 48 h after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01.
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and noninfected with infected pigs at 24 h (n=12) (Two-way analysis o f variance performed
after ranking the raw data. P<0.01).
'’Used to compare no-dexamethasone pigs with dexamethasone treated pigs and noninfected pigs with infected pigs at 48 h (n=12) (Two-way analysis o f variance
performed after ranking the raw data. P O .O l).
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different column and mobile phase, but using a control urine sample from this study
(Dr. Joseph Kawalek. unpublished data). Desethylene-ciprofloxacin was used to make a
previous standard curve, but was not detected in the urine samples. A peak in the 24
and 48 h urine samples did co-elute at the same time (6.3 min) as desethyleneciprofloxacin and was between the unknown peak (7 minutes retention time) and
pipemidic acid. This peak was an endogenous product, because it appeared in the zero
hour urine samples and had an absorption maxima at 250 nm. Flouroquionolones have
a characteristic absorption maxima at about 280 nm. but not at 250 nm. In vitro studies
with liver microsomes have supported this observation where oxo-ciprofloxacin.
desethylene-ciprofloxacin and desethylene-enrofloxacin were not detected (Dr. Joseph
Kawalek. unpublished. FDA/CVM final report 275.16). Ciprofloxacin was detected in
urine after a short incubation and oxo-enrofloxacin was detected after a prolonged
incubation o f porcine hepatic microsomes from pigs unrelated to this study (Dr. Joseph
Kawalek. unpublished. FDA/C VM final report 275.16).

Total urine creatinine is not significantly different for the control group
compared to the dexamethasone group (Table 2.6). Total urine enrofloxacin is not
significantly different at 24 h. but the total urine enrofloxacin was significantly less for
the dexamethasone group compared to the control group at 48 h (Table 2.6). Total urine
ciprofloxacin is not significantly different at 24 h. but the total urine ciprofloxacin was
significantly less for the dexamethasone group compared to the control group at 48 h
(Table 2.6).
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The urine enrofloxacin/creatinine ratios are not significantly different in the 24 h
urine samples (Table 2.7; Figure 2.18). The urine enrofloxacin/creatinine ratios were
significantly less in the dexamethasone treated pigs compared to the no-dexamethasone
pigs at 48 h (Table 2.7; Figure 2.18). The urine ciprofloxacin/creatinine ratios are not
significantly different in the 24 and 48 h urine samples (Table 2.7; Figure 2.19)
Discussion
The infected animals developed signs of APP infection within 2 h which was
verified by gross pathology and histopatholgy (Figures 2.1-2.6). The establishment of
APP infection was further supported by increased lung weights and increased plasma
interleukin-6 in the infected pigs (Table 2.2; Figure 2.3). There was only a slight but
statistically different elevation o f plasma IL-6 in infected pigs. This proved that IL-6
was released systemically. but returned to baseline by 48 (Table 2.3; Figures 2.7 and
2.8). The intensity and duration o f IL-6 release was much less than expected and it is
unlikely that cytochrome P450's w'ere suppressed. Nonetheless, the signs, pathology
and systemic IL-6 release all demonstrated that the APP disease model was standardized
and reproducible in this study.
Statistical analysis was a challenge because many pharmacokinetic parameters,
such as volume o f distribution, half-life, mean residence time and clearance, do not have
a normal distribution which prevents parametric testing (Dyke & Sams. 1994).
Parametric tests are based on larger sample sizes of 30 or more observations (Dyke &
Sams. 1994). The infection study data had 6 animals per group or 11 to 12 animals. If
there was no interaction, the two infected groups, and two dexamethasone groups could
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be pooled which allowed two-way analysis of variance. The ranking o f raw data was
necessary, because the two by two factorial designs could not be applied to the nonparametric Kruskal-Wallis test to detect differences among three or more groups. A
distribution free test was not available that would allow analysis o f a two by two
factorial by non-parametric methods. Therefore, a compromise approach was used to
rank the data and perform two-way analysis of variance on the ranked data with a
P<0.01 to guard against Type II error or false positives.
Pharmacokinetic parameters were calculated on the assumption that the
extrapolated area under the curve from the last measured time point to infinity did not
bias the calculation o f clearance, volume of distribution, mean residence time and halflife. When the AUC(inf) was compared to AUC(last). the outcome o f the statistical
analysis was the same (Table 2.3; Figure 2.10). The ratios o f AUC(last)/AUC(inf)
among the control, dexamethasone. endotoxin and endotoxin-dexamethasone treatment
groups were acceptable, because the area under the curve from the last measured time
points to infinity was calculated based on values above the limit o f detection for
enrofloxacin (Figure 2.11). A long half-life may be associated with a large extrapolated
area under the curve which is not important provided that the error o f the last measured
time point is minimal. Error around the last measured time point may be o f little
consequence because an extrapolated area under the curve could contribute 10% of the
total area under the curve, but only contribute 5% error with a bias o f 50% (Purves.
1992). This means that the subsequent calculations of pharmacokinetic parameters were
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not strongly biased due to error associated with enrofloxacin plasma concentrations
around the limit of detection.
Pharmacokinetic parameters were calculated from the dose. AUC(inf).
AUCM(inf) and P (elimination constant) for clearance. Cl=dose/AUC; volume o f
distribution o f the elimination phase; Vp=dose/(P x AUC); volume o f distribution at
steady state. Vss=(dose/AUC) x (AUMC/AUC)=C1 x MRT; mean residence time.
MRT=AUMC/AUC: and terminal half-life, t 1/r>=0.693/p=(0.693 x Vp)/Cl. Clearance is
a measure o f efficiency o f removal of a chemical from an organ or the body. The
volume o f distribution during the terminal phase. Vp. is the proportionality constant
between the amount o f drug in the body post distribution and the plasma concentration
during the elimination phase. Volume of distribution based on the terminal phase (Vp)
depends on the rate o f elimination from the central compartment (Ritschel & Denson.
1991). Volume of distribution at steady state. Vss. is the proportionality constant
between the amount of drug in the body and the plasma concentration at steady state for
intravenous bolus or constant-rate infusion administration of a drug. Mean residence
time is the average amount o f time that all molecules spend in the body or the mean
transit time. Plasma half-life is the amount of time for a 50% reduction in the
concentration of a xenobiotic in the plasma which is a constant if elimination is
independent from the dose.
Volume of distribution based on the elimination phase will be influenced in
disease-altered elimination, whereas distribution changes independent of elimination are
reflected by Vss (Ritschel & Denson, 1991). With decreasing Vp, the concentration in
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plasma increases (Ritschel & Denson. 1991). The volume of distribution at steady state
is affected by both plasma and tissue binding, decreasing as the free fraction in plasma
and tissues increases and the bound fraction decreases. The volume o f distribution for
both the elimination phase and steady state were decreased for the infected animals but
not for dexamethasone treated animals (Table 2.5; Figures 2.13 and 2.14). Volume of
distribution o f the elimination phase. Vp decreases as plasma concentration increases
(Ritschel & Denson. 1991). Decreased Vss would indicate decreased plasma and tissue
protein binding and increased plasma and tissue free fraction (Ritschel & Denson.
1991). As the free fraction in plasma increases, plasma clearance should increase
(Ritschel & Denson. 1991). At steady state, distribution is in equilibrium with
elimination and the amount o f drug bound to plasma and tissue protein is at a
maximum. At ail other times, the amount o f drug bound to tissue protein depends upon
the time course o f the drug during distribution or elimination phases.
The infected pigs had a significantly larger elimination rate constant compared
to the non-infected pigs (Table 2.5). The elimination rate constant increased while the
AUC remained the same, and the volume o f distribution of the elimination phase
decreased for the infected pigs (Figures 2.10 and 2.13). This explanation is further
supported by the decreased half-life o f the infected pigs versus the non-infected pigs
where the elimination rate constant is related to half-life by the equation: t|/2=0.693/p
(Figure 2.15). As the elimination rate constant increases, the half-life decreases. Mean
residence time would be expected to parallel half-life where the MRT of the infected
pigs was less than the non-infected pigs. The literature value for ciprofloxacin half-life
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was 6 to 8 h in pigs , which is much less than the enrofloxacin median half-life (21.4 h)
or MRT (31.3 h) o f the control group (Table 2.5; Figure 2.15) (Rung et a i. 1993a.b).
Clearance in the infected pigs was not altered as expected if there was an
increase in the free fraction o f plasma enrofloxacin with a decreased volume of
distribution. The free fraction o f enrofloxacin may have increased without an increase
in clearance because a decrease in volume of distribution could have offset an increase
in the elimination rate constant, p. where clearance is mathematically related to volume
o f distribution and elimination rate constant by the equation: Cl=Vyp (Table 2.5). The
elimination rate constant, p. was significantly greater for the infected pigs compared to
the non-infected pigs (Table 2.5). Thus, volume o f distribution of the elimination phase
in the infected pigs was affected by an increase in the elimination rate constant
(Vp=dose/(P x AUC). However, volume of distribution at steady state was also
significantly decreased for the infected pigs, but is independent o f the elimination rate
constant. This suggests that some other factor, such as decreased protein binding in
tissues and increased protein binding in plasma, is also a component of the decreased
volume of distribution for the infected pigs. The loss o f plasma proteins to the alveolar
space may also account for the decreased volume o f distribution as observed in the
photomicrograph o f a section o f lung from an infected pig (Figure 2.6).
In addition to protein binding, several disease conditions can affect the
elimination rate constant and Vp such as alterations in blood flow and pH changes for
healthy and diseased animals (Ritschel & Denson, 1991). The onset and duration of
action of a drug is dependent on the rate or extent o f distribution and a change in the
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apparent volume of distribution may change the drug concentration in plasma, tissues
and at the receptor site. The volume o f distribution may be reduced by reduced blood
supply to peripheral tissues in shock and the concentration at the site o f action may be
diminished. The infected pigs may have had poor pulmonary perfusion and respiratory
acidosis due to labored breathing caused by pulmonary infection (Figures 2.5 and 2.6).
Enrofloxacin is amphoteric with acid and base properties. A small change in acid-base
balance may have an amplified effect on the degree o f ionization o f weak organic acids
and bases. Increased ionization could reduce the tissue penetration by affecting the
solubility o f enrofloxacin and result in decreased volume o f distribution. Depending on
pH. enrofloxacin could bind to albumin as an acid or to a,-glycoprotein as a base and be
displaced in plasma or tissues. However, neither the blood concentration, nor pH
affected the low serum protein binding of other fluoroquinolones (Greene & Budberg.
1993). Low serum protein binding would promote rapid elimination by renal and
extrarenal mechanisms. In pigs, low plasma protein binding (23.6%) o f ciprofloxacin
was previously attributed to interference by fatty acids with albumin or more binding
sites on plasma proteins such as albumin and a |-acid glycoprotein (Nouws et al.. 1988:
Belpaire. 1986). In humans. AGP plasma concentration can increase as much as two
fold during the acute-phase respose (Kremer et. al., 1988). Although AGP has an
affinity for basic drugs, it can bind acidic drugs (Kremer et. a*.. 1988). The acidic drugs
which exhibit a high or intermedicate affinity to AGP do not contain a carboxyl moiety
and share a common binding site on human serum albumin, called site I or the warfarin
site. In comparison, all drugs having a low affinity or no affinity to AGP exhibit
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carboxyl groups and bind specifically to another human serum albumin site, called site
II or the diazepam site (Kremer et. al.. 1988). Enrofloxacin is an amphoteric compound
with a basic nitrogen in the piperazinyl ring and an acidic carboxyl group on the other
end o f the molecule (Figure 1.2). The decreased volumes o f distribution in the infected
pigs may occur subsequent to the release of AGP. The basic nitrogens on the
piperazinyl ring may preferentially bind to AGP molecules because it takes longer for
albumin to decrease in the acute-phase response while AGP is increasing.
While enrofloxacin volumes of distribution are not altered in pigs receiving
dexamethasone. clearance for the dexamethasone treated pigs compared to the nodexamethasone pigs was increased (Table 2.5; Figures 2.13 and 2.14). The reason for
the increase in clearance may be related to increased glomerular filtration rate. A five
day regimen o f adrenocorticotropin (ACTH) and glucocorticoids (GC) raised blood
pressure, caused marked antinatriuresis. expansion of extracellular fluid and plasma
volume, and altered renal function in humans (Connell, et al.. 1987). Both treatments
raised glomerular filtration rate (GFR). as demonstrated by inulin clearance. Creatinine
clearance was not changed and it proved to be an unreliable index of GFR during steroid
administration. Filtration fraction also increased during both ACTH and GC treatment,
and renal blood flow fell only during cortisol treatment. Effective renal plasma flow,
measured by para-aminohippurate clearance, remained unchanged. The mechanism for
changes in GFR may be a reduction in the availability o f angiotensin II at glomerular
receptor sites, because dexamethasone increases the activity o f aminopeptidase as
shown in human glomerluar epithelial cells (Stefanovic et al.. 1991). Aminopeptidase
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splits off the N-terminal Asp from angiotensin II and inactivates angiotensin II.
Therefore, the increased clearance o f enrofloxacin in the dexamethasone treated pigs
could be due to increased GFR and filtration fraction.
The major metabolite, ciprofloxacin and a suspect peak, oxo-enrofloxacin. were
found in the urine (Figures 2.16 and 2.17). The peak corresponding to oxoenrofloxacin. a minor metabolite, is intriguing because it contradicts the absence of
metabolites in another investigation where ciprofloxacin was administered to pigs
(Nouws et. al., 1988) (Figures 2.16 and 2.17). There was no statistical difference
among the treatment groups at 24 h for the total urine enrofloxacin and ciprofloxacin;
and urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios (Tables 2.6 and 2.7
Figures 2.18 and 2.19). However, the 48 h sample had a reduced
enrofloxacin/creatinine ratio for the dexamethasone treated pigs compared to the nodexamethasone pigs, but the 48 h ciprofloxacin/creatinine ratio was unchanged. The
reduced enrofloxacin/creatinine ratio could be due to the depletion o f enrofloxacin in
the first 24 h of urine collection, because the clearance o f enrofloxacin is increased in
dexamethasone treated pigs. Creatinine clearance would be expected to increase with
increased GFR after dexamethasone treatment, but total urine creatinines were not
significantly different (Table 2.6). However, it has already been stated that creatinine
clearance is an unreliable index during steroid treatment (Connell et al.. 1987). It is
curious that a concomitant decrease in the ciprofloxacin/creatinine ratio was not seen in
the dexamethasone treated pigs, where a lack of statistical significance could be due to
small sample size or lack o f biological significance.
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Apparently, there was no effect o f APP infection on either the
enrofloxacin/creatinine ratio or the ciprofloxacin/creatinine ratio in infected pigs (Tables
2.6 and 2.7; Figures 2.18 and 2.19). The hypothesis in this study included the alteration
o f metabolism in conjunction with other pharmacokinetic changes that have alreadybeen described. There was a small systemic elevation of interleukin-6, but interleukin-1
was not systemically elevated. Therefore, it is probable that metabolism o f enrofloxacin
to ciprofloxacin was not affected by infection, because there was no increase in the
enrofloxacin/creatinine ratio and a decrease in the ciprofloxacin/creatinine ratio in
infected pigs. Any changes in metabolism of enrofloxacin to ciprofloxacin would have
been easily observed because of the large amount of ciprofloxacin excreted in the urine
o f control animals. Whatever the metabolic pathway, cytochrome P450 or flavincontaining monooxygenase, is responsible for the dealkylation of enrofloxacin to
ciprofloxacin, it is still intact in the APP infected and dexamethasone treated pigs.
In contrast to the absence o f metabolic changes in this study, a previous
investigation reported the suppression o f oxidative hepatic biotransformation in pigs
infected with APP (Monshouwer et al., 1995a). The hepatic clearance of antipyrine and
caffeine were decreased by 72 and 68%, respectively. Renal function and hepatic blood
flow were not affected. The APP infected pigs in the Netherlands did not exhibit a
change in microsomal uridine diphosphate glucuronyl transferase activities
(Monshouwer et al.. 1995b). No glucuronide conjugates o f ciprofloxacin or its
metabolites were detected in the urine o f calves and piglets (Nouws et. al.. 1988).
Additionally, the urine samples were subjected to a mixture of 0.05 N sodium hydroxide
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and acetonitrile in a two to one ratio, respectively. This may have been sufficient to
hydrolyze any enrofloxacin and ciprofloxacin urine conjugates as reported in a study of
fenoprofen and oxprenolol in horses (Delbeke & Debackere. 1994). Hydrolysis of
fenoprofen conjugates was accomplished by treating urine samples with a final sodium
hydroxide concentration of 0.025 N. The final concentration of sodium hydroxide that
was used to prepare urine samples for HPLC analysis in this study was 0.032 N.
Therefore, glucuronated enrofloxacin and ciprofloxacin metabolites were not measured
in this study.
The different results found in the present study compared to the Netherlands
study are not necessarily contradictory. The previous study was done at a different
location using a different genetic base of pigs that were infected with a different
serotype o f APP that may have differed in virulence. No change in clearance and
metabolism was found in this study compared to decreased oxidative metabolism of
antipyrine and caffeine in the Netherlands study. The antipyrine and caffeine were used
as model drugs to test oxidative biotransformation in the infected pigs. Instead of
model drugs, a therapeutic drug, enrofloxacin. was tested in this study. Enrofloxacin
clearance was not altered by APP infection. Enrofloxacin can be biotransformed to
oxygenated metabolites but this is not an important pathway in pigs (Dr. Joseph
Kawalek. unpublished; Nouws et al.. 1988). Dealkylation results in the major
metabolite, ciprofloxacin. Oxidation of enrofloxacin to the suspect minor metabolite,
oxo-enrofloxacin. requires confirmation by mass-spectroscopy.
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CHAPTER III
ENDOTOXIN MODEL
Introduction
Endotoxin derived form Eschericia coli has been used as a model for septic
shock in swine (Myers et. al. 1997; Monshouwer et al., 1996a). The administration of
intravenous endotoxin in this study and any associated pharmacokinetic changes was
intended to provide a comparison to Actinobacillus pleuropneumoniae infection and the
subsequent plueropneumonia. Drug disposition and metabolism can both be affected by
infection and endotoxin challenge. Other toxins besides endotoxins are certainly
present in porcine pleuropneumonia and may contribute to pathological changes.
However, endotoxin has been used extensively as a model of septic shock and the acutephase response. Endotoxin is not directly cytotoxic to tissue, but it does induce release
of TNF-a and IL-6 (Edwards et al.. 1994). A CD14 leukocyte receptor appears to
initiate TNF-a release after binding endotoxin to LPS binding protein.
Viral, bacterial or parasitic infections and inflammatory stimuli from endotoxin
or turpentine induce physiological, hematological and metabolic changes that
characterize the acute-phase response (Ballmer et al.. 1991; van Miert. 1990). The
acute-phase response may be triggered by cytokines released from macrophagesmonocytes. Interleukins l a and ip. TNFs a and P and interferons a and P are
cytokines that inhibit oxidative and conjugative drug metabolism in laboratory animals
(Craig et al.. 1989b; Ghezzi et al., 1986a.b; Morgan & Norman. 1990; Renton &
Knickle. 1990). Furthermore, active infection with bacterial proliferation is not
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necessary for changes to occur in drug biotransformation. Endotoxins from Gramnegative and positive bacterial cell walls are potent inhibitors o f hepatic mixed-function
oxidase (Azri & Renton. 1987: Gorodischer et al.. 1976; Lavicky et al.. 1988: Sasaki et
al.. 1984: Sonawane et al.. 1982; Stanley et al.. 1988; Williams & Szentivanyi. 1983:
Yoshida et al., 1982). Escherichia coli. Bordatellapertussis. diphtheria toxoid and
tetanus toxoid all contain cell wall endotoxins that alter P450 activity (Ashner et al..
1992: Fantuzzi et al.. 1994a.b).
A previous study compared an LPS model to an Actinobacillus
pleuropneumoniae model and demonstrated a distinct similarity with respect to effects
on hepatic drug metabolism (Monshouwer et. al.. 1996a). The experimentally induced
APP infection in pigs was reported to induce a mild acute-phase response and inhibition
o f P450. The plasma clearance o f caffeine and antipyrine were shown to be decreased
by 70% at 24 h after inoculation (Monshouwer et al.. 1995a.b).
The goal o f the endotoxin study was 1) to characterize pharmacokinetic changes
associated with endotoxin administration in swine after receiving enrofloxacin and 2) to
evaluate the endotoxin model as a substitute for the APP infection model or other Gramnegative-pathogens. Plasma concentrations o f IL-6 were determined from 0 to 9 h after
endotoxin administration. Aspartate aminotransferase plasma concentrations were
determined for 0. 24 and 96 h after endotoxin infusion. Plasma concentrations of
enrofloxacin and ciprofloxacin were determined for pharmacokinetic analysis from 24
to 96 h after endotoxin infusion. Urine enrofloxacin and ciprofloxacin were also
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measured and normalized with urine creatinine concentrations. Gross necropsies were
performed and included lung weights.
Materials and Methods
Animal management
The experiment utilized 24 crossbred. Hampshire x Yorkshire, castrated pigs
that were procured from a local vendor. All of the pigs were weighed prior to
intravenous catheterization and were within a 25 to 35 kg weight range. Housing
consisted of a heated building with a concrete floor and all animals were fed 3 kg/day
from a single batch o f a commercial com-based ration without antibiotics. The pigs had
been fed a commercial ration that was medicated with tylosin before procurement. All
pigs were examined upon arrival and were clinically healthy at the start o f the study.
Experimental design
The design consisted o f a 2 x 2 factorial of treatment groups (Table 3.1).
Eschericici coli 055: B5 endotoxin (2 pg/kg. Sigma. St. Louis. Missouri) was dissolved
in about 5 ml of phosphate buffered saline (0.0067 M o f phosphate. 0.15 M sodium
chloride. pH 7.4; Sigma. St. Louis. Missouri) as the first treatment. This endotoxin dose
(2 pg/kg) was previously determined by previous studies at the Center for Veterinary
Medicine. The second treatment was dexamethasone (0.5 mg/kg. Phoenix
Pharmaceuticals. St. Joseph Missouri). Endotoxin was infused by i.v. bolus at zero hour
into two of the four groups as a comparison to APP infection. Two groups (12 pigs)
were procured at a time and one group was placed in stainless steel metabolism cages
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Table 3.1. Experimental design for the endotoxin study.

Treatment

Sham Infusion

Endotoxin

Sham Infusion

Endotoxin

No Dexamethasone

No Dexamethasone

Sham Infusion

Endotoxin

Dexamethasone

Dexamethasone

No Dexamethasone

Dexamethasone
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for four days followed by the second group. This process was repeated with another
two groups of pigs over a one month period. The endotoxin treatment was administered
as single i.v. injection to two groups while the other two groups received a sham saline
infusion (Table 3.1). One endotoxin group and one sham group received i.v.
dexamethasone at -18 h . 0 h and 12 h. A bolus dose o f 5 mg/kg enrofloxacin (Baytril .
Bayer. Shawnee Mission. Kansas) was administered intravenously 24 h after saline or
endotoxin infusion to all four groups o f pigs.
Blood collection
Intravenous cannulation and blood collection was identical to the infection
study. Cytokine blood samples were collected in heparin tubes (Monovette. Sarstedt.
Germany) at 0. I. 3. 6 and 9 h after endotoxin and sham infusion. Plasma samples for
HPLC analysis were collected in EDTA tubes (Monovette. Sarstedt. Germany) at 0.
0.25. 0.5. 1. 2. 3. 4. 6. 8. 12, 24. 36. 48. 60 and 72 h after enrofloxacin infusion.
Pharmacokinetic analysis
Urine and plasma sample preparation
Plasma sample preparation was identical to the infection study. Urine samples
were collected at 24 hour intervals starting 24 h after endotoxin infusion or saline at 0.
24. 48 and 96 hours.
Urine creatinine
Urine creatinine preparation was identical to the infection study. A plot o f the
standard curves for creatinine gave a linear response, “y” (absorbance) versus "c”
(concentration. mg/L): y=0.007 c + 0.197. R= 1.0. y=0.008 c + 0.219. R=0.9995.
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y=0.007 c + 0.203. R=1.0. y=0.007 c + 0.21. R= 1.0 and y=0.008 c + 0.207. R=0.9995
where the coefficient of variation was less than 5% and 10% for the standards and
samples, respectively.
Aqueous standard curves for urine and plasma
Aqueous standard curves for plasma and urine were constructed by first
preparing desethylene-ciprofloxacin, enrofloxacin and ciprofloxacin stock standards
which was similar to the infection study.
The linearity of the response, "y“ (ratio o f peak height counts using the internal
standard, pipemidic acid) versus "c" (concentration. mg/L) were tested over eight
standard solutions o f desethylene-ciprofloxacin, ciprofloxacin and enrofloxacin. The
typical response standard curves for plasma samples were represented by the linear
equations: y=17.1 c - 0.00478. R=0.9997 for enrofloxacin; y=12.3 c - 0.0216. R=0.9997
for ciprofloxacin: and y=127 c + 0.0366, R=0.9997 for desethylene-ciprofloxacin. The
typical response standard curves for urine samples were linear and represented by the
same equations that were presented in the infection study: y=16.0 c - 0.00379.
R=0.9996 for enrofloxacin: y= 1 1 .8 c- 0.00253, R=0.9997 for ciprofloxacin and y=124
c + 0.0434. R=0.9997 for desethylene-ciprofloxacin.
Five replicates of each of the 8 concentrations (3.9 - 500 pg/L for ciprofloxacin
and enrofloxacin and 1.22 - 156 pg/L for desethylene-ciprofloxacin) o f standard
resulted in a coefficient of variation ranging from 0.7% to 9% for the plasma standard
curves and 0.7% to 11% for the urine standards curves to include enrofloxacin.
ciprofloxacin and desethylene-ciprofloxacin.
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High-performance liquid chromatography
High-performance liquid chromatography analysis was identical to the infection
study for urine and plasma.
Interleukin-6 bioassay
Interleukin-6 assay was performed as previously described in the infection
study. The standard curve was plotted as a log-logit transformation using Cytocalc
(Millipore. New Bedford. Massachusetts). The log-logit transformations gave linear
response, "y" (absorbance) versus “c" (concentration, pg/ml). curves for each o f the five
microplates: y=2.74 c - 9.48. R=0.9180; y —1.52 c - 1.01. R=0.986; y=2.76 c - 9.85.
R=0.917; y=2.51 c - 8.85. R=0.903 and y=2.42 c - 8.67. R=0.903.
Plasma aspartate aminotransferase assay
The plasma aspartate aminotransferase (AST) assay was performed using an
AST/GOT Transaminase Diagnostic Test Kit to measure plasma AST at 0. 24 and 48 h
after endotoxin (Sigma. St. Louis. Missouri). The AST assay was undertaken as an
indicator of liver damage after endotoxin administration. All four groups were tested by
adding 50 pi of plasma or standard to 250 pi of substrate reagent. The mixture was
vortexed and placed in a 37°C water bath for 1 hour. A color reagent (250 pi) was
added after incubation. The mixture was vortexed and incubated at room temperature
for twenty minutes. Next, a 2.5 ml aliquot of 0.4 N sodium hydroxide was added and
the test tube was mixed by inversion. After waiting 5 minutes, a 200 pi aliquot sample
mixture was pipetted, in triplicate, into a 96 well microplate. The results were read at
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503 nm absorbance using a microplate spectrophotometer (Spectra Max 250. Molecular
Devices. Sunnyvale. California).
A standard curve was prepared for each microplate by diluting standards with
water and substrate to the following concentrations: 0. 9.6. 26.4. 45.6. 69.6 and 103.7
lU/ml where 0.48 international unit (IU) was equivalent to one Sigmund-Frankel unit.
The standards were prepared for reading on the microplate spectrophotometer by adding
50 pi o f standard to 250 pi o f substrate reagent. The mixture was vortexed and
incubated at room temperature for 20 minutes. A 2.5 ml aliquot o f 0.4 N sodium
hydroxide was added and the test tube was mixed by inversion. After a 5 minute wait,
triplicate 300 pi aliquots o f each standard were transferred into the microplates. The
resulting standard curves were nonlinear, "y” (absorbance) versus "c" (concentration.
lU/ml): y={-0.603/[l + (c/255)0827]} + 0.801. R=0.999: y={-0.607)/[l + (c/273)0 723]} +
0.801. R=0.999; y={-0.573)/[l + (c /227)0856]} + 0.741. R=0.9995 and y={-0.641/[l +
(c /283)0 8-9]} + 0.831. R=0.999. The coefficient of variation for the standards and
samples was less than 3% and 11%, respectively. The sample values were interpolated
from the standard curves using Softmax Pro (Version 1.2. Molecular Devices.
Sunnyvale. California).
Health observations and necropsies
Health observations were made during the entire study period of 4 days. Gross
necropsies were performed on all animals in the infection study. The pigs were
euthanized with Euthasol® which contained sodium pentobarbital (Delmarva
Laboratories, Inc.. Bristol. Tennessee). Brain and spinal cord were not examined. Fresh
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liver (100 to 200 grams) was collected and frozen at -80°C for Northern or Western
blots, if required. Lung weights and gross necropsy observations were recorded on a
necropsy form. The color, texture. location and size o f gross lesions were also noted on
the necropsy form. After trimming the trachea from the lung at the level o f the cranial
bronchi, the lung was weighed.
Statistics
Statistical analyses o f pharmacokinetic parameters, urine creatinine,
enrofloxacin and ciprofloxacin concentrations. IL-6 plasma concentrations, plasma
aspartate transaminase and lung weights were similar to the infection study. One-way
analysis o f variance was performed where the predominant statistical difference was due
t the endotoxin group or an endotoxin and dexamethasone interaction.
Results
Animal observations and pathology
The endotoxin treated pigs became depressed and dyspnic within 30 to 60
minutes after i.v. injection. One endotoxin treated pig vomited. Signs o f labored
breathing and depression were reduced 24 h after endotoxin administration, but all pigs
were anorectic. At 48 h. all pigs were more active and consumed almost all o f their
ration. At 72 h, all endotoxin treated pigs appeared normal and had finished their ration.
There were no gross lesions present in the lungs at necropsy. No significant
differences (P O .O l) in the lung/body weight ratio (g/kg) were found among control,
dexamethasone, endotoxin and endotoxin-dexamethasone treatment groups (Table 3.2;
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Figure 3.1). However, there was a significant interaction (P<0.01) between
dexamethasone and endotoxin. Histopathology was not done in the endotoxin study.
Plasma aspartate aminotransferase was elevated in endotoxin treated pigs at 24 h
and returned to baseline levels at 96 h after endotoxin administration (Table 3.3). The
rank means at 0 and 96 h for plasma aminotransferase were not significantly different
for no-dexamethasone pigs versus dexamethasone treated pigs, and no-endotoxin pigs
versus endotoxin treated pigs (Figure 3.2). The rank means for plasma aminotransferase
at 24 h were significantly greater (PO .O l) for the no-dexamethasone pigs versus
dexamethasone treated pigs and the endotoxin treated pigs versus no-endotoxin pigs.
Plasma interleukin-6
The mean plasma interleukin-6 concentration was markedly elevated for the
endotoxin treatment group compared to the control, dexamethasone and endotoxindexamethasone treatment groups (Figure 3.3). Rank means o f area under the curve
from zero to 9 h (A U C o ^ ) were significantly greater (P<0.01) for the endotoxin versus
the no-endotoxin pigs (Table 3.4; Figure 3.4).
Interleukin-6 synthesis is increased by tumor necrosis factor-a (Edwards et al.,
1994). Usually, tum or necrosis factor is released from macrophages and monocytes as a
proximal-mediator before the release IL-1 and IL-6 in septic shock. Endotoxin
increases serum T N F -a concentrations by enhancing T N F -a gene transcription
approximately 10-fold, cellular TNF-a mRNA 100-fold and a 10,000-fold increase in
the quantity o f protein secreted from activated monocytes. Dexamethasone and other
glucocorticoids inhibit TN F-a mRNA accumulation (Beutler et al., 1986; Han et al.,
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1990b; Luedke et al.. 1990). Glucocorticoids act both at the transcriptional and posttranscriptional level to block TN F-a synthesis (Han et al.. 1990a; Trinchieri. 1991).
This mechanism o f T N F -a release that is stimulated by endotoxin and inhibited by
glucocorticoids can explain why the IL-6 plasma concentration was decreased in the
endotoxin-dexamethasone group compared to the endotoxin group (Figures 3.3 and
3.4).
Plasma enrofloxacin pharmacokinetic changes
Area under the curve
The area under the curve for the endotoxin treatment groups was significantly
greater (P<0.01) compared to control, dexamethasone and endotoxin-dexamethasone
treatment groups for both area under the curve from zero to infinity, AUC(inf), and area
under the curve from zero to the last measured time point AUC(last) (Table 3.5: Figures
3.5 and 3.6). There was a significant interaction (P O .O l) between endotoxin and
dexamethasone for AUC(last) values. The AUC(last)/AUC(inf) ratios were 0.86. 0.92.
0.89, 0.93 and 0.86 for control, dexamethasone. endotoxin and endotoxindexamethasone groups, respectively (Figure 3.7). Therefore, the area o f the
extrapolated curve from the last measured time point to infinity was less than 14%.
which should not bias pharmacokinetic calculations. Furthermore, the one-way analysis
o f variance o f AUC(last) and AUC(inf) produced identical results where the endotoxin
group was significantly different from the control, dexamethasone and endotoxindexamethasone groups.
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Clearance, volume o f distribution, mean residence time, half-life and elimination rate
constant
Clearance was significantly greater (P O .O l) for the dexamethasone treated pigs
compared to the no-dexamethasone pigs by two-way analysis o f variance (Table 3.6:
Figure 3.8). Clearance was significantly greater (P O .O l) for the endotoxin group
compared to the control, dexamethasone and endotoxin-dexamethasone groups by one
way analysis o f variance (Figure 3.8). Volume of distribution based on the elimination
phase (Vp) and volume o f distribution at steady state (Vss) were both significantly
greater (P O .O l) for dexamethasone treated pigs compared to the no-dexamethasone
pigs (Table 3.6; Figures 3.9 and 3.10). Mean residence time was significantly greater
(PO .O l) for the endotoxin group compared to control, dexamethasone and endotoxindexamethasone groups and there was a significant interaction (P O .O l) between
endotoxin and dexamethasone (Table 3.6: Figure 3.11). There was no significant
difference (P O .O l) in half-life among the control, dexamethasone. endotoxin and
endotoxin-dexamethasone treatment groups (Table 3.6: Figure 3.11).
Urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios
Ciprofloxacin was the major enrofloxacin metabolite that was detected in the
urine of the endotoxin study pigs as observed in the infection study (Figures 2.17 and
3.12). The minor metabolite, oxo-enrofloxacin. was a suspect peak in the urine but oxoenrofloxacin ratios were not calculated (Figure 2.17 and 3.12). The suspect oxoenrofloxacin peak had a similar retention time (7 min) as the suspect oxo-enrofloxacin
peak in the infection study (Figures 2.17 and 3.12). Ciprofloxacin and enrofloxacin
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were both detected in the 24. 48 and 72 h urine samples (Tables 3.7 and 3.8). The
ciprofloxacin, oxo-enrofloxacin and enrofloxacin peaks did not appear in the 0 h blank
samples (Figure 3.12). Desethylene-ciprofloxacin was not detected in the urine samples
even though an unknown endogenous product co-eluted at the same time (6.3 min) as
desethylene-ciprofloxacin (Figure 3.12). As in the infection study, this unknown peak
was determined not to be desethylene-ciprofloxacin because it co-eluted with an
endogenous peak in the 0 h urine sample and had an ultraviolet absorption maximum at
250 nm. The characteristic fluoroquinolone absorption maxima occurs around 280 nm.
Total urine creatinine was not significantly different among the control,
dexamethasone. endotoxin and endotoxin-dexamethasone groups at 24, 48 and 72 h
(Table 3.7). Total urine enrofloxacin and ciprofloxacin were not significantly different
at 24 and 48 h (Table 3.7). Total urine enrofloxacin and ciprofloxacin were
significantly greater (P<0.01) for the endotoxin group compared to the control,
dexamethasone and endotoxin-dexamethasone groups at 72 h by one-way analysis of
variance (Table 3.7).
The urine enrofloxacin/creatinine ratios were not significantly different (P O .O l)
for the 24 h urine samples (Table 3.7; Figure 3.13). The enrofloxacin/creatinine ratio of
the 48 h urine samples for the endotoxin group was significantly greater (P O .O l) than
the control, dexamethasone. and endotoxin-dexamethasone treatment groups. There
was a significant interaction (P O .O l) between endotoxin and dexamethasone (Table
3.7; Figure 3.13). The 48 h urine samples also had a significantly lower (P O .O l)

185

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 3.2. Lung/body weight (g/kg) ratios in control, dexamethasone. endotoxin and
endotoxin-dexamethasone treatment groups. The lung weights were normalized with
body weights.

LW/BW (g/kg)

Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

10.8

9.36

10.1

10.5

(8.38-10.5)
(8.21-10.5)
(9.68-12.2)
(min-max)_______ (8.84-11.9)
LW/BW; the ratio o f the lung weight to total body weight.
Values are raw data medians and (min-max) represents the range o f raw data within a
treatment group.
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Figure 3.1. Rank means±SD of lung/body weight ratios in control, endotoxin,
dexamethasone and endotoxin-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01
*. indicates a significant interaction between endotoxin and dexamethasone.
aUsed to compare control, dexamethasone, endotoxin and endotoxin-dexamethasone
treatment groups (n=6) (One-way analysis o f variance performed after ranking the raw
data. P<0.01).
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Table 3.3. Plasma aspartate am inotransferase in control, endotoxin, dexamethasone and
endotoxin-dexam ethasone treatment groups

Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

Oh

13.9

10.2

17.1

13.4

(min-max)

(9.74-25.4)

(3.72-12.7)

(12.3-20.1)

(9.27-23.3)

24 h

18.9

11.4

41.2

16.2

(min-max)

(13.5-21.7)

(6.80-13.9)

(17.7-708)

(11.4-33.9)

96 h

16.7

13.3

18.1

15.9

(min-max)

(8.76-21.9)

(6.64-16.8)

(13.5-29.6)

(10.9-18.6)

AST
(IU/ml)

AST (IU/ml). plasma aspartate aminotransferase
Values are means and (min-max) represents the range o f raw data within a group.
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Figure 3.2. Rank means±SD of plasma aspartate aminotransferase in control,
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups at 0. 24 and
72 h after endotoxin administration.
Values with identical superscripts are not significantly different. P< 0.01
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no
endotoxin pigs with endotoxin treated pigs at 0 h (n=12) (Two-way analysis o f variance
performed after ranking the raw data. P.0.01).
tdUsed to compare no-dexamethasone pigs with dexamethasone treated pigs at 24 h
(n=12) (Two-way analysis o f variance performed after ranking the raw data. P<0.01).
CD
Used to compare no-endotoxin pigs with endotoxin treated pigs at 24 h (n=12) (Twoway analysis o f variance performed after ranking the raw data. P<0.01).
eUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no
endotoxin pigs with endotoxin treated pigs at 96 h (n=l2) (Two-way analysis of
variance performed after ranking the raw data. P O .O l).
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Figure 3.3. Mean plasma concentration o f interleukin-6 measured at 0. 1. 3. 6 and 9
hours after endotoxin (2 pg/kg BW) administration at 0 h.
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10

Table 3.4. Area under the curve for plasm a interleukin-6 in pigs in control,
dexamethasone. endotoxin and endotoxin-dexam ethasone treatm ent groups.

Area Under the
Curve

Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

AUCo_9h

387

203

17243

1100

(min-max)

(44.4-489)

(131-440)

(1447-23579)

(483-16748)

(units/ml x h)

AUC q^ qh; area under the curve from 0 to 9 h.
Values are raw data medians and (min-max) represents the range o f raw data within a
group.
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Figure 3.4. Rank means±SD of area under the curve for plasma interleukin-6 in control,
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01).
Used to compare no-endotoxin pigs with endotoxin treated pigs (n=12) (Two-way
analysis o f variance performed after ranking the raw data. P<0.01).
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Figure 3.5. Semilogrithmic plot of mean plasma concentrations of enrofloxacin
measured at 0. 0.25. 0.5. 1. 2, 3, 4, 6, 8. 12. 24. 36. 48. 60. and 72 h after i.v.
enrofloxacin (5 mg/kg BW) administration and 24 h after endotoxin or sham endotoxin
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Table 3.5. Area under the curve (mg/L x h) for plasm a enrofloxacin in control,
dexamethasone. endotoxin and endotoxin-dexam ethasone treatment groups.

Area Under the
Curve (mg/L x h)

Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

AUC(in0

11.2

9.43

22.4

9.22

(min-max)

(9.13-14.2)

(8.41-13.7)

(18.7-36.6)

(6.20-13.2)

A U C d^

10.4

8.47

21.2

7.71

(min-max)

(8.02-13.2)

(7.05-12.0)

(16.0-34.6)

(5.65-11.7)

AUC,inr). area under the curve from zero to infinity
AUC(Iast). area under the curve from zero to the last measured hour.
Values are raw data medians and (min-max) represents the range of raw data within a
group.
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Figure 3.6. Rank means±SD o f area under the curve for plasma enrofloxacin in control,
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups, comparing
AUC(last) with AUC(inf).
AUC(inf). area under the curve from zero to infinity
AUC(last). area under the curve from zero to the last measured hour.
Values with identical superscripts are not significantly different. P<0.01.
* indicates an interaction between endotoxin and dexamethasone.
abUsed to compare the endotoxin group with the control, dexamethasone and endotoxindexamethasone group for AUC(inf) (n=6) (One-way analysis o f variance performed
after ranking the raw data. P<0.01).
cd
•
Used to compare the endotoxin group with the control, dexamethasone and endotoxindexamethasone group for AUC(last) (n=6) (One-way analysis o f variance performed
after ranking the raw data, P<0.01).
CD
w
Used to compare endotoxin-dexamethasone group with control and dexamethasone
groups for AUC(last) (n=6).(One-way analysis o f variance performed after ranking the
raw data. P<0.01).
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Figure 3.7. Means o f area under the curve ratios for plasma enrofloxacin in control,
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups.
AUC(inf) area under the curve from zero to infinity
AUC(last), area under the curve from zero to the last measured hour.
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Table 3.6. Plasma pharmacokinetic parameters of enrofloxacin in control, endotoxin, dexamethasone and endotoxin-dexamethasone
treatment groups.
Pharmacokinetic
Parameters

Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

Cll0, (L/li/kg)
(min-max)

0.447
(0.353-0.548)

0.531

0.223

0.542

(0.366-0.594)

(0.137-0.267)

(0.379-0.806)

V„(L/kg)

6.11

8.64

4.62

9.21

(min-max)

(4.60-8.56)

(6.03-10.5)

(2.52-7.13)

(7.24-11.6)

Vss(L/kg)

5.12

7.16

4.37

7.07

(min-max)

(4.01-6.14)

(5.52-7.42)

(2.59-6.25)

(5.69-9.55)

MRT (h)

12.0

12.7

21.6

13.3

(min-max)

(8.75-13.6)

(10.8-16.9)

(14.1-28.0)

(9.07-17.4)

11/2 (h)
(min-max)

10.5

12.7

16.2

11.8

(6.96-11.3)

(8.22-14.1)

(9.70-20.4)

(8.46-14.7)

P(1/h)

0.0658“

0.0624“

0.0432“

0.0589“

(min-max)

(0.062-0.100)

(0.0491-0.0844)

(0.0340-0.0714)

(0.0473-0.0819)

to

o

to

CIU)1, total body clearance; V,, volume of distribution based on the terminal phase; Vss, volume of distribution at steady state; MRT,
mean residence time; t !/2, half-life and (i, elimination rate constant.
Values are raw data medians and (min-max) represents the range of raw data within a group.
Values with identical superscripts are not significantly different, P< 0.01.
“Used to compare the endotoxin group with the control, dexamethasone and endotoxin-dexamethasone groups after ranking the data
(n=6) (One-way analysis of variance performed after ranking the raw data, P<0.01).

Figure 3.8. Rank means±SD o f clearance for plasma enrofloxacin in control, endotoxin,
dexamethasone and endotoxin-dexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=12)
(Two-way analysis o f variance performed after ranking the raw data. P<0.01).
■\B
*
w
Used to compare the endotoxin group with the control, dexamethasone and
endotoxin-dexamethasone groups (n=6) (One-way analysis o f variance performed after
ranking the raw data. P O .O l).
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Figure 3.9. Rank means±SD o f volume of distribution of the elimination phase for
plasma enrofloxacin in control, endotoxin, dexamethasone and endotoxindexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=l2)
(Two-way analysis o f variance performed after ranking the raw data. P O .O l).
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Figure 3.10. Rank means±SD of volume o f distribution at steady state for plasma
enrofloxacin in control, endotoxin, dexamethasone and endotoxin-dexamethasone
treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs (n=12)
(Two-way analysis o f variance performed after ranking the raw data. P.O.01).
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Figure 3.11. Rank means±SD o f mean residence time (MRT) and half-life (tl/2) for
plasma enrofloxacin in control, endotoxin, dexamethasone and endotoxindexamethasone treatment groups.
Values with identical superscripts are not significantly different. P< 0.01.
*. indicates a significant interaction between endotoxin and dexamethasone.
abUsed to compare the endotoxin group with control, dexamethasone and endotoxindexamethasone groups for mean residence time (n=6) (One-way analysis of variance
performed after ranking the raw data, PO .O l).
cUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no
endotoxin pigs with endotoxin treated pigs for half-life (n=12) (Two-way analysis of
variance performed after ranking the raw data. P<0.01).

209

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

30

Rank Means of Mean Residence Time and Half-Life for Enrofloxacin

Control
Dexamethasone
Endotoxin
Endotoxin-Dexamethasone
25

20 j

15
a

0

MRT

Half-Life

Pharmacokinetic Parameter

210

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

l.2e+6
Standard
Oh
72 h

Ciprofloxacin

l.0e+6 !■
Enrofloxacin

Suspect Oxo-enrofloxacin
Pipemidic Acid

8.0e+5

r
\ ' J

s

i

i

11

3

5

''

•3 6.0e+5 j-

11 ■
'i ■
l *

i

!

Vs

-a;
3
Su

v '

I I ■
v

I'i
i
i

! i

i 1
i 1
11
M

M

i

\
i

r\ 1 1 i

\

■ '" V [i
rv—

4.0e+5

r

2.0e+5

0

1

i

4

5

6

7

8

9

10

11

12

Tim e (min)
Figure 3.12. Chromatographs of standards (ciprofloxacin and enrofloxacin) and the
internal standard (pipemidic acid); 0 h urine sample: and 72 h urine samples in an
endotoxin treated pig.
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Table 3.7. Total urine creatinine, enrofloxacin and ciprofloxacin in control, endotoxin,
dexamethasone and endotoxin-dexamethasone treatment groups.
Creat (mg), total urine creatinine; Enro (mg), total urine enrofloxacin; and Cipro (mg),
total urine ciprofloxacin.
Values are raw data medians and (min-max) represents the range of raw data within a
group.
Values with identical superscripts are not significantly different. P< 0.01.
aUsed to compare control, dexamethasone. endotoxin and endotoxin-dexamethasone
treatment groups for total urine creatinine at 24. 48 and 72 h (n=6) (One-way analysis of
variance performed after ranking the raw data. P<0.01).
^ Used to compare the endotoxin group with the control, dexamethasone and endotoxindexamethasone groups for total urine enrofloxacin at 24. 48 and 72 h (n=6) (One-way
analysis of variance performed after ranking the raw data. P<0.01).
u Used to compare the endotoxin group with the control, dexamethasone and endotoxindexamethasone groups for total urine ciprofloxacin at 24. 48 and 72 h (n=6) (One-way
analysis of variance performed after ranking the raw data. P<0.01).
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Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

24 h Creat (mg)

I223a

832a

751a

1042a

(min-max)

(60.8-1539)

(354-1292)

(6.94-1161)

(289-1409)

48 h Creat (mg)

987a

1128a

856a

1022a

(min-max)

(723-1488)

(854-1697)

(218-1148)

879-1373)

72 h Creat (mg)

922a

73 2a

1209a

III 4a

(min-max)

(353-1414)

(445-1241)

(488-1790)

(580-1843)

24 h Enro (mg)

10.4°

8.14°

8.86°

7.60°

(min-max)

(8.82-13.0)

(5.59-15.6)

(0.003-16.3)

(4.09-8.87)

48 h Enro (mg)

4.15c

4.03c

5.39°

2.04c

(min-max)

(2.31-4.98)

(1.74-9.06)

(0.951-11.3)

(1.13-3.31)

72 h Enro (mg)

1.19C

1.04c

2.38d

0.746°

(min-max)

(0.468-1.49)

(0.715-1.92)

(1.60-4.57)

(0.589-0.957)

24 h Cipro (mg)

11.3°

12.5°

6.37c

15.4°

(min-max)

(8.36-14.0)

(7.90-18.6)

(0.027-18.2)

(8.75-17.2)

48 h Cipro (mg)

4.54e

5.07e

8.60°

4.32e

(min-max)

(3.39-5.52)

(3.40-9.86)

(1.91-11.0)

(2.49-6.25)

72 h Cipro (mg)

1.23e

1.15C

4.311'

1.88°

(min-max)

(0.468-2.27)

(0.201-2.11)

(3.38-5.93)

(0.743-4.72)
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Table 3.8. Urine ciprofloxacin/creatinine and enrofloxacin/creatinine ratios in control.
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups.

Control

Dexamethasone

Endotoxin

EndotoxinDexamethasone

24 h
Enro/Creat
(pg/mg)

9.84

14.4

10.7

6.77

(min-max)

(5.73-11.4)

(5.15-19.5)

(0.383-14.1)

(2.91-30.7)

48 h
Enro/Creat
(pg/mg)

3.78

3.53

6.45

2.06

(min-max)

(2.89-5.38)

(2.03-5.87)

(4.36-9.85)

(0.826-3.26)

72 h
Enro/Creat
(pg/mg)

1.23

1.07

2.19

0.586

(min-max)

(0.923-3.03)

(1.00-1.71)

(1.50-4.99)

(0.378-1.40)

24 h
Cipro/Creat
(pg/mg)

9.22

20.3

8.31

15.7

(min-max)

(6.91-12.1)

(7.81-22.3)

(3.85-15.7)

(6.21-50.3)

48 h
Cipro/Creat
(pg/mg)

4.01

4.07

9.16

4.17

(min-max)

(3.01-7.02)

(3.83-6.40)

(7.01-11.2)

(2.07-7.11)

72 h
Cipro/Creat
(pg/mg)

1.99

1.07

4.34

2.31

(min-max)

(0-2.70)

(0.451-1.70)

(2.40-6.92)

(0.705-2.90)

Enro/Creat (pg/mg). ratio o f urine enrofloxacin/urine creatinine.
Cipro/Creat (pg/mg). ratio o f urine enrofloxacin to urine creatinine.
Values are raw data medians and (min-max) represents the range o f raw data within a
group.
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Figure 3.13. Rank means±SD o f urine enrofloxacin/creatinine ratios in control,
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups at 24.48
and 72 h after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01
*. indicates a significant interaction between endotoxin and dexamethasone.
aUsed to compare no-dexamethasone pigs with dexamethasone treated pigs and no
endotoxin pigs with endotoxin treated pigs at 24 h (n=12) (Two-way analysis of
variance performed after ranking the raw data. P<0.01).
udUsed to compare the endotoxin group with control, dexamethasone and endotoxindexamethasone groups at 48 h (n=6) (One-way analysis o f variance performed after
ranking the raw data. P<0.01).
CD
w
Used to compare the endotoxin-dexamethasone group with the control group at 48 h
(n=6) (One-way analysis o f variance performed after ranking the raw data. P O .O l).
l' tUsed to compare the endotoxin-dexamethasone group with the control, dexamethasone
and endotoxin groups at 72 h (n=6) (One-way analysis o f variance performed after
ranking the raw data. P<0.01).
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Figure 3.14. Rank means±SD o f urine ciprofloxacin/creatinine ratios in control,
endotoxin, dexamethasone and endotoxin-dexamethasone treatment groups at 24. 48
and 72 h after enrofloxacin administration.
Values with identical superscripts are not significantly different. P< 0.01.
abUsed to compare no-dexamethasone pigs with dexamethasone treated pigs at 24 h
(n=12) (Two-way analysis o f variance performed after ranking the raw data. P<0.01).
LliUsed to compare the endotoxin group with the control, dexamethasone and endotoxindexamethasone groups at 48 h (n=6) (One-way analysis of variance performed after
ranking the raw data. P<0.01).
dUsed to compare endotoxin group with control, dexamethasone and endotoxindexamethasone groups at 72 h (n=6) (One-way analysis o f variance performed after
ranking the raw data. P<0.01).
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enrofloxacin/creatinine ratio for the endotoxin-dexamethasone group compared to the
control group (Table 3.7; Figure 3.13). The 72 h enrofloxacin/creatinine ratios for the
endotoxin-dexamethasone group were significantly less (P<0.01) for the endotoxindexamethasone group compared to the control, dexamethasone and endotoxin groups
(Table 3.7; Figure 3.13). There was a significant interaction (P<0.01) between
endotoxin and dexamethasone (Table 3.7; Figure 3.13).
The ciprofloxacin/creatinine ratios were significantly greater (P<0.01) for the
dexamethasone treated pigs compared to no-dexamethasone pigs in the 24 h urine
samples (Table 3.8; Figure 3.14). The ciprofloxacin/creatinine ratio was significantly
greater (P O .O l) for the endotoxin group compared to the control, dexamethasone and
endotoxin-dexamethasone groups in the 48 and 72 h urine samples (Table 3.8; Figure
3.14).
Discussion
All o f the endotoxin treated pigs exhibited signs o f labored breathing and
lethargy within two hours which confirmed that the pigs received enough endotoxin to
induce systemic illness. The plasma AST concentrations were elevated at 24 hours and
returned to baseline by 96 h after endotoxin administration. This meant that the liver
injury present at 24 h was repaired by 96 h. Transient liver injury is logical because the
plasma interleukin-6 concentrations were significantly elevated in the endotoxin treated
pigs at 3 h but had decreased to near baseline by 9 h (Table 4.3; Figures 3.3 and 3.4).
Therefore, the stimulus for liver injury and possible suppression o f cytochrome P450's
was absent after 9 h.
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Pharmacokinetic parameters were calculated on the assumption, similar to the
infection study, that the extrapolated area under the curve from the last measured time
point to infinity did not bias the calculation o f clearance, volume o f distribution, mean
residence time and half-life. When the AUC(inf) was compared to AUC(last). the
outcome of the statistical analysis was the same, based on one-way analysis of variance
(Table 3.5: Figures 3.5 and 3.6. Unlike the infection study for AUC(last) and AUC(inf).
the endotoxin group was significantly greater than the control, dexamethasone and
endotoxin-dexamethasone groups (Figure 3.6). The biological significance of the
endotoxin and dexamethasone interaction for AUC(last) can not be readily explained
based on AUC data (Figure 3.6). The dexamethasone treatment seems to counteract the
endotoxin response. The ratios o f AUC(last)/AUC(inf) among the control,
dexamethasone. endotoxin and endotoxin-dexamethasone treatment groups were
acceptable because less than 10% o f the total area was extrapolated (Figure 3.7). The
calculation of pharmacokinetic parameters based on AUC(inf) is still valid .
The volume o f distribution o f enrofloxacin for both the elimination phase and
steady state was increased for the dexamethasone treated animals but not the endotoxin
treated animals compared to the no dexamethasone and no-endotoxin pigs (Table 3.5:
Figures 3.9 and 3.10). Increased Vp may indicate decreased plasma protein binding and
increased free fraction while the increased Vss could indicate increased plasma and
tissue protein binding and decreased free fraction for enrofloxacin (Ritschel & Denson.
1991). Thus, the free fraction in the plasma and tissues should decrease and the
clearance of enrofloxacin in the endotoxin group should increase for the dexamethasone
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treated pigs (Figures 3.8 - 3.10). The increased clearance in the dexamethasone treated
pigs is more likely due to increased GFR and filtration fraction as a glucocorticoid
effect on the kidney (Connell et al.. 1987: Stefanovic et al.. 1991). The rate o f
elimination from the central compartment and the AUC could both contribute to a
change in Vp in the dexamethasone treated pigs, because the elimination rate constant
and AUC are both inversely related to the volume o f distribution o f the elimination
phase by the equation: Vp=dose/([3 x AUC). A decrease in one or both parameters could
increase Vp. The AUC did decrease for the dexamethasone treated pigs but the
elimination rate constant did not change, which could account for the increase in Vp
(Table 3.6: Figures 3.9 and 3.10).
The half-life for the endotoxin group was not significantly different from the
control, dexamethasone and endotoxin-dexamethasone groups (Figure 3.11). Mean
residence time would be expected to parallel half-life., but MRT o f the endotoxin group
is greater than the control, dexamethasone and endotoxin-dexamethasone groups
(Figure 3.11). The graphical profiles are similar even though the statistical outcomes
are different (Figure 3.11).
The most likely explanation for increased protein binding in tissues leading to
increased volumes o f distribution in dexamethasone treated pigs would be lack of
interference by fatty acids with albumin and more binding sites on albumin or a,-acid
glycoprotein (Greene & Budberg, 1993). This assumes that other factors, such as
enrofloxacin blood concentration or pH. did not affect the serum protein binding of
enrofloxacin. While volumes o f distribution were altered for the dexamethasone treated
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pigs, the volumes o f distribution are not altered for the endotoxin treated pigs compared
to the no-endotoxin pigs (Table 3.5; Figures 3.9 and 3.10). In the infection study, the
volumes o f distribution were decreased in the infected pigs and unchanged for the
dexamethasone treated pigs (Figures 2.13 and 2.14). In comparison to the infection
study, the failure o f endotoxin to change the volume o f distribution in the endotoxin
treated pigs can not be readily explained. There are many more toxins associated with
APP infection than would be associated with endotoxin administration, and the
endotoxin was administered as a single i.v. dose.
Ciprofloxacin and suspect oxo-enrofloxacin were found in the urine(Figures
2.17 and 3.12). This is consistent with the infection study where the suspect lesser
metabolite, oxo-enrofloxacin. was also detected in the urine after i.v. administration of
enrofloxacin. There was no significant difference among the treatment groups at 24 h
for the urine enrofloxacin/creatinine ratio, but the urine ciprofloxacin/creatinine ratio
was significantly greater for the dexamethasone treated pigs compared to the nodexamethasone pigs at 24 h (Table 3.7 and 3.8; Figures 3.13 and 3.14). The effect of
dexamethasone on GFR and clearance was not evident at 24 h for the urine
enrofloxacin/creatinine ratio, but the increased urine ciprofloxacin/creatinine ratio in the
dexamethasone treated pigs at 24 h might be explained by increased clearance related to
augmented GFR (Figures 3.13 and 3.14).
At 48 h. the urine enrofloxacin/creatinine ratio was greatest for the endotoxin
group compared to control, dexamethasone and endotoxin-dexamethasone groups; and
the endotoxin-dexamethasone was less than the control and dexamethasone groups.
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(Table 3.7; Figure 3.13). The interaction between endotoxin and dexamethasone in the
48 h urine enrofloxacin/creatinine ratios was probably due to GFR “washout” in the
dexamethasone group and peripheral vasodilatation followed by renal vasoconstriction
in the endotoxin group (Figure 3.13). In other words, the endotoxin group may have
developed hypotension associated with endotoxic shock, with a subsequent renal
vasoconstriction to maintain homeostasis. In fact, endotoxin treated pigs had a flushed,
red skin until they were necropsied. This supports a physiological effect o f endotoxin
on enrofloxacin clearance rather than a metabolic effect. The urine
ciprofloxacin/creatinine ratio in the endotoxin group should have decreased relative to
the control group, if metabolism of enrofloxacin had been decreased (Tables 3.7 and
3.8; Figure 3.14). The ciprofloxacin/creatinine ratio for the endotoxin group was
actually increased at 48 and 72 h which means that there was no liver injury present to
cause a decrease in total cytochrome P450 protein (Figure 3.14). Liver damage for the
endotoxin treated pigs was transient as indicated by plasma AST (Figure 3.2). At 24 h
after endotoxin administration, the dexamethasone treated pigs had decreased plasma
AST concentrations compared to the no-dexamethasone pigs while the endotoxin
treated pigs had increased plasma AST concentrations compared to no-endotoxin pigs.
This implies a sparing effect o f dexamethasone on liver damage.
Two or more AST isozymes are located in the cytosol and the mitochondria and
catalyze the conversion o f aspartate and alpha-ketoglutarate to glutamate and
oxaloacetate (Duncan & Prasse. 1986). The enzyme occurs in almost all cells. It is
considered to be a diagnostic enzyme for liver and muscle disease, because o f high
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activity in these tissues. The plasma AST half-life for swine is about 18 hours. Plasma
AST activity increases with changes in heptocellular permeability due to sublethal
injury and necrosis. The magnitude o f the increase approximates the number o f cells
affected in acute disease. In acute hepatic sublethal injury or necrosis and high serum
AST. hepatic insufficiency may be minimal. Consequently, the 24 h
enrofloxacin/creatinine and ciprofloxacin/creatinine ratios were elevated for the
endotoxin group 48 h after endotoxin administration which is 24 h after AST elevation.
By 48 h. liver damage (plasma AST concentration) was on the decline which would
suggest that any depression o f total cytochrome P450 protein content was increasing.
This seems reasonable, because total cytochrome P450 content and enzyme activities
were decreased 24 h after five doses o f endotoxin (17 pg/kg) in the Netherlands study
(Monshouwer et. al.. 1996a) compared to a single i.v. dose (2 pg/kg) used in this study.
Resolving liver damage and elevated urine ciprofloxacin/creatinine ratio point to a
physiological mechanism for decreased enrofloxacin clearance in the endotoxin group.
A decrease in enrofloxacin conversion to ciprofloxacin is not likely in the endotoxin
treated pigs.
Dexamethasone depressed IL-6 concentrations after endotoxin administration
(Table 3.4; Figures 3.3 and 3.4). Then, the effect o f endotoxin could have depended
upon concurrent dexamethasone concentration. Therefore, the endotoxin treated pigs
showed no changes in clearance or volume of distribution of enrofloxacin. The changes
in urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios at 48 h may be the

224

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

result o f enrofloxacin and ciprofloxacin "washout7' due to increased GFR (Figures 3.13
and 3.14).
At 72 h, the urine enrofloxacin/creatinine and ciprofloxacin/creatinine ratios
were greatest for the endotoxin group compared to the control, dexamethasone and
endotoxin-dexamethasone groups (Tables 3.7 and 3.8; Figures 3.13 and 3.14). Again,
there was a significant interaction at 72 h between endotoxin and dexamethasone in the
enrofloxacin/creatinine ratios (Figure 3.13). Presumably, the interaction may have
occurred for the same reasons as in the 48 h urine enrofloxacin/creatinine ratios. The
prolonged enrofloxacin/creatinine and ciprofloxacin/creatinine ratios were most likely
due to physiological mechanisms rather than reduced metabolism o f ciprofloxacin.
It is also possible that dexamethasone could induce cytochrome P450
metabolism o f enrofloxacin to ciprofloxacin and contribute to the clearance o f
enrofloxacin. Endotoxin could suppress P450's and decrease enrofloxacin clearance,
but endotoxin did not have an effect on clearance. Endotoxin decreased clearance of
enrofloxacin compared to control, dexamethasone and endotoxin-dexamethasone groups
(One-way analysis o f variance) (Figure 3.8).
While the enrofloxacin clearance was not decreased and the volume o f
distribution was not increased for the endotoxin group, the mean residence time was
significantly increased for the endotoxin group compared to the control, dexamethasone
and endotoxin-dexamethasone groups with no effect on half-life ( Table 4.5; Figure
3.11). This verifies that the transit time for enrofloxacin is increased by endotoxin.
Assuming that biliary excretion or transenteric secretion remains the same as healthy
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animals, the most likely cause for the increased transit time is renal vasoconstriction.
Dexamethasone did not inhibit enrofloxacin clearance in both the infection and
endotoxin studies. Therefore, a direct effect of dexamethasone on enrofloxacin
metabolism is doubtful. Liver injury was transient at 24 h after endotoxin
administration and returned to baseline by 96 h. as measured by plasma AST. This was
not long enough to promote suppression o f cytochrome P450 by systemic cytokine
release and cause a subsequent reduction o f enrofloxacin biotransformation to
ciprofloxacin or oxo-enrofloxacin. Then, the direct effect o f endotoxin on enrofloxacin
metabolism is also doubtful. In female rats. IL-1 and dexamethasone significantly
depressed total P450. and P450IIC12 apoenzyme. and mRNA (Wright & Morgan.
1991). Induction o f IL-1 and IL-6 was inhibited by dexamethasone which would
prevent the cytokine induced suppression of cytochrome P450's (Menzozzi et al..
1994). In this study, dexamethasone did suppress the endotoxin induced release of IL-6
(Figures 3.3 and 3.4) but did not increase urine enrofloxacin/creatinine ratio with a
concomitant decrease o f the ciprofloxacin/creatinine ratio in the endotoxin and
dexamethasone pigs. This strongly suggests that metabolism o f enrofloxacin was not
affected by dexamethasone.
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SU M M ARY AND CONCLUSIONS
Previous pharmacokinetic studies have used healthy animals while diseased
animals were used in efficacy studies. The lack o f pharmacokinetic studies in diseased
animals was not through scientific neglect, but the fact that the drug or antimicrobial
must be tested in healthy animals who may be screened for age. weight, medical history,
blood chemistry and receive the test article at the same time of day. with similar
conditions o f fasting, food, and activity. The performance o f a drug or antimicrobial or
its formulation is a tested in healthy animals by keeping all variables that might affect
pharmacokinetics parameters constant. However, many veterinary drugs are not
intended for healthy animals, but rather for those animals with one or more pathological
conditions that are manifested as disease processes. These disease processes alter the
normal function of the body. Consequently, the normal functions involved in
distribution and elimination of a drug may be altered by disease.
Because the body handles many drugs and endogenous substances similarly,
diseases that alter the pharmacodynamics of endogenous substances may also alter the
pharmacodynamics o f drugs. Diseases that alter pharmacodynamics can also alter
pharmacokinetic parameters. The onset and duration o f action of a drug is dependent on
the rate and extent o f distribution. A change in the apparent volume of distribution may
change the drug concentration in blood or plasma and at the receptor site. Diseases can
modify a number of kinetic parameters and alter steady state concentrations and.
thereby, influence efficacy or toxicity. Unfortunately, it is not easy to standardize
disease models. Disease models are ever changing and never constant, dependent on the

227

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

state o f the disease, which makes it difficult to find a population o f animals who are
homogenous for the disease, disease state, therapy, age, weight, genetics, diet, housing
and stress factors.
One o f the objectives o f this investigation was to determine whether a
Actinobacillus pleuropneumoniae pulmonary infection model could be standardized.
This goal was accomplished as demonstrated by the pigs becoming ill within 2 hours of
inoculation with APP. where signs o f labored breathing and lethargy were observed.
Systemic interleukin-6 concentrations were highly elevated in the infected pigs. This
was another indication that APP infection was accomplished. Infection was verified by
gross pathology observations, increased lung weights and microscopic pathology results
of necrotizing, fibrinopurulent pneumonia.
The second objective was to examine the effect of infection and dexamethasone
on pharmacokinetic parameters in swine after administering enrofloxacin. Clearance
was reduced for the dexamethasone treated pigs, but clearance was not altered in
infected pigs. This change was attributed to increased glomerular filtration rate and
filtration fraction. The volume o f distribution based on the elimination phase was
decreased in the infected pigs, and was influenced by the elimination rate constant. The
volume o f distribution at steady state was also decreased in the infected pigs and is
independent o f the elimination rate constant. This means that decreased volumes of
distribution may be due to not only an increased elimination rate constant but could also
be to decreased protein binding in plasma and tissues and/or changes in blood pH or
flow. Mean residence time and half-life were decreased in the dexamethasone treated
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pigs. The changes in mean residence time and half-life reflected the change of
increased clearance in the dexamethasone treated pigs. The urine
enrofloxacin/creatinine ratio was decreased for the dexamethasone treated pigs which
demonstrated a "washout” effect of dexamethasone by increasing the glomerular
filtration rate and filtration fraction. The ciprofloxacin/creatinine ratio and clearance in
the infected pigs were not changed which means that enrofloxacin metabolism was not
altered by infection. Finding the suspect oxo-enrofloxacin peak in the urine samples of
the control, dexamethasone. infected and non-infected dexamethasone pigs was
completely unexpected. Other investigators not did not find metabolites or conjugates
after ciprofloxacin administration (Nouws et al., 1988). The presence of oxoenrofloxacin should be confirmed by mass-spectroscopy before HPLC analysis o f the
urine peaks. Dexamethasone could have depressed metabolism by cytochrome P450's
but this would not be obvious from the data because excretion and metabolism are
components o f clearance. Infection may change the appropriate dosage of enrofloxacin
because the volume o f distribution is changed. Decreased volume o f distribution could
mean less drug at the receptor site. Withdrawal times should not be altered because
infection did not change enrofloxacin clearance.
The third objective was to compare the results o f the infection study to an
endotoxin study. It was postulated that the use o f endotoxin would mimic the
Actinobacillus pleuropneumoniae infection and induce similar pharmacokinetic
changes. The endotoxin treated pigs became ill within 30 minutes as shown by very
elevated interleukin-6 plasma concentrations, which proves that systemic signs were
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initiated. As observed in the infection study, clearance o f enrofloxacin was increased in
the dexamethasone treated pigs. The volumes o f distribution o f the elimination phase
and at steady state were also increased in the dexamethasone treated pigs which was not
observed in the infection study. The combined effect of volume of distribution increase
and clearance increase resulted in no change in half-life in the dexamethasone treated
pigs. Mean residence time was increased for the endotoxin group. Clearance was
decreased for the endotoxin group which was further manifested as increased urine
enrofloxacin/creatinine and ciprofloxacin/creatinine ratios. In the endotoxin study, the
washout of enrofloxacin and ciprofloxacin was evident in the urine samples of
dexamethasone treated pigs as in the infection study. If the clearance of enrofloxacin
was decreased by reduced metabolism of enrofloxacin. it is assumed that renal function,
hepatic function and blood flow were not altered. However, it is more probable that
renal blood flow was decreased as a response to endotoxic shock and hypotension.
Dexamethasone enhanced enrofloxacin clearance and suppressed IL-6 plasma
concentrations which suggests that cytochrome P450 activity was not decreased in
endotoxin treated pigs. Therefore, dexamethasone had a positive influence on
enrofloxacin clearance, rather than producing a blockade o f cytochrome P450
metabolism and decreased clearance, along with its anti-inflammatory role.
Additionally, the transient liver injury caused by endotoxin may not have been
substantial enough to depress hepatic metabolism o f enrofloxacin as indicated by
aspartate aminotransferase plasma concentrations. It is not likely that cytochrome
P450’s are involved in the decreased clearance and increased mean residence time of
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enrofloxacin in the endotoxin group for the following reasons: 1) urine
ciprofloxacin/creatinine ratios were not elevated; 2) liver injury was transient as
indicated by plasma aspartate aminotransferase concentrations. However, the presence
of a suspect oxo-enrofloxacin peak in the endotoxin study may prove interesting after
mass-spectroscopy confirmation and HPLC analysis as already mentioned for the
infection study. If the oxo-enrofloxacin ratios are not decreased for the endotoxin group
compared to the control, dexamethasone and endotoxin-dexamethasone groups, this
would support the physiological explanation for decreased enrofloxacin clearance as
opposed to reduced metabolism.
The infection and endotoxin studies confirm that the use o f dexamethasone in
conjunction with enrofloxacin may result in reduced efficacy because of increased
clearance. Furthermore, the infected pigs had a decreased volume of distribution which
may reduce the concentration of enrofloxacin at the receptor site and decrease efficacy.
The contradiction o f no effect o f dexamethasone on volumes o f distribution in the
infection study but increased volumes of distribution in the endotoxin study can not be
readily explained, except that the genetic make up of the pigs was different between the
two studies; Landrace x Yorkshire in the infection and Hampshire x Yorkshire in the
endotoxin study.
The use o f model drugs, such as antipyrine, to investigate pharmacokinetic
parameters with diseased animals is a useful screening tool but can only viewed as
preliminary information prior to testing therapeutic agents. However, the variables
involved in the disease process, compared to healthy animals, make interpretation of the
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results with model drugs difficult and the prediction o f efficacy and toxicity impractical.
Thus, the best way to assess the influence o f disease on pharmacokinetic parameters is
to use a specific therapeutic drug or antimicrobial instead of a model drug in the
presence of a disease model with a particular gene pool of domestic animals. This study
showed that Actinobacillus pleuropneumoniae. serotype 1. could be used as a disease
model in United States domestic pigs (Yorkshire crosses) to test the effects of infection
on pharmacokinetic parameters o f enrofloxacin. a therapeutic fluoroquinolone.
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